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11General introduction and outline of thesis
1Fluid resuscitation is a crucial intervention in the treatment of critically ill patients with circulatory shock. Fluids are primarily administered for reversal of absolute 
hypovolemia due to external fluid losses or due to relative hypovolemia as a 
consequence of an increase in venous capacitance as seen in septic shock for instance. 
However, there is little conclusive evidence to guide clinicians on the optimal type of 
resuscitation fluid; the appropriate timing, volume, and rate of fluid administration; or 
on the optimal way to monitor the efficacy and safety of fluid resuscitation in various 
clinical conditions. The main goal of fluid resuscitation is restoration or conservation, 
at least in part, of an effective circulating volume which is required to maintain 
optimal oxygen delivery, which in turn is necessary for adequate tissue oxygenation 
and cellular metabolism. Persistent hypovolemia may contribute to microcirculatory 
compromise, leading to organ dysfunction and, ultimately, multiple organ failure and 
should therefore be avoided or corrected, if possible1,2. On the other hand, abundant 
fluid administration accompanied with a cumulative positive fluid balance may also 
negatively influence outcome due to the development of pulmonary and interstitial 
edema which may prolong the duration of mechanical ventilation and ICU stay3-7. 
Therefore, it seems reasonable that fluid therapy should be tailored and directed 
on clearly defined (hemodynamic) endpoints, also called “goal directed therapy”, 
which is associated with improved outcome. Indeed, in the last decade it has been 
demonstrated that goal directed fluid therapy reduces mortality in surgical as well as 
non-surgical patients with (impending) shock8-14, which now has formed the basis of 
(international) guidelines on treating patients with circulatory shock2,15. Nevertheless, 
there is ongoing debate on a) the type of fluid to be used and b) whether hemodynamic 
monitoring may be beneficial to guide fluid therapy. Answering these two important 
questions will provide the basis of this thesis. 
PART I 
Fluids: type, dosing and timing
The Surviving Sepsis Campaign Guidelines2 recommend fluid resuscitation with either 
natural or artificial colloids or crystalloids, as they conclude that evidence-based 
support in favor of one type of fluid is lacking. This arbitrariness is however debatable, 
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12 Chapter 1
since on (patho)physiological grounds more crystalloids than colloids need to be 
infused for reaching the same hemodynamic endpoints, which may increase the risk 
of fluid overload and harmful pulmonary edema. In addition, an emerging body of 
evidence suggests that the type of resuscitation fluid may adversely affect outcome 
in specific clinical conditions. For instance, administration of albumin solutions is 
associated with increased mortality in patients with traumatic brain injury16 and 
high-molecular-weight preparations of hydroxyethyl starch are associated with 
acute kidney injury in patients with severe sepsis17. Conversely, improved outcomes 
associated with the use of albumin for resuscitation purposes have been shown in 
children with severe malaria18 and in adults with severe sepsis19,20. However, these 
reports were not sufficiently conclusive to justify strong clinical recommendations on 
the use of a specific type of fluid. Surveys among European ICUs on the use of preferred 
plasma volume expanders for critically ill patients demonstrate a more frequent use of 
colloids than of crystalloids in first line treatment, whereas hydroxyethyl starch is the 
most widely used synthetic colloid, but with large differences between countries21-24. 
Despite a demonstrated lack of survival benefit with the use of colloids25, this did not 
seem to be convincing enough to adapt local habits, unless other properties may 
render colloids a preferable resuscitation fluid. It may be hypothesized that one of 
the reasons for the widespread colloid use may be the potential hemodynamic effects 
associated with a lower volume needed to reach certain hemodynamic end-points. 
This hypothesis will further be explored in this thesis.
PART II 
Monitoring fluid therapy
The effectiveness of hemodynamic monitoring depends on both the available 
technology and on the ability to diagnose and effectively treat the disease processes for 
which it is being used. The utility of hemodynamic monitoring has evolved as it merged 
with information technology while our understanding of disease pathophysiology has 
also improved. Within this context, hemodynamic monitoring represents a functional 
tool that may be used to derive estimates of performance and physiological reserve 
that may in turn direct treatment, for instance fluid resuscitation, in order to reverse 
the disease process identified. 
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13General introduction and outline of thesis
1It must be emphasized that a monitoring tool itself cannot improve outcome unless 1) the data obtained from the monitoring device is sufficiently accurate to be able 
to influence therapeutic decision making, 2) the data obtained from the monitoring 
system is relevant to the patient being monitored, and 3) changes in management 
made as a result of the data obtained are able to improve outcomes26. If the data 
are interpreted or applied incorrectly, then fluid therapy itself may be ineffective or 
harmful, and the resultant change in management will not improve outcome and may 
even be deleterious26. If these three conditions are not met, monitoring is unlikely to 
be associated with improved outcomes, and this may count for the lack of evidence 
of improved outcomes in critically ill patients with the use of any monitoring device27.
In this thesis we will focus on the pulmonary artery catheter and the transpulmonary 
(thermo)dilution technique and compare both techniques for guiding fluid therapy 
and hemodynamic management in patients with different disease etiologies.  
Pulmonary artery catheter
The pulmonary artery catheter (PAC) has been used for decades for monitoring 
hemodynamics in the perioperative setting or in critically ill patients. By measurement 
of the pulmonary artery occlusion pressure (PAOP) via balloon occlusion of the 
pulmonary artery, an estimation can be made for left ventricular end-diastolic pressure 
as a surrogate for left ventricular preload (Figure 1). In addition, by generating a 
thermodilution curve via a central venous bolus of isotonic saline, right ventricular 
stroke volume and cardiac output (CO) can be measured. The PAC derived PAOP and 
CO provide bedside estimations of left ventricular performance in critically ill patients, 
which may help the clinician diagnose and treat circulatory shock. 
Pulmonary artery occlusion pressure. The PAOP is most often used for assessment of 
(a) pulmonary edema, (b) pulmonary vasomotor tone, (c) intravascular volume status 
and (d) left ventricular performance. In mechanically ventilated patients however, 
the atmospheric pressure referenced PAOP may be confounded by airway pressures 
and may thereby poorly predict cardiac preload, fluid responsiveness, and pulmonary 
capillary filtration28. These technical limitations however are surmountable; by using 
a firm understanding of the technical determinants of PAOP during ventilation, PAOP 
values may be interpreted correctly at the bedside under many circumstances29. 
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Nevertheless, the use of the PAC in general has rapidly decreased over the last decade, 
mainly due to negative results of prospective, randomized trials that failed to show 
any associated clinical benefit30,31.  
 
Figure 1. Pulmonary artery catheter tip pressure tracings and chamber location during placement. 
Specific chamber location and representative tracings are shown for the right atrium (A), right ventricle 
(B), pulmonary artery (C), and pulmonary capillary wedge pressure (D). An entire pulmonary artery 
catheterization pressure tracing is shown in (E). (Modified from Mihm FG, Rosenthal MH: Pulmonary 
artery catheterization. In Benito JL, ed.: Clinical Procedures in Anesthesia and Intensive Care, p 416. 
Philadelphia, JB Lippincott, 1994).
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15General introduction and outline of thesis
1Transpulmonary (thermo)dilution techniqueA relatively new, less invasive hemodynamic monitoring technique is the 
transpulmonary (thermo)dilution technique, which was introduced in the 1990s. This 
technique uses a double-indicator thermal dye dilution, with ice-cold indocyanine 
green allowing intravascular determination of the dye and the thermal signal after 
central venous injection. The mean transit time of the dye (detected in the aorta via 
a femoral artery catheter) multiplied by cardiac output (CO) yields the intrathoracic 
blood volume (ITBV), whereas the mean transit time of the thermal signal multiplied 
by CO yields the intrathoracic thermal volume (ITTV). The CO is derived from the 
transpulmonary thermodilution curve based on the Stewart-Hamilton formula32. 
Combining ITBV and ITTV, additional parameters can be computed such as the global 
end-diastolic volume (GEDV), reflecting cardiac preload, and extravascular lung water 
(EVLW), which reflects the amount of water outside the pulmonary vasculature 
(note: without any distinction between interstitial and alveolar water). This double-
indicator thermal dye dilution technique is however very time consuming and using 
indocyanine green as an intravascular indicator is relatively expensive and requires 
specialized densitometry equipment or a fiberoptic catheter to detect the dye curve. 
Therefore, after validation, the thermal-dye technique has now been replaced by 
the current transpulmonary thermodilution (TPTD) technique allowing simultaneous 
measurement of CO, GEDV and EVLW using a single thermal indicator (Figure 2). 
Furthermore, by using an algorithm based on the analysis of the arterial pulse 
contour, it is possible to continuously monitor cardiac output since the contour of the 
arterial pressure curve is proportional to the stroke volume and pulse pressure33. This 
technique yields beat to beat variations of stroke volume and pulse pressure and thus 
cardiac output in response to changing preload conditions and allows the clinician 
to predict fluid responsiveness without actually giving fluids. It has however been 
demonstrated that these dynamic indices only have predictive value under certain 
conditions, since interpretation of these parameters is highly dependent on multiple 
factors, such as ventilatory settings and heart rhythm34,35. 
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Figure 2. Principles of extravascular lung water (EVLW) estimation by the single-indicator dilution 
method. The intrathoracic blood volume (ITBV) is derived from the measurement of the global end-
diastolic volume (GEDV) with the equation ITBV = 1.25 × GEDV. The difference between the volume 
of distribution of the thermal indicator and ITBV yields EVLW. CO, cardiac output; MTt, mean transit 
time; Dst, down slope time; RA, right atrium; RV, right ventricle; PBV, pulmonary blood volume; LA, left 
atrium; LV, left ventricle. (from: Michard F. Bedside assessment of extravascular lung water by dilution 
methods: Temptations and pitfalls. Crit Care Med 2007;35:1186-1192).
Global end-diastolic volume. Global end-diastolic volume (GEDV) represents the volumes 
of the right and left heart at the end of diastole and often reflects left ventricular 
end-diastolic volume as estimated by echocardiography in the absence of overt right 
ventricular dilatation36 and has been demonstrated to reflect cardiac preload better 
than filling pressures37,38. A relatively low GEDV predicts fluid responsiveness (and a 
relatively high GEDV the absence thereof), but its predictive value is not perfect and 
the role of (right ventricular) systolic and/or diastolic dysfunction remains unclear, even 
though changes in stroke volume or cardiac output correlates to changes in GEDV (or 
intrathoracic blood volume)38-40. Therefore, it may be hypothesized that in patients with 
systolic dysfunction, due to a right- and downward shift of the cardiac function curve, 
pressures may better predict and monitor fluid responsiveness than volumes, which has 
been suggested previously41-43. 
Extravascular lung water. The pathologic accumulation of pulmonary edema 
can be quantified as extravascular lung water (EVLW). Although pulmonary edema 
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17General introduction and outline of thesis
1can be assessed by oxygenation indexes and chest radiographic techniques, EVLW has been shown to be more sensitive than these assessments44,45. EVLW estimated 
by TPTD has been shown to correlate quite closely with EVLW assessed by the 
thermal-dye technique46 and gravimetric measurement47. It the last few years it has 
been demonstrated that a persistently increased EVLW is well correlated with poor 
outcome48,49 while conservative fluid management has shown to reduce the duration 
of mechanical ventilation and length of stay in the ICU in patients with acute lung 
injury5. As has previously been suggested, the use of EVLW as an additional guidance 
for fluid therapy may influence outcome50. Restriction of fluid therapy based on upper 
limits of EVLW may potentially affect duration of mechanical ventilation or even 
outcome.
Outline of the thesis
The first part of this thesis is focused on the controversy of crystalloids versus colloids 
for fluid resuscitation and aims to elucidate the possible (hemodynamic) benefits of 
colloids versus crystalloids weighed against potential harmful side effects. In Chapter 2 
we study whether crystalloid versus colloid fluid loading in patients with sepsis versus 
nonsepsis with clinical hypovolemia may differ with regard to hemodynamic effects. 
In Chapter 3 we will describe the mechanisms of fluid loading on cardiac output and 
review the clinical data regarding the crystalloid-colloid volume ratio in determining 
hemodynamic effects. In Chapter 4 we will discuss the major controversial issues of 
fluid resuscitation in acute lung injury/acute respiratory distress syndrome with regard 
to dosing, timing and choosing the type of fluid. In Chapter 5 we will review the merits 
and detriments, in particular the risk of acute kidney injury, of the use of synthetic 
colloids, as compared to natural colloids and crystalloids in critically ill patients with 
sepsis.  
The second part is focused on hemodynamic monitoring as guidance for fluid 
therapy. We will discuss whether disease etiology and (related) cardiac (dys)function 
may play a distinctive role in using pulmonary artery catheter derived parameters 
versus transpulmonary (thermo)dilution derived parameters for hemodynamic 
management. It may be hypothesized that hemodynamic management based on tool-
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derived parameters may differ among disease etiologies and that interpretation of 
these parameters may be influenced by cardiac (dys)function. In Chapter 6 we will 
compare cardiac filling volumes versus pressures for predicting fluid responsiveness 
after cardiovascular surgery, and examine whether systolic cardiac function may have 
a contributing role. In Chapter 7 we will study whether cardiac dilatation, reflected 
by increased values of global end-diastolic volumes, affects fluid responsiveness 
in sepsis-induced cardiac depression. In Chapter 8 we will review current insights 
concerning the measurement of extravascular lung water as an index of pulmonary 
edema using transpulmonary dilution techniques. Lastly, in Chapter 9 we performed a 
large two center prospective, randomized controlled trial comparing volume-limited 
versus pressure-limited fluid therapy and hemodynamic management in septic and 
nonseptic shock and hypothesized that incorporation of extravascular lung water 
and global end-diastolic volume compared to pulmonary artery occlusion pressure in 
hemodynamic management algorithms may decrease the risk of fluid overloading and 
explored whether septic and nonseptic shock may differ in this respect.  
The results of all studies are summarized and discussed in Chapter 10, together with a 
general discussion and future perspectives.
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Abstract
Background and objective 
The hemodynamics of crystalloid and colloid fluid loading may depend on underlying 
disease, i.e. sepsis vs. nonsepsis.
Design and setting 
A single-center, single-blinded, randomized clinical trial on 24 critically ill sepsis and 24 
nonsepsis patients with clinical hypovolemia, assigned to loading with normal saline, 
gelatin 4%, hydroxyethyl starch 6% or albumin 5% in a 90 min (delta) central venous 
pressure (CVP)-guided fluid loading protocol. Transpulmonary thermal-dye dilution 
was done each 30 min, yielding, among others, global end-diastolic volume and cardiac 
indices (GEDVI, CI).
Results 
Sepsis patients had hyperdynamic hypotension in spite of myocardial depression and 
dilatation, and greater inotropic/vasopressor requirements than nonsepsis patients. 
Independent of underlying disease, CVP and GEDVI increased more after colloid than 
saline loading (p < .018), so that CI increased by about 2% after saline and 12% after colloid 
loading (p = .029). The increase in preload-recruitable stroke work was also greater with 
colloids and did not differ among conditions.
Conclusions
Fluid loading with colloids results in a greater linear increase in cardiac filling, output and 
stroke work than saline loading, in both septic and nonseptic clinical hypovolemia, in 
spite of myocardial depression and presumably increased vasopermeability potentially 
decreasing the effects of colloid fluid loading in the former. 
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Introduction
Hypovolemia is common in septic and nonseptic critical illness and fluid resuscitation is 
aimed at a rapid increase of cardiac output and tissue oxygenation. It is still controversial 
whether crystalloid or colloid (albumin) fluids should be used, since, among others, the 
clinical outcome may not differ according to fluid types or may be even somewhat worse 
for colloids (albumin)1,2. Other studies3,4 suggest that resuscitation with albumin tends to 
benefit morbidity and survival over that with saline during sepsis. 
The crystalloid-colloid controversy includes the role of colloid osmotic pressure (COP) 
in plasma in retaining fluids intravascularly and in the speed and extent by which colloids, 
maintaining COP, restore plasma volume and blood flow as opposed to crystalloids, 
which dilute plasma proteins, lower COP and rapidly leak into the interstitium1,5-9. When 
using crystalloids, 2 to 4 times more fluid may be required to restore and maintain 
intravascular fluid volume compared to colloids1,5-8. This is controversial, however, since, 
for instance, the ratio in the SAFE study comparing albumin with saline resuscitation was 
1:1.3, whereas the rise in central venous and arterial blood pressures was only slightly 
greater with albumin3. A potential difference between fluid types may critically depend 
on underlying disease, so that, during sepsis, a decrease of cardiac function and an 
increase of vasopermeability may attenuate hemodynamic differences between fluids 
by decreasing the slope of the cardiac function curve and diminishing the contribution 
of plasma COP and thus the ability of colloids in retaining fluids intravascularly, 
respectively1,8,10-14. If so, a potential survival benefit of albumin over saline in sepsis4 may 
not relate to its colloid osmotic properties15. Indeed, the colloid-colloid controversy 
refers to the potential of artificial colloids to replace human protein colloids1,2,8. For 
instance, starch infusions may result in better cardiac performance than infusions of 
albumin11, which may have negative inotropic effects via binding of circulating calcium16. 
Finally, controversies may also stem in part from the monitored endpoints for fluid 
resuscitation, which, if imprecise, may mask hemodynamic differences. Absolute (rather 
than changes in) filling pressures of the heart may be poor indicators of cardiac preload 
and fluid responsiveness and global end-diastolic volume, assessed from transpulmonary 
thermodilution, may be superior17-19. In our study on cardiovascular surgery and fluid 
loading guided by (delta) filling pressures, colloid had more effects on plasma volume 
and cardiac filling and output than saline loading9.
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For the current study, the hypothesis was that fluid loading with colloids results in a 
greater increase in preload-recruitable cardiac output and stroke work than saline 
loading, more so in patients with nonseptic than in those with septic clinical hypovolemia 
in the intensive care unit (ICU), because of differences in cardiac and vascular function. 
We thus compared saline with colloids and evaluated COP and cardiac output and 
function, using a standard (delta) central venous pressure-guided fluid challenge 
protocol over 90 min9, verified by the transpulmonary thermal-dye dilution technique17, 
in septic and nonseptic clinical hypovolemia. We also hypothesized for this study that 
exogenous colloids perform similarly to human albumin. 
Patients and methods
 
This is a companion study on the same patients of a prospective study involving 
pulmonary (and few (t=0-90 min) raw hemodynamic) data regarding fluid loading20. 
Patients were included after random assignment (sealed envelope method to 4 
different groups of n=6, both in n=24 sepsis and n=24 nonsepsis patients), to normal 
saline (NaCl 0.9%), or the roughly isooncotic colloid solutions GelofusinR (gelatin 40 
g/L, B Braun Medical, Melsungen AG, Germany, in 154/120 mmol/L NaCl), HemohesR 
(hydroxyethyl starch (HES) 6%; MW 200,000 substitution 0.45-0.55, Braun Melsungen 
AG, Germany, in saline) or albumin 5% (100 mL Cealb® 20%, Sanquin, CLB, Amsterdam, 
The Netherlands, diluted in 300 mL of saline). The inclusion criteria were clinical 
hypovolemia, defined by a systolic blood pressure <110 mmHg, and by a reduced central 
venous pressure (CVP ≤12 mm Hg if positive end-expiratory pressure, PEEP, ≤15 cm H2O, 
and CVP ≤16 mm Hg if PEEP >15 cm H2O) in the presence of a central venous (n=45, or 
pulmonary artery, n=3) catheter inserted in the subclavian or internal jugular vein and 
in the absence of overt major bleeding. Exclusion criteria were age <18 or >78 years, 
pregnancy, preterminal illness with life expectancy <24 hours, recent traumatic brain 
injury, and known anaphylactic reactions to colloids. Sepsis was defined by two or more 
of the following clinical findings: body temperature >38 or <36°C; heart rate (HR) >90/
min; presence of mechanical ventilation; abnormal white blood cell counts >12,000 or 
<4,000 x109/L and a clinically evident or microbiologically proven source of infection. 
The origin of sepsis was defined by clinical signs and symptoms and positive local and/or 
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blood cultures. Nonsepsis was defined as an injury severity score above 15 for multiple 
trauma, gastrointestinal hemorrhage or major, non-cardiovascular surgery, for which 
admission into the ICU was required. 
Measurements. Pressures were measured after calibration and zeroing to 
atmospheric pressure at mid-chest level (Tramscope®, Marquette, Wisc., USA). CVP was 
taken at end-expiration, with patients in the supine position. For the measurement of 
cardiac output (CO), stroke volume (SV) and global end-diastolic volume (GEDV), the 
transpulmonary thermal-dye dilution technique was used9,17,18,20. This involves a central 
venous injection of a dye and thermal bolus, 15 mL of 1 mg/mL indocyanine green in 
an ice-cold (4°C) dextrose 5% solution and concomitant registration of the dye dilution 
and thermal shift in the femoral artery, using a 3F catheter equipped with a thermistor 
and fiberoptic (PV 2024, Pulsion Medical Systems, Munich, Germany) connected to a 
bedside computer (COLD Z-021, Pulsion Medical Systems, Munich, Germany). The 
catheter was introduced via the introducing sheath. Measurements were done in 
duplicate, irrespective of the ventilatory cycle, and averaged values were taken. The 
technique yields the transpulmonary thermodilution CO and GEDV, typically at 10% 
reproducibility (17). CO, SV and GEDV were indexed to body surface area (m2), yielding 
cardiac index (CI, L/min/m2), SV index (SVI, mL/m2) and GEDV index (GEDVI, n 680-800 
mL/m2), respectively. The ratio between SVI and GEDVI/4 is the global ejection fraction 
(GEF, n 0.25-0.35), an index of systolic cardiac function (18). The left ventricular stroke 
work index (LVSWI, gm/m2) was calculated from SVI x (mean arterial pressure (MAP) 
minus CVP) x 0.0136, where the CVP was substituted for the PCWP since in the 3 patients 
in whom the PCWP was measured CVP and PCWP highly correlated (r = .97, p < .001, 
n=15) and differed by only 3±1 mm Hg. The LVSWI to GEDVI/4 relation is denoted as 
preload-recruitable stroke work, another index of systolic cardiac function. Arterial and 
central venous blood samples were obtained for determinations of Hb/Hct, creatinine 
(Sysmex SE-9000, Sysmex Corporation, Kobe, Japan), O2 pressures and saturations. The 
colloid oncotic pressure (COP) was measured by a membrane osmometer (Osmomat 
050, Gonotex, Berlin, molecular cut-off at 20 kDa). Systemic vascular resistance index 
(SVRI), O2 delivery (DO2) and oxygen consumption (VO2) were calculated according to 
standard formulae.
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Protocol. This was started within 3 hrs after surgery or gastrointestinal hemorrhage 
and 12 h after meeting criteria for sepsis. At baseline, patient characteristics and clinical 
data were recorded, including the acute physiology and chronic health evaluation 
(APACHE) II score. Doses of vasoactive drugs, ventilatory settings and hemodynamics 
were recorded. After baseline measurements (t=0 min), fluids were given during 90 min 
on the basis of the response within predefined limits and changes in CVP, according 
to a fluid challenge protocol as described20. Boluses of maximum 200 mL were given 
per 10 min, so that the maximum fluid challenge was 1800 mL in 90 min. Concomitant 
treatment was unchanged. All measurements were repeated after completing the fluid 
challenge (t=90 min). Every 30 min until t=90 min, CVP, CO and GEDV were measured 
also. 
Statistical analysis. The study had 80% power to detect a statistically significant 
difference between saline and colloid fluids (at α<0.05) in fluid loading-induced 
increases in CI, the primary study parameter, of 10% (at standard deviation of 10% of the 
increase). Data are expressed as mean±standard deviation (SD), except in the figures, 
where mean±standard error of mean (SEM) are shown. Data were normally distributed 
(Kolmogorov-Smirnov test), after logarithmic transformation where appropriate. 
We used GEE to test for effect of underlying disease and fluid type on baseline values 
and, taking repeated measurements in the same patients and first order interactions 
into account, on changes in time with baseline values as covariates. Then, interactions 
allowed to assess whether effects of fluid types in time were dependent of underlying 
disease. Fishers exact or X2 tests were used for categorical variables. A similar analysis 
was done to compare colloid fluids. A value of P<0.05 was considered statistically 
significant and exact values >0.001 are reported.  
Results
 
Patient characteristics. Patient characteristics are shown in Table 1, 2 A+B. Groups were 
comparable, except for a higher APACHE II score, creatinine, PEEP, more inotropic/
vasopressor treatment and less diuresis in sepsis (Table 1). More colloid than saline fluid 
had been administered, irrespective of underlying disease.
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Table 1. Patient characteristics.
Nonsepsis Sepsis p value
Saline 
(n=6)
Colloid 
(n=18)
Saline 
(n=6)
Colloid 
(n=18)
U Ty UxTy
Age 54±19 55±17 63±12 59±11 .196 .819 .599
Sex (male/female) 4/2 13/5 5/1 13/5 .563 .805 .563
APACHE II 9±3 11±4 14±6 14±5 .002 .402 .498
Nonsepsis
     Abdominal surgery 4 11
     Polytrauma 1 4
     Spinal surgery 1 2
     Miscellaneous 1
Sepsis
     Abdominal
C. Albicans 1
P. Aeruginosa 2
     Pneumonia
Gram-positive 4
Gram-negative 2 2
M. Tuberculosa 1
C. Albicans 1
A. Fumigatus 1
     Urogenital
E. Coli 1
     Catheter-related sepsis
Gram-positive 3
C. Albicans 1
     Meningitis
S. Epidermidis 1
N. Meningitidis 1
     Unknown focus
Β-Hemolytic 
Streptococcus
1
Bacteremia 1 9
Dopamine, μg/kg/min 0.7±1.2 2.0±2.8 7.2±5.2 5.9±3.6 <.001 .663 .297
Norepinephrine, μg/kg/min 0 0.00±0.02 0.03±0.06 0.09±0.10 .002 .126 .247
PEEP, cm H2O 5.6±0.9 7.9±3.4 7.8±5.6 13.4±4.7 .004 .003 .215
Fluid input t=0-90 min , mL 1642±387 1531±328 1783±41 1380±290 .962 .004 .098
Diuresis t=0-90 min, mL 800±595 496±384 263±198 163±180 .001 .239 .423
Creatinine, μmol/L 77±9 88±22 107±65 153±88 .003 .074 .292
Mortality in the ICU 0 2 (11) 2 (33) 7 (39) For fluid types:
1.0 (nonsepsis)
1.0 (sepsis)
Mean ± SD or number (percentage) where appropriate APACHE acute physiology and chronic health 
evaluation, PEEP positive end-expiratory pressure. p: U underlying disease (sepsis vs. nonsepsis), Ty fluid 
type (saline versus colloids), UxTy interaction. Fishers exact test for mortality. 
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Sepsis patients had hyperdynamic hypotension, as indicated by higher HR and CI 
(after fluid loading) and lower MAP, in spite of myocardial depression and dilatation as 
indicated by higher CVP and GEDVI, and lower GEF and LVSWI (to GEDVI/4 ratio, indicative 
of preload-recruitable stroke work) compared to nonseptic patients, respectively 
(Table 3). Baseline SVRI was lower in sepsis than in nonsepsis (p = .013, data not shown). 
The albumin level was also lower (p < .001). Sepsis carried a higher ICU mortality than 
nonsepsis (p = .017), irrespective of fluid types. 
Table 2A. Patient characteristics: nonsepsis. 
HES 6% (n=6) Gelatin 4% (n=6) Albumin 5% (n=6)
Age (yr) 53±18 54±21 58±15
Sex (male/female) 4/2 5/1 4/2
APACHE II APACHE II APACHE II APACHE II
Nonsepsis:
  Abdominal surgery 4 4 3
  Polytrauma 1 1 2
  Spinal surgery 1 1
  Miscellaneous 1
Dopamine, μg/kg/min 1.0±1.8 3.3±3.6 1.8±2.7
Norepinephrine, μg/kg/min 0.00±0.01 0 0.01±0.03
PEEP, cm H2O 8.2±4.3 8.2±4.3 8.3±4.5
Fluid t=0-90 min, mL 1617±172 1483±422 1492±380
Diuresis, mL 252±121 659±344 537±498
Creatinine, μmol/L 87±19 97±34 82±10
Mortality in the ICU 1 (17) 1 (17) 0
Mean ± SD or number (percentage) where appropriate HES hydroxyethyl starch, APACHE acute 
physiology and chronic health evaluation, PEEP positive end-expiratory pressure. See Table 2B for 
statistics.
Baseline values were comparable among fluid types, except for a slightly lower 
hemoglobin and a higher PEEP and thus CVP in colloid than in saline-loaded patients. 
Hemoglobin levels fell more in colloid than in saline loading whereas COP increased 
in colloid-loaded patients only, irrespective of underlying disease (Table 4). The rises 
in MAP, CVP, GEDVI and CI were greater with colloid than saline loading, independent 
of underlying disease and baseline values (Table 3). Indeed, CVP and CI increased with 
time (t=0, 30, 60, 90 min), dependent on fluid type (p = .007 or lower), irrespective of 
underlying disease (Figure 1).
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Table 2B. Patient characteristics: sepsis.
HES 6% 
(n=6)
Gelatin 4% 
(n=6)
Albumin 5% 
(n=6)
p value
           U                      Ty                UxTy
Age 57±14 60±12 60±9 .419 .70 .953
Sex (male/female) 5/1 4/2 4/2 1.000 .844 .650
APACHE II 14±6 13±5 16±2 .018 .568 .661
Sepsis
     Abdominal
C. Albicans 1
P. Aeruginosa 1
     Pneumonia
Gram-positive 1 1 2
Gram-negative 1 1
M. Tuberculosa 1
C. Albicans 1
     Urogenital
E. Coli 1
    Catheter-related sepsis
Gram-positive 1 2
C. Albicans 1
     Meningitis
S. Epidermidis 1
     Unknown focus
Β-Hemolytic Streptococcus 1
Bacteremia 1 6 2
Dopamine (μg/kg/min) 5.9±4.2 6.9±1.5 4.8±4.5 <.001 .135 .589
Norepinephrine (μg/kg/min) 0.07±0.13 0.07±0.06 0.11±0.12 <.001 .531 .880
PEEP (cm H2O) 10.8±4.7 14.2±4.3 14.5±4.1 <.001 .180 .515
Fluid input t=0-90 min (mL) 1358±344 1317±240 1467±308 .126 .729 .603
Diuresis t=0-90 min (mL) 149±101 96±59 244±288 <.001 .018 .005
Creatinine (μmol/L) 174±117 151±62 134±90 .002 .660 .797
Mortality in the ICU 3 (50) 2 (33) 2 (33) For fluid 
types: 
.80 nonsepsis
.80 sepsis
Mean ± SD or number (percentage) where appropriate HES hydroxyethyl starch, APACHE acute physiology 
and chronic health evaluation, PEEP Positive End-Expiratory Pressure. p: U underlying disease (sepsis vs. 
nonsepsis) Ty fluid type (HES versus gelatin versus albumin), UxTy interaction. X2 test for mortality.
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Table 3. Hemodynamics.
Nonsepsis Sepsis p value
Saline 
(n=6)
Colloid 
(n=18)
Saline 
(n=6)
Colloid 
(n=18)
U Ty UxTy
HR, beats/min
t=0 min 72±27 69±19 93±33 97±22 .004 .964 .721
t=90 72±28 70±17 89±29 98±18 .411 .165 .115
MAP, mm Hg
t=0 min 82±12 82±15 74±10 75±10 .033 .889 .804
t=90 84±6 93±15 83±10 89±16 .212 .004 .398
CI, L/min/m2
t=0 min 3.6±1.4 3.8±1.7 4.3±1.2 3.7±1.1 .450 .621 .342
t=90 3.5±1.2 4.1±1.1 4.6±0.9 4.4±1.3 .001 .029 .371
CVP, mm Hg
t=0 min 4±4  6±3 5±2 8±4 .064 .003 .319
t=90 5±3  9±3 6±4 13±4 .180 <.001 .551
SVI, mL/m2
t=0 min 51±9  55±15 5224 3912 .147 .434 .114
t=90 49±9  60±13 4617 4512 .330 .059 .009
GEDVI, mL/m2
t=0 min 664±102 813±234 698±264 846±215 .010 .832 .039
t=90 653±117 898±276 1029±215 921±232 .276 .018 .117
LVSWI, gm/m2
t=0 min 55±14 5±715 50±25 35±10 .022 .248 .139
t=90 54±13 69±15 60±22 46±13 .706 .040 .005
GEF
t=0 min 0.31±0.05 0.28±0.06 0.21±0.06 0.19±0.07 <.001 .198 .756
t=90 0.31±0.06 0.28±0.06 0.22±0.05 0.20±0.07 .568 .895 .890
DO2 ,mL/min/m
2
t=0 min 533±204 495±173 623±217 474±145 .979 .110 .184
t=90 546±149 498±156 667±272 505±143 .262 .511 .568
VO2 ,mL/min/m
2
t=0 min 106±50 140±48 148±68 127±61 .999 .609 .301
t=90 124±38 138±64 163±78 125±66 .901 .902 .192
Mean ± SD 
HR heart rate, MAP mean arterial pressure, CI cardiac index, CVP central venous pressure, SVI stroke volume 
index, GEDVI global end-diastolic volume index, LVSWI	left ventricular stroke work index, GEF global ejection 
fraction, DO2 oxygen delivery, VO2 oxygen consumption, p : U underlying disease (sepsis vs. nonsepsis), Ty 
fluid type (saline versus colloids), UxTy, interaction. 
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The latter shows that the increases of GEDVI (t=0, 30, 60, 90 min) were greater with 
colloid than saline loading in septic and nonseptic patients (p = .003). Indeed, the 
change in GEDVI predicted the change in CI (p < .001), irrespective of underlying disease 
or fluid types. However, the rise in SVI and LVSWI with saline loading was greater in 
sepsis than in nonsepsis patients, but greater in colloid than in saline-loaded patients 
(Figure 2). The S
cv
O2 increased, particularly in the colloid-loaded patients with nonsepsis, 
while lactate levels did not change. DO2 increased and VO2 was unchanged, independent 
of underlying disease and fluid type. 
Baseline values did not differ among colloid fluid types. Albumin loading increased 
albumin levels; COP similarly increased with all colloid fluids, irrespective of underlying 
disease. The lactate level decreased with HES and albumin (Table 5 A+B). For the 
increase in CI (from 0-30-60-90 min), there was no difference among underlying diseases 
and fluid types and the increase in CVP and GEDVI was greatest with HES (p = .012, 
p = .029 respectively), irrespective of underlying disease (Table 6 A+B). However, 
preload-recruitable stroke work was comparable between colloid fluid types (Figure 3). 
Table 4. Biochemical data.
        Nonsepsis             Sepsis p value
Saline 
(n=6)
Colloid 
(n=18)
Saline 
(n=6)
Colloid 
(n=18)
U Ty UxTy
Hemoglobin, mmol/L 
t=0 min 6.9±1.1 5.7±1.1 6.2±1.4 5.4±0.5 .134 .009 .548
t=90 6.7±0.8 5.0±0.8 5.9±1.3 4.7±0.5 .205 <.001 .385
Colloid osmotic pressure, mm Hg
t=0 min 15±2 15±3 15±3 16±2 .693 .444 .800
t=90 13±1 19±3 14±3 19±2 .993 <.001 .737
S
cv
O2
t=0 min 0.80±0.04 0.76±0.09 0.78±0.04 0.76±0.09 .471 .125 .552
t=90 0.80±0.07 0.80±0.09 0.81±0.05 0.77±0.08 .920 .514 .030
Lactate, mmol/L
t=0 min 1.3±0.7 1.4±0.8 1.6±1.3 1.8±0.8 .326 .548 .913
t=90 1.2±0.6 1.4±0.8 1.6±1.2 1.7±0.7 .638 .897 .424
Mean ± SD 
ScvO2 central venous oxygen saturation, p: U underlying disease (sepsis vs. nonsepsis), Ty fluid type (saline 
versus colloids), UxTy interaction.
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Figure 1. a. Mean±SEM for cardiac index (CI) versus global end-diastolic volume index (GEDVI) according 
to fluid type (A saline; B colloid), at four time points of fluid loading, in nonsepsis patients. b. Mean±SEM 
for cardiac index (CI) versus global end-diastolic volume index (GEDVI) according to fluid type (A saline; 
B colloid), at four time points of fluid loading, in sepsis patients. For GEDVI and CI: increases differed 
between fluid types (p = .007 or lower), indicating greater rises in colloid than in saline-loading, irrespective 
of underlying disease.
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Figure 2. Mean ± SEM for left ventricular stroke work index (LVSWI) versus global end-diastolic volume 
index (GEDVI/4) as index of preload-recruitable stroke work, in nonsepsis and sepsis, according to fluid 
types. The figure suggests myocardial depression of sepsis (vs. nonsepsis) and increases of preload-
recruitable stroke work that are greater with colloids than saline, particularly in nonseptic patients (for 
statistics see Table 3).
Table 5A. Biochemical data: nonsepsis.
HES 6% (n=6) Gelatin 4% (n=6) Albumin 5% (n=6)
Hemoglobin, mmol/L
t=0 min 5.2±0.9 5.7±0.7 6.3±1.4
t=90 4.6±0.8 5.1±0.6 5.4±0.7
Albumin, g/L
t=0 min 18±4 19±5 19±4
t=90 15±3 16±4 31±6
Colloid osmotic pressure, mm Hg
t=0 min 14±3 16±3 16±3
t=90 19±4 19±2 18±2
S
cv
O2
t=0 min 0.71±0.09 0.79±0.06 0.80±0.09
t=90 0.76±0.11 0.83±0.04 0.82±0.08
Lactate, mmol/L
t=0 min 1.4±0.8 1.5±1.1 1.5±0.5
t=90 1.4±0.7 1.5±1.1 1.4±0.5
Mean ± SD 
HES hydroxyethyl starch, S
cv
O2 central venous oxygen saturation. See Table 5B for statistics.
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Table 5B. Biochemical data: sepsis.
HES 6% 
(n=6)
Gelatin 4% 
(n=6)
Albumin 5% 
(n=6)
p value
       U             Ty         UxTy
Hemoglobin, mmol/L
t=0 min 5.8±0.7 5.1±0.4 5.3±0.3 .187 .444 .036
t=90 5.0±0.7 4.5±0.2 4.6±0.3 .525 .729 .558
Albumin, g/L
t=0 min 12±4 12±1 11±2 <.001 .903 .737
t=90 10±3 10±1 27±3 .151 <.001 .236
Colloid osmotic pressure, mm Hg
t=0 min 15±2 17±2 15±2 .483 .171 .724
t=90 19±2 20±2 18±2 .715 .097 .547
S
cv
O2
t=0 min 0.76±0.12 0.76±0.08 0.77±0.07 .934 .441 .442
t=90 0.76±0.11 0.77±0.09 0.79±0.05 .070 .795 .670
Lactate, mmol/L
t=0 min 1.9±1.0 1.5±0.5 2.0±0.9 .188 .647 .566
t=90 1.7±0.8 1.6±0.6 1.7±0.7 .495 .029 .142
Mean ± SD
HES hydroxyethyl starch, ScvO2 central venous oxygen saturation, p: U underlying disease (sepsis vs. 
nonsepsis), Ty fluid type (HES versus gelatin versus albumin), UxTy interaction.
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Figure 3. Mean ± SEM for left ventricular stroke work index (LVSWI) versus global end-diastolic volume 
index (GEDVI/4) as index of preload-recruitable stroke work, in nonsepsis and sepsis, according to fluid 
types (A+D, HES; B+E, Gelatin; C+F, Albumin). For statistics: see Table 6B. The figure suggests myocardial 
depression of sepsis (versus nonsepsis) and increases of preload-recruitable stroke work independent of 
underlying disease and fluid type.
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Table 6A. Hemodynamics: nonsepsis.
HES 6% (n=6) Gelatin 4% (n=6) Albumin 5% (n=6)
HR, beats/min
t=0 min 63±21 67±16 78±19
t=90 66±18 70±20 74±16
MAP, mm Hg
t=0 min 84±20 84±15 78±8
t=90 96±16 96±12 87±16
CI, L/min/m2
t=0 min 3.4±1.5 3.8±0.9 4.4±2.7
t=90 3.5±1.0 4.2±0.9 4.6±1.5
CVP, mm Hg
t=0 min 6±2 5±4 6±4
t=90 10±1 8±4 9±4
SVI, mL/m2
t=0 min 54±13 61±18 51±18
t=90 55±12 63±18 63±9
GEDVI, mL/m2
t=0 min 711±101 887±256 873±340
t=90 768±149 947±317 1030±351
LVSWI, gm/m2
t=0 min 55±11 64±22 50±13
t=90 64±12 73±21 721±1
GEF 
t=0 min 0.30±0.06 0.28±0.05 0.25±0.08
t=90 0.29±0.05 0.27±0.05 0.27±0.10
DO2 ,mL/min/m
2
t=0 min 398±122 561±128 558±248
t=90 390±83 549±176 596±140
VO2 ,mL/min/m
2
t=0 min 126±33 143±47 159±71
t=90 137±66 113±57 170±72
Mean ± SD
HES hydroxyethyl starch, MAP mean arterial pressure, CVP central venous pressure, CI cardiac index, SVI 
stroke volume index, GEDVI global end-diastolic volume index, LVSWI	left ventricular stroke work index, 
GEF global ejection fraction, DO2 oxygen delivery, VO2 oxygen consumption. See Table 6B for statistics.
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Table 6B. Hemodynamics: sepsis.
HES 6% 
(n=6)
Gelatin 4% 
(n=6)
Albumin 5% 
(n=6)
p value
         U               Ty             UxTy
HR, beats/min
t=0 min 95±33 96±14 100±18 <.001 .88 .809
t=90 102±26 85±13 97±16 .049 .147 .323
MAP, mm Hg
t=0 min 73±8 76±13 77±10 .094 .902 .442
t=90 89±13 94±17 84±18 .708 .216 .759
CI, L/min/m2
t=0 min 3.7±1.2 4.1±1.5 3.3±0.6 .810 .698 .584
t=90 4.4±1.5 4.7±1.4 4.0±1.0 .050 .677 .512
CVP, mm Hg
t=0 min 7±1 10±5 9±4 .012 .515 .273
t=90 12±2 13±6 13±4 .072 .041 .401
SVI, mL/m2
t=0 min 41±8 43±19 35±8 .001 .391 .080
t=90 43±6 50±18 4±212 .249 .007 .117
GEDVI, mL/m2
t=0 min 882±31 790±163 864±334 .783 .634 .670
t=90 987±62 826±163 945±350 .400 .022 .126
LVSWI, gm/m2
t=0 min 37±11 36±13 32±8 <.001 .265 .670
t=90 46±13 52±15 40±12 .618 .046 .126
GEF 
t=0 min 0.18±0.04 0.22±0.09 0.17±0.06 <.001 .370 .405
t=90 0.18±0.03 0.25±0.09 0.19±0.07 .618 .046 .271
DO2 ,mL/min/m
2
t=0 min 496±73 534±234 402±87 .604 .237 .097
t=90 502±168 558±116 456±148 .699 .293 .444
VO2 ,mL/min/m
2
t=0 min 116±96 153±41 117±23 .445 .492 .451
t=90 114±62 150±92 113±43 .512 .816 .236
Mean±SD
HES hydroxyethyl starch, MAP mean arterial pressure, CVP central venous pressure, CI cardiac index, SVI 
stroke volume index, GEDVI global end-diastolic volume index, LVSWI left ventricular stroke work index, 
GEF global ejection fraction, DO2 oxygen delivery, VO2 oxygen consumption. p: U underlying disease (sepsis 
vs. nonsepsis), Ty fluid type (HES versus gelatin versus albumin), UxTy interaction.
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Discussion
 
As expected, sepsis patients had lower baseline albumin levels, presumably following 
increased vasopermeability, and MAP, but higher HR and cardiac filling than nonsepsis 
patients. The latter may have resulted from myocardial depression, characteristic for 
severe sepsis, as shown by a lower GEF and down- and rightward displacement of 
preload-recruitable stroke work10. Nevertheless, the hemodynamic response to fluid 
loading was similar to that in nonsepsis, in disagreement with the literature10. The slope 
of preload-recruitable stroke work did not differ among fluid types, suggesting unaltered 
cardiac function during fluid loading, so that the difference between fluid types in 
cardiac output responses were primarily caused by differences in filling. However, a rise 
in LVSWI that, in contrast to cardiac filling and output, seemed somewhat greater in 
saline loading in sepsis than in nonsepsis patients, can be explained in part by a greater 
effect on SVI. The greater cardiac filling and output with colloid than with saline loading 
maintained in sepsis, argue against increased vasopermeability that may increase 
(rapid) equilibration of infused proteins and artificial colloids with the extravascular 
space and thereby limit the intravascular retention of fluids, but such effect in more 
severely ill septic patients with higher permeability cannot be excluded1,7,8,12. We neither 
can exclude a slowly increased extravasation of colloids in sepsis, even though nearly 
complete equilibration between the intra- and extravascular space is expected within 
90 minutes7. The similar COP in sepsis and nonsepsis after colloid fluid loading agrees 
with the literature showing that colloid/albumin solutions are able to increase, at 
least transiently, a low COP/albumin in critically ill patients with sepsis and shock6,7,12. 
Our results may also help explain a potential survival benefit of albumin over saline 
resuscitation in sepsis3. In animal experiments, some authors13,14 found that, even in sepsis 
and shock, colloids were effective, and even more so than crystalloids, in maintaining 
COP, cardiac filling and output. Otherwise, that colloids, per unit volume and time, are 
better able to recruit cardiac preload than rapidly extravasating crystalloid solutions 
is in line with our previous study in cardiovascular surgery patients with less elevated 
permeability9,20. When using crystalloids, 2 to 4 times more fluid may be required to 
restore and maintain intravascular fluid volume compared to colloids, but true evidence 
is scarce1,5-7,9. Our results agree with the idea, even in septic clinical hypovolemia, since 
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the difference in cardiac output increase multiplied by the difference in volume infused 
was 3 for colloids versus saline. The ratio in the SAFE study3 comparing albumin with 
saline resuscitation was 1:1.3, however. This can be explained by either insufficient need 
for fluid resuscitation, severely increased permeability, poor monitoring and guidance 
of therapy, or combinations. The current data finally indicate that our clinical criteria 
were useful in selecting patients with, on average, a linear increase in cardiac output 
upon fluid loading in the steep part of the cardiac function curve.
There was no evidence for a different hemodynamic effect among colloid solutions 
(at roughly isooncotic concentrations), in accordance with the literature6,19. This may 
refute the clinical suggestion of a negative inotropic effect of albumin infusion11,16, the 
experimental observations that albumin may have a positive inotropic effect after 
endotoxin injection21, and the idea that HES may plug leaks and thereby exert a greater 
hemodynamic benefit than albumin infusion11,13. Nevertheless, we cannot exclude that 
the study was too small to detect small differences among colloid fluids. However, it 
was apparently not too small to reveal a small effect of HES as compared to gelatin and 
albumin, irrespective of underlying disease. Even though the rise in CVP and GEDVI was 
greater and the rise in SVI was smaller with HES than with gelatin or albumin, the slopes 
of preload-recruitable stroke work did not significantly differ, suggesting similar cardiac 
contractility during loading with HES as compared to that with gelatin or albumin. 
Although groups differed in baseline serum creatinine levels and urinary output during 
fluid infusion, with greater impairments in the sepsis group, the diuretic response to 
HES was particularly diminished in the nonsepsis group in spite of presumably similar 
renal function as in the other fluid groups, in line with the potential adverse effects of 
HES on the kidney. Impaired diuresis may have contributed to the seemingly greater 
cardiac preload response following HES. The somewhat greater fall in lactate with HES 
and albumin than with gelatin loading can be attributed to somewhat higher baseline 
values in the former.
The limitations of our study include the coincidental imbalance in hemoglobin and 
CVP between fluid types at baseline. The latter can be explained by a coincidental 
imbalance in PEEP and the effect of transmitted airway pressure on atmospheric 
pressure-referenced CVP. We did not measure mixed venous SO2, which may be lower 
than S
cv
O2. However, changes may be similar, so that the unchanged VO2 is probably true. 
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The increase in DO2 did not differ among fluid types since a higher cardiac output was 
offset by greater hemodilution after colloid than saline loading. The relatively high S
cv
O2 
and low lactate levels may otherwise imply adequate tissue oxygenation. Admittedly, 
the number of patients in this study was relatively small, but sufficient for analyses of 
fluid pathophysiology, the principal aim, rather than therapy, of our study. Finally, we 
cannot exclude that infusion of even more saline, for instance guided by GEDVI19, would 
have resulted in greater rises in preload-recruitable CI and LVSWI. By comparing (and 
pooling) different, roughly isooncotic colloid fluids, our study carries the advantage over 
others, in which only one or two colloid fluid types were studied3,4,6,7,12,13,19, of evaluating 
the contribution of COP independent of other fluid properties. Finally, most studies, 
unlike ours, did not separate effects in sepsis from those in nonsepsis2,3,6. 
In conclusion, fluid loading with colloids results in a greater linear increase in 
cardiac filling, output and stroke work than saline loading, in both septic and nonseptic 
clinical hypovolemia, in spite of myocardial depression and presumably increased 
vasopermeability potentially decreasing the effects of colloid fluid loading in the former. 
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Introduction
Fluid infusion is a key element in the treatment of critically ill patients with hypovolemia 
and shock. The debate on the relative merits and detriments of (isotonic) crystalloid 
versus (roughly isooncotic) colloid fluids is ongoing. Large clinical trials and systemic 
reviews suggest that the use of one fluid type over the other does not affect overall 
mortality, but this similarity does not exclude heterogeneity of effects on hemodynamics, 
adverse effects and outcome among patient populations, so that benefits may be offset 
by detriments in some but not in other patient populations1-7. In the SAFE study, for 
instance, albumin 4% versus saline loading may improve survival of septic patients but 
not of those with traumatic brain injury1.  
This narrative review of the available literature on the topic is meant to summarize 
current knowledge on the hemodynamic differences, if any, between the fluid types, 
governed by heart function and underlying condition on the one hand and infusion 
volume on the other, since, in contrast to standard textbook statements, review 
papers, guidelines and common beliefs4,5,8, the volume of crystalloid required may not 
be 3 to 4 times the volume of colloid in the treatment of hypovolemia and shock1,3,6,7. 
This is an important issue in an era where fluid restriction policies to avoid harmful fluid 
overloading are increasingly propagated, taking the relative, dose-dependent adverse 
effects of fluid types into account3,4,6. 
First, we will review the mechanisms of a cardiac output increase with fluid loading. 
Second, we will review the clinical data regarding the crystalloid-colloid volume ratio in 
determining hemodynamic effects, excluding hypertonic or hyperoncotic solutions and 
animal studies. We will not address the issue of balanced versus unbalanced solutions 
either.
How does fluid loading increase cardiac output?
The response of the heart to fluid loading is far more complex than usually assumed. It 
is commonly believed that fluid infusion increases cardiac output by increasing plasma 
volume. However, this relationship may not be straightforward when infused fluids are 
differently partitioned in stressed and unstressed plasma volume compartments and 
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thereby variably increase end-diastolic volume, as demonstrated for instance in cardiac 
surgery patients9,10. Figure 1 shows the relation between plasma volume changes 
calculated from hemoglobin/hematocrit changes, which may have shortcomings, and 
changes in global end-diastolic volume upon crystalloid or colloid loading in septic 
and nonseptic patients that do not differ in this respect in spite of septic myocardial 
depression (unpublished data from ref 11). This relatively loose relationship confirms 
earlier findings and suggests that the relationship between plasma volume and cardiac 
filling and output, apart from measurement difficulties, is not straightforward9,11,12. 
Although end-diastolic volume of the ventricles (preload) is an important determinant 
of cardiac output, fluid loading may also affect blood viscosity and may (thereby) lower 
cardiac afterload and increase contractility, both in healthy volunteers as well as in 
critically ill septic or nonseptic patients, so that changes in cardiac output upon fluid 
loading are not solely determined by changes in preload9-11,13-15. Finally, baseline loading 
and function of both ventricles and their interaction may affect the (mechanisms of the) 
cardiac output increase with fluid loading16. Indeed, fluid responsiveness, i.e. the increase 
in stroke volume or cardiac output upon fluid loading, is not only a matter of (type and 
volume) of fluid infused but also of baseline biventricular filling and (systolic and diastolic) 
function, that may differ among patients, conditions and stages of disease. Conversely, 
the imperfect and sometimes controversial value of parameters thought to help predict 
fluid responsiveness is partly related to the complexity of effects of fluid loading on the 
heart and differences herein among patients and conditions. Otherwise, the increase 
in cardiac output with fluid loading mostly outweighs concomitant hemodilution, so 
that O2 delivery is increased, but a potential difference in hemodynamic effects of fluid 
types may not translate in a difference in tissue oxygenation, when a greater increase in 
cardiac output is offset by greater hemodilution (with colloids)10,11,17-19. 
More saline than colloid needed?
One of the arguments used in favor of colloids is that their infusion increases plasma 
volume and cardiac preload more (rapidly) than that of crystalloids4,12. If colloids are 
capable of expanding the plasma volume to a greater extend than crystalloids, then the 
same volume of colloids would have greater effects on hemodynamics than crystalloids. 
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Figure 1. Loose correlation between the change in plasma volume and the change in global end-diastolic 
volume index (GEDVI) after 90 minutes of fluid loading in septic and nonseptic patients, according to fluid 
types (unpublished data from ref. 11): r = .51, p <.001.
The volume ratio of crystalloid to colloid relative to hemodynamic effectiveness 
depends on the rate and fate of the infused fluids and the hemodynamic monitoring 
tool and endpoint utilized. The hemodynamic endpoint of resuscitation varies from one 
study to the other between clinical judgment, arterial and central venous pressures, 
to pulmonary artery occlusion pressures and cardiac output and variables obtained 
by transpulmonary thermodilution. The variety is likely responsible, in part, for the 
widely varying volume ratios during resuscitation reported in the literature. In the 
SAFE study (comparing albumin with saline), for instance, the volume and rate of fluid 
administration was determined by treating clinicians according to each patients clinical 
status and response to treatment, without using a specific fluid loading protocol1. 
This resulted in an albumin to saline volume ratio of 1.4 to 1, but also in higher central 
venous pressures in the albumin group, suggesting dissimilar resuscitation. Conversely, 
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judging the difference in hemodynamic effects during fixed and similar volume infusions 
depends on the parameter that is monitored to judge that response and how well 
the parameter reflects (changes in) plasma volume, which is only rarely (and certainly 
not routinely) measured9-12,17,18,20-23. For instance, in a fluid non-responsive state, in the 
presence of severe cardiac dysfunction, the type of fluid infused would not translate into 
hemodynamic differences upon infusion, irrespective of plasma volume changes. We 
now elaborate on the theoretical and the practical differences reported in the literature 
on the hemodynamic effects and volume ratios of (isotonic/isooncotic) crystalloid and 
colloid fluids.  
Theory: fluid properties
 
In theory, crystalloid solutions expand the plasma volume by about 200 mL per liter 
infused, concomitantly with lowering, by diluting circulating proteins, of plasma colloid 
osmotic pressure (COP), as indeed demonstrated in patients4,10-12,21,24-26. Depending 
on the rate of infusion, the equilibration rate of crystalloid with the interstitial space 
is rapid (minutes) even in patients with hypovolemia or shock, thereby resulting 
in potentially harmful interstitial overhydration4,17-19,26-29. In theory, crystalloids thus 
need to be administered at volumes approximately 3 to 5-fold greater than those of 
(isooncotic) colloids, that are largely maintained in the plasma compartment because of 
maintenance of COP, in order to achieve comparable plasma volumes and resuscitation 
endpoints4,8,10,11,24-26,30. Conversely, the intravascular COP after colloid infusion is influenced 
by baseline COP, the degree of hemodilution and the COP of the infused volume and its 
plasma retention, determined by the molecular weight distribution. Albumin solutions 
are monodisperse (molecular weight of 69 kDa). Gelatins are polydisperse and in 
excess of 75% of the molecules are thought to be smaller than the renal threshold of 30 
kDa. The large number of small molecules exerts a powerful initial COP effect making 
gelatins good for short-term volume expansion, but molecules with a molecular weight 
less than 15 kDa have a similar clearance to that of creatinine and will be filtered by the 
glomerulus. They are thus rapidly cleared from the intravascular space, with a half-life 
of 3.5-4 hours8. Hydroxyethyl starch solutions are very polydisperse, defined by degree 
of substitution (via partial hydrolysis) and by molecular weight, both of which affect 
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pharmacokinetics8,30. The greater the degree of substitution the greater the resistance 
to degradation, which therefore prolongs the effectiveness of hydroxyethyl starch as 
a plasma expander. After substitution, the starch is refined into the final product by 
hydrolysis to the required molecular weight. The molecular weight distribution can be 
described using the COP50/COP10 ratio8,30. This is the ratio of measured COP’s across 2 
different membranes, with a 50-kDa and a 10-kDa pore size, respectively, and reflects 
the relative proportion of molecules retained by filters with those pore sizes. Colloids 
with a low COP50/COP10 ratio will be lost more rapidly from the intravascular space. 
Small particles with a low molecular weight exert a greater COP effect and, for a given 
number of molecules, will have a lower viscosity than larger molecules. Thus, the 
concentration and molecular weight of colloid molecules and hence the COP, determine 
the initial degree of volume expansion, whereas both the molecular weight and surface 
charge characteristics determine the rate of loss through the capillary endothelial 
barrier and loss into the urine by glomerular filtration. Therefore, the intravascular 
retention and half time of colloids amount to hours, dependent on dispersion and 
weight of molecules. Conversely, plasma volume expansion differences with crystalloid 
fluid infusions may depend on time19. In addition, (endothelial) properties of the 
vessel wall and overlying luminal glycocalyx, which may change in disease states, may 
ultimately affect permeability (for proteins and colloids) and hydraulic conductance 
(to plasma water)4. Due to its electrostatic properties, albumin penetrates and binds 
to the endothelial surface glycocalyx and influences its barrier function. The resulting 
sealing effect may attenuate fluid extravasation independently of the COP by albumin. 
Similarly, large hydroxyethyl starch molecules have been claimed to ‘seal pores’ but the 
clinical significance thereof is not yet convincingly demonstrated. During conditions 
with increased vasopermeability as in septic shock, albumin or starch administration 
may help in ameliorating the permeability defect on the one hand but may increasingly 
filtrate into the interstitium on the other thereby attenuating the potential superiority 
of colloids in increasing plasma volume17,21,22,31,32. Finally, hypovolemia and shock are likely 
to lower capillary hydrostatic filtration pressure and promote resorption of interstitial 
fluids, so that intravascular retention of infused fluids may differ from that in normal 
individuals, without negating potential differences between fluid types29,33. We will 
now summarize the evidence obtained in clinical practice for the volume differences 
between fluid types.
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Practice
Volunteers 
A recent study in healthy volunteers demonstrated that for the same volume of 
administered fluids, saline was a less effective plasma volume expander than gelatin 4% 
and hydroxyethyl starch 6%, which did not differ in this respect up to 6 h after starting 
infusion34. After infusion, 68%, 21% and 16% of the infused volumes of saline, gelatin and 
starch, respectively, had escaped from the intra- to the extravascular space, as estimated 
from hematocrit/hemoglobin changes. This indeed concord with a 3-fold greater (and 
prolonged) effectiveness, for a given volume infused, of colloids than of crystalloids in 
plasma volume expansion26. 
Iso- or normovolemic hemodilution
Anesthetized patients undergoing hemodilution and receiving 3 times the volume of 
crystalloid for each unit of blood removed, or the same volume of (icooncotic) colloid 
fluid for the volume of blood removed achieved similar hemodynamic endpoints35. 
In volunteers receiving equal volumes of crystalloid or colloid for a given volume of 
withdrawn blood, the latter had better restoration of hemodynamics, unless twice the 
volume of crystalloid was given27,33. 
Perioperative states and trauma
Following spinal anesthesia, fluid requirements of colloids were higher than during 
crystalloid-based regimens, resulting in higher cardiac outputs in the former36. The 
increase in plasma volume, for a given fluid infusion volume, was about 5x greater 
with albumin 5% than with crystalloid after cardiac surgery9,18. Older studies already had 
suggested that colloid resuscitation required about twice less volume than that with 
crystalloids in reaching similar hemodynamic endpoints during and after (cardiovascular) 
surgery thereby avoiding some postoperative complications of fluid overload21,24,25,29,37-44. 
During emergency resuscitation from trauma and hemorrhage, colloid regimens were 
more (rapidly) effective in restoring the circulation than crystalloid regimens, at volume 
ratios of about 1 to 345,46. More recently, Lang et al. again demonstrated that for reaching 
the same central venous pressure in patients after major abdominal surgery, 2-fold 
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higher volumes of Ringer’s lactate than hydroxyethyl starch 6% were required47. Verheij 
et al. showed that 4-6% colloid fluid loading (for 90 min) according to changes in filling 
pressures after cardiac or major vascular surgery resulted in a 4-fold greater increase 
in preload-recruitable stroke work than that with saline, because of a greater plasma 
volume expansion following an increase in plasma COP, whereas about 15% less colloid 
than crystalloid was administered (volume ratio about 1.2:1; ref. 10). A recent study in 
postoperative patients with hypovolemia showed that the administration of different 
types (but similar volumes) of colloids was associated with greater increases in cardiac 
filling, output and O2 delivery than that of Ringer’s lactate
19. 
Sepsis 
Ernest et al. suggested that albumin 5 % infusion results in greater fluid extravasation in 
septic than in nonseptic patients, but the (5-fold) superiority over saline in expanding 
the plasma versus interstitial volumes, per fluid volume administered, was maintained17. 
Hence, twice the volume of saline was needed to reach the same hemodynamic 
endpoints as with albumin 5% loading. Nevertheless, Marx et al. suggested that 
severe septic shock accompanied by clinical evidence of a capillary leak syndrome was 
associated with shorter and less intravascular retention of intravenously administered 
albumin 20% than in controls22. The VISEP trial documented that target values of 
central venous pressure in severe sepsis were reached faster with hydroxyethyl starch 
10% loading than that with Ringer’s lactate, at an averaged volume ratio of 1:1.3, but 
mortality did not differ3. The central venous pressure and central venous O2 saturation 
in the hydroxyethyl starch group were somewhat higher than in the Ringer’s lactate 
group, perhaps suggesting underestimation of saline requirements or overinfusion of 
starch. Trof et al., however, demonstrated, in perhaps less severely ill septic patients, 
that 90 min fluid loading with 4-6% colloids results in greater linear increase in cardiac 
filling, output and left ventricular stroke work than that with saline loading both in septic 
and nonseptic patients, probably due to a larger plasma volume following increased 
COP with the former and in spite of the characteristic myocardial depression of sepsis11. 
The effectiveness of colloids was 3-fold greater than of saline, regardless of underlying 
condition, even though about 17% more crystalloid was infused (volume ratio 1.2:1 see 
electronic supplement to ref. 11), confirming older data suggesting 2 to 5-fold greater 
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fluid requirements with crystalloids in hypovolemic and septic shock aiming at similar 
hemodynamic endpoints28,48. In children with Dengue shock syndrome, Ringer’s lactate 
administration resulted in higher hematocrits, lower arterial (pulse) pressures and 
cardiac outputs, and slower shock reversal than that of (similar volumes of) colloids2,32. 
In children with septic shock, up to 67% more saline than gelatin (volume ratio 1.7:1) was 
required to reach similar plasma volume and hemodynamic targets23.
General critical conditions 
In patients with respiratory insufficiency and hemodynamic instability from sepsis 
or nonsepsis, Ringer’s lactate was compared to 5% albumin infusions to maintain 
hemodynamic ‘stability’49. In attaining similar hemodynamics, 1.8 volume of crystalloid 
for 1 volume of colloid had to be infused, although the difference did not reach statistical 
significance49. As mentioned, the SAFE study1 compared 4% albumin with saline, guided 
by clinical parameters, and the volume ratio was about 1:1.4. 
Conclusion
Although a mortality benefit has not been documented, the use of (isooncotic) colloids 
results in more (rapid) plasma volume expansion and hemodynamic optimization 
than resuscitation with (isotonic) crystalloids, in a variety of conditions, even when 
accompanied by presumed increased vasopermeability. Although recently suggested 
otherwise, the volume ratio for similar hemodynamic endpoints is approximately 1 
colloid to 3 crystalloids. The factor is maintained when multiplying lower ratios, when 
applied, with the difference in hemodynamic endpoints attained. In randomized 
trials comparing colloids with crystalloids for fluid resuscitation and deviating from 
the ratio, the accurateness of hemodynamic monitoring and guiding of fluid therapy 
should be evaluated. Indeed, potential dissimilar resuscitation among groups may 
confound interpretation of relative benefits and detriments of solution types and future 
metaanalyses should take that disparity into account. 
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Introduction
The ongoing debate on fluid resuscitation includes effects of timing, dosing, and choosing 
the type of fluid on pulmonary hydration status, particularly during (impending) acute 
lung injury (ALI)/acute respiratory distress syndrome (ARDS), when pulmonary capillary 
permeability may be increased1. 
From physiological considerations, animal and (limited) clinical observations, it can 
be assumed that extravasation of fluids in vivo is governed by pericapillary hydrostatic 
and colloid osmotic pressures (COP), and permeability. This does not necessarily equate 
with edema formation, however, when increased lymph flow (up to a factor 9 in normal 
lungs) may offset increased fluid filtration. Also, the effect of plasma COP to attenuate 
filtration (or a low COP to increase filtration) is expected to increase when hydrostatic 
pressure increases and drives fluids out of the bloodstream2. Furthermore, an increased 
permeability and a resultant decrease in the pericapillary COP gradient may attenuate 
potential differences between fluid types, decreasing (crystalloids) and maintaining or 
even increasing plasma COP (colloids), respectively. Figure 1 illustrates these concepts, 
based on filtration forces rather than adaptations in lymph flow and suggests that 
differences in fluid types are expected to be less in modulating pulmonary edema 
formation in the steep part of the cardiac function curve, which is associated with a 
relatively low hydrostatic filtration pressure in the lungs. 
Both pulmonary capillary permeability and edema can be measured at the bedside; 
many ALI and all ARDS patients meeting accepted criteria have a measurably increased 
pulmonary capillary permeability but only up to 70% have supranormal extravascular 
lung water (EVLW)3-7. Indeed, the single transpulmonary thermal dilution technique is 
currently the reference standard for measuring and monitoring extravascular thermal 
volume in the lungs as a measure of accessible lung water - EVLW - at the bedside. This 
technique has shown excellent correlation with the gravimetric method8 and may have 
prognostic significance6,9. With this technique, however, pleural fluid is not measured. 
CT scanning gives an indirect measure of edema but is, by nature, intermittent at 
best, involving transportation and interruption of, for instance, renal replacement 
therapy instituted to attenuate fluid overloading. There is some evidence that EVLW 
(plus pulmonary blood volume) fairly correlates to tissue lung weights (i.e. pulmonary 
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blood plus extravascular fluid volumes) estimated from CT scans10. CT scanning carries 
the advantage of assessing pleural fluid also. Indeed, accumulation of pleural fluid 
in mechanically ventilated patients is common and physiology predicts that this may 
serve as an overflow system for increased intrapulmonary fluid filtration, when draining 
lymph flow is overwhelmed. Increased pleural pressure hampering parietal resorption 
in the course of mechanical ventilation may further contribute. 
After elaborating these basic physiologic principles, we will now address the major 
controversial issues on fluid resuscitation, when clinically needed, in ALI/ARDS or in 
patients at high risk for these syndromes. We will focus on clinical studies.
0 10 20 30
0
5
10
Figure 1. Schematic representation of the classical cardiac
function curve: Cardiac output (CO) versus pulmonary artery
occlusion pressure (PAOP). A. denotes the area in which only
little oedema occurs regardless of the colloid osmotic pressure
(COP). B. denotes the area in which substantial pulmonary
oedema may occur in which the effect of COP depends on
capillary permeability.
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Figure 1. Schematic representation of the classical cardiac function curve: CO cardiac output versus PAOP 
pulmonary artery occlusion pressure. A denotes the area in which only little edema occurs regardless of 
the COP colloid oncotic pressure. B denotes the area in which substantial pulmonary edema may occur in 
which the effect of COP depends on capillary permeability.
Controversy 1: guiding fluid resuscitation and avoi ing overhydration
The goals of fluid resuscitation, when needed, in (impending) ALI/ARDS is aimed 
at preventing or decreasing new organ failures and ultimately survival. However, 
intermediate hemodynamic and metabolic endpoints aimed at reaching those goals 
vary among studies. In any case, overhydration, particularly with crystalloids, is a serious 
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threat and may, among other adverse effects, confound diagnosing and aggravate 
(pulmonary edema in) ALI/ARDS11-13. Fluid overloading is probably also a common 
cause of pleural fluid which in turn may compress the lungs, thereby, together with 
an increased permeability, aggravate edema, contributing to ventilatory dependency 
in ALI/ARDS. Fluid overloading leading to an abdominal compartment syndrome may 
further compromise pulmonary function12.
Fluid overloading can be prevented by defining goals of fluid resuscitation and 
refining monitoring techniques. Indeed, predicting fluid responsiveness (i.e. a rise in 
stroke volume, cardiac output and thus oxygen delivery upon fluid loading) by dynamic 
or static preload indicators or their combination may help to decide on fluid challenges, 
provided that there is a clinical problem likely ameliorated by an increased oxygen 
delivery1,14-21. Obviously, instead of measuring and monitoring preload indicators as 
surrogate markers of fluid responsiveness, (semi-)continuous measurements of stroke 
volume or cardiac output could serve that purpose as well, provided that they are 
accurate14-19,21-23. Fluid loading should be continued until direct or indirect measures reach 
a particular point likely associated with improved and sufficient tissue oxygenation. To 
this end, regional as well as global parameters can be used, together with a careful clinical 
assessment, including near infrared spectroscopy/tissue oxymetry, microcirculatory 
imaging and gastrointestinal PCO2 tonometry for the former, or central or mixed venous 
oxymetry for the latter19,20,24,25. Adequate, optimal, goal-directed, goal-oriented or 
targeted fluid therapy/resuscitation, terms used in the literature, are not unequivocally 
defined, but may nevertheless imply similar or related endpoints for resuscitation, albeit 
varying among studies14,16-21,23,24. In any case, continuing fluid loading when cardiac output 
does not further increase on the plateau of the cardiac function curve, might result in 
harmful fluid overloading, particularly in the lungs, deteriorating gas exchange and 
compliance, while fluid loading in the steep part of the cardiac function curve may not 
(measurably) increase edema formation, even in case of mildly increased permeability 
edema and ALI after major surgery (ref 1,4,11; conform Figure 1). However, when using 
refined monitoring tools, including EVLW measurements, in patients with or at risk for 
ALI/ARDS, after major surgery for instance, the amount of fluid given and the duration 
of mechanical ventilation were, paradoxically, greater than when fluid loading was 
based on traditional filling pressure measurements22. Yet, there is no single, universally 
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accepted tool to prevent fluid overloading, when fluid resuscitation is deemed to be 
necessary.
Controversy 2: is ‘dry’ better than ‘wet’ in preventing/ameliorating 
pulmonary edema in ALI/ARDS?
Whereas completely withholding fluids or deliberately overhydrating patients for some 
time will certainly overwhelm physiologic (renal) compensation mechanisms and carry 
a fatal outcome, restrictive and liberal fluid therapy may be relatively meaningless 
terms if departing from different fluid regimens. Hence, the use of fixed, for instance 
perioperative, fluid dosages is probably also less useful than individual optimization. The 
key question thus is the adequacy of fluid resuscitation, as elaborated above, rather 
than the relative superiority of a restrictive or liberal regimen. 
Nevertheless, authors have advocated perioperative restricted rather than liberal 
fluid therapy, in order, among others, to prevent occasionally fatal postoperative 
pulmonary edema, associated with too liberal fluid therapy and not preceded by any 
warning signs26-29. Indeed, the widely held belief that surgery may be associated with 
contraction of the extracellular fluid volume necessitating liberal fluid therapy, may be 
incorrect30. When departing from (fixed dose) liberal fluid therapy, some fluid restriction 
can indeed reduce some morbidity (but not mortality) of surgical patients27-29, whereas 
a more liberal (as in individualized goal-directed) fluid therapy better maintained tissue 
oxygenation and decreased morbidity after surgery, as compared to a more restricted 
or standard policy in other studies14,16-21,24,25,29,31. However, the effect on pulmonary 
(permeability) edema and even gas exchange remained unclear in most of these 
latter studies on patients often at risk for ALI/ARDS after surgery14,16-19,21,24,25,28,29,31,32. The 
discussion on restricted versus liberal fluid therapy otherwise also applies to trauma/
hemorrhagic shock, in which, when bleeding cannot be immediately controlled, small 
rather than large volume resuscitation may be recommended33.
The restricted and liberal policies may affect the lungs in keeping them ‘dry’ or 
rendering them ‘wet’, respectively, even though some studies on liberal policies, 
paradoxically reported unchanged or even diminished duration of ventilation after 
surgery, associated with improved ventilatory function20,27,31,32. More complete 
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resuscitation may thus shorten ventilation and ICU durations of stay14,21,23. Nevertheless, 
a positive fluid balance has been associated with an increasing EVLW, prolonged 
mechanical ventilation/ICU stay and a worse outcome in sepsis and ALI/ARDS, and vice 
versa, but this does not necessarily imply cause-effect relationships13,22,34-37. Refining 
and guiding fluid resuscitation in the course of (impending) ALI/ARDS may benefit 
from predicting fluid responsiveness and monitoring EVLW in order to prevent edema 
formation and thus prolonged need for mechanical ventilation1,4,11,13,22,23,34,38. In patients 
requiring pulmonary artery catheter monitoring who had an elevated EVLW, a fluid 
strategy based on EVLW measurements, for instance, resulted in less fluid balance 
positivity and a shorter ventilation duration / ICU stay than a strategy based on the 
pulmonary artery occlusion pressure38. In patients with risk factors for ALI/ARDS, 
such as sepsis and major surgery, or those with established pulmonary edema or ALI/
ARDS, restricting fluids after the initial phase of resuscitation may be beneficial13,39. In 
fact, the ARDS Network trial suggests that, after initial resuscitation, a regimen aimed 
at less positivity of 7-daily and cumulative fluid balance may improve lung function 
(edema ?) and reduce ventilator/ICU days but may not reduce mortality in the first 28 
days, in patients with ALI/ARDS39. Obviously, keeping the lungs ‘dry’ rather than ‘wet’ 
should be weighted against potential hypoperfusion of extrapulmonary, injured or vital 
organs such as the kidneys13. This may require additional attention and monitoring, but, 
apparently, additional organ failure was minimal in the restricted fluid group of the 
ARDS network trial39. Taken together, timing and dosing fluid therapy in patients with or 
at risk for ALI/ARDS is still a controversial issue.
Controversy 3: colloid versus crystalloid in preventing/ameliorating 
pulmonary edema during ALI/ARDS
It follows from physiology that the ‘dry’ and ‘wet’ issue should also include a discussion 
on potential merits and detriments of fluid types (crystalloids versus colloids) in ALI/
ARDS or patients with an elevated risk for these syndromes40,41. Although, roughly, 
colloids may not confer a survival benefit nor prevent pulmonary edema as compared 
to crystalloids in mixed patients populations, albumin administration may be associated 
with less pulmonary complications, according to meta-analyses, even though edema 
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was not directly measured40-42. Hence, the controversy on colloid and crystalloids, when 
used for fluid resuscitation in ALI/ARDS is ongoing. Notwithstanding, adverse effects of 
gross overhydration are, obviously, independent of fluid types. 
In a small series of mechanically ventilated ALI/ARDS patients with hypoproteinemia 
and presumably a low COP, albumin and furosemide versus furosemide alone 
ameliorated gas exchange and some other surrogate indices of pulmonary edema, 
which again was not directly measured43. In critically ill, hypoalbuminemic patients with 
a presumably low COP, albumin administration was associated with less positive fluid 
balance and improved pulmonary function37. Verheij et al. used a bedside technique 
for measuring pulmonary permeability for proteins that is specific for ALI/ARDS4. 
They showed in postoperative, presumably hypovolemic patients with ALI, in half of 
them accompanied by mild permeability edema, that the type of fluids (saline versus 
gelatin, albumin or starch) did not affect pulmonary edema formation in the presence 
of an increased cardiac output, i.e. in the steep part of the cardiac function curve (as in 
Figure 1). Alternatively, increased permeability may have diminished the contribution of 
plasma COP on edema formation, thereby diminishing differences between fluid types, 
or adaptation of Starling forces and increased lymph flow may have fully compensated 
for slightly increased fluid transport, or both. 
Controversy 4: colloid versus colloid in preventing or ameliorating 
pulmonary edema and lung injury in ALI/ARDS
Among the colloids, albumin and high-molecular weight starch preparations have 
potential anti-inflammatory and anti-permeability properties, respectively, as suggested 
by animal experiments. Indeed, HES as compared to gelatin used after abdominal 
aortic surgery was suggested to ameliorate some gas exchange and other respiratory 
abnormalities, used as surrogate indices of edema44. Verheij et al.4 confirmed a mild 
attenuation of directly measured permeability in the lungs, in patients after major 
surgery, but the clinical consequences remained unclear. Conversely, the favorable 
effects of albumin suggested by others37,43 could have been caused, in part, by a mild 
anti-inflammatory effect rather than by amelioration of hypoproteinemia, a low COP and 
pulmonary edema. However, sufficient clinical data to decide in this matter are lacking.
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Summary
Many questions regarding fluid resuscitation during ALI/ARDS remain unanswered, and 
this is partly related to the frequent use of surrogate indicators of pulmonary edema, 
including gas exchange parameters and chest radiography, which may not reflect 
pulmonary edema. This prompts for using direct measures of permeability and edema, 
with proven feasibility at the bedside4, in evaluating fluid resuscitation in patients with 
or at risk for ALI/ARDS after sepsis, trauma or major surgery.
Key points for clinical practice
1. The timing, dosing and choosing the type of fluid therapy, when clinically 
needed, in patients with or at risk for ALI/ARDS, is best accomplished by careful 
weighing potential benefits and hazards for the individual patient in the course 
of disease. There is no consensus on this issue.
2. Fluid resuscitation remains the treatment of choice, provided that the patient is 
likely to be fluid responsive, in case of hypotension and tissue hypooxygenation 
(accompanied by clinical signs). Adequate fluid resuscitation may ameliorate 
morbidity/mortality and prevent harmful fluid overloading.
3. While relative fluid restriction, after initial resuscitation, may ameliorate 
pulmonary edema formation and shorten ventilator days particularly when 
permeability is increased (in ALI/ARDS), this is likely to benefit only when 
hemodynamically tolerated and when tissue oxygenation and renal perfusion 
are unlikely to be severely diminished.
4. In the steep part of the cardiac function curve, the type (and dose) of fluid 
used for resuscitation, i.e. colloid or crystalloid, probably does not have a 
major impact on fluid accumulation in the lungs, regardless of permeability. 
Predicting and monitoring fluid responsiveness as well as EVLW may prevent 
(further) pulmonary edema formation and may guide fluid loading, when 
needed, during ALI/ARDS, regardless of dose and type of fluid.
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Abstract
 
In this narrative review, the studies and analyses are discussed that pertain to benefits 
and detriments of synthetic colloids versus natural colloids or crystalloids used for fluid 
resuscitation in sepsis and septic shock. The relative amount of fluid infusions used to 
reach clinical or hemodynamic endpoints are reviewed, as well as potential toxicity of 
starch solutions and on the kidney. Hence, it cannot be excluded that adverse effects 
partly offset beneficial hemodynamic effects that are similar to that of natural colloids, 
so that in most analyses a mortality benefit of synthetic colloid fluid resuscitation in 
sepsis and septic shock cannot be demonstrated.
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Introduction
Although administration of fluids is one of the most common interventions in the 
management of patients with sepsis in the intensive care unit (ICU), there is limited high 
quality evidence for the safety/benefit ratios of the most commonly used fluid types1. 
In a recently published systematic review comparing crystalloids with colloids used for 
resuscitation, the authors argued that colloids are not associated with improved survival 
and that, as they are more expensive than crystalloids, their continued use may not be 
justified outside the context of clinical trials2. This may also be applied to children3. An 
older metaanalysis even suggested that colloids could be detrimental in sepsis, possibly 
because of increased extravascular leakage4. Formal sepsis guidelines, however, state 
that either colloids or crystalloids can be used for resuscitation in a volume ratio of 
approximately 1 to 3, but the evidence for the latter, again, is scarce5.
In contrast, surveys among ICUs on the use of preferred plasma volume expanders 
for critically ill patients demonstrate more frequent use of colloids than of crystalloids 
in the first-line treatment, whereas hydroxyethyl starch (HES) is the most widely used 
colloid, with large differences between countries6-9. It seems that the observed variation 
depends on local practice rather than on (individual) patient characteristics9. So, current 
research evidence suggesting a lack of survival benefit with the use of colloids may 
not be convincing enough to override local habits, unless other properties may render 
colloids as a resuscitation fluid preferable in order to justify their continued use. 
One of the reasons of continuing widespread colloid use is the possible beneficial 
hemodynamic effect associated with perhaps lower needs for volume infusion for a 
given hemodynamic endpoint. Use of colloids may thus beneficially limit the amount 
of fluids infused without the risk for underresuscitation10. Indeed, fluid overhydration is 
associated with increased mortality in sepsis11,12, partly because of prolonged pulmonary 
edema and dependency on ventilators6. Conversely, potential adverse effects may 
offset beneficial actions so that overall patient benefits are small and hard to prove. In 
fact, synthetic colloids may have adverse effects and recent evidence accumulates that 
HES preparations in particular may have deleterious effects on renal function13-17.
In this paper we will critically review merits and detriments of the use of synthetic 
colloids as gelatins and HES solutions, as compared to natural colloids and crystalloids, 
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in critically ill, septic patients. This includes studies solely on septic patients or studies in 
which >25% of patients had documented sepsis, including those with acute lung injury/
acute respiratory distress syndrome and children, in contrast to the limited number 
of studies used by Wiedermann in his recent metaanalysis on HES in sepsis18. We will 
not discuss animal experiments nor include papers by a German group against which 
doubts have recently been raised19. For a general overview of pharmacology, properties 
or safety of fluids, the reader is referred to recent literature17,20-22. We will focus the 
discussion around three questions and will not dwell upon hyperoncotic or hypertonic 
solutions nor upon dextrans since use of the latter is not widespread. 
1. Are synthetic colloids more effective than crystalloids and similarly 
effective as natural colloids in sepsis? 
 
It is widely believed that severe sepsis and septic shock, are characterized, among 
others, by myocardial depression, endothelial injury and vascular leakage, both in the 
lungs and systemically, that may, in theory, limit the relative hemodynamic efficacy 
of colloid versus crystalloid fluid resuscitation23. Indeed, the plasma disappearance of 
intravenously injected large molecules including (radiolabeled) albumin is more rapid in 
septic than nonseptic conditions, perhaps depending on the severity of sepsis24-27.
In theory, crystalloid solutions expand the plasma volume by about 200 mL per 
liter infused, concomitantly with lowering, by diluting circulating proteins, of plasma 
colloid osmotic pressure (COP), as demonstrated in nonseptic subjects27,28. Depending 
on the rate of infusion, the equilibration rate of crystalloid with the interstitial space 
is rapid (minutes) even in patients with hypovolemia or shock, thereby resulting in 
potentially harmful interstitial (pulmonary) overhydration27,29,30. Crystalloids thus 
need to be administered at volumes approximately 3 to 5-fold greater than those of 
(isooncotic) colloids, that are largely maintained in the plasma compartment because of 
maintenance of COP, in order to achieve comparable plasma volumes and resuscitation 
endpoints21,27,28. Conversely, the intravascular COP after colloid infusion is influenced by 
baseline COP, the degree of hemodilution and the COP of the infused volume and its 
plasma retention, determined by the molecular weight (Mw) distribution. Colloid Mw is 
important because of its relationship to pharmacokinetics; small particles with a low Mw 
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exert a greater oncotic effect and, for a given number of molecules, will have a lower 
viscosity than larger molecules31. In contrast, they have a shorter intravascular retention 
before being filtered in the glomerulus or lost into the interstitium. Larger molecules 
are retained in the intravascular space longer but, as there are fewer of them, exert less 
osmotic forces across the semi-permeable membrane of the endothelium and therefore 
have a less volume expanding effect31. While albumin solutions are monodisperse 
(molecular weight of 69 kDa), hydroxyethyl starch (HES) solutions are polydisperse, 
defined by the degree of substitution (MS) (via partial hydrolysis) and by Mw, both of 
which affect pharmacokinetics21. The greater the degree of substitution the greater 
the resistance to degradation, which therefore prolongs efficacy of HES as a plasma 
expander. After substitution, the starch is refined into the final product by hydrolysis to 
the required Mw. The molecular weight distribution can be described using the COP50/
COP10 ratio31. This is the ratio of measured COP’s across 2 different membranes, with 
a 50 kDa and a 10 kDa pore size, respectively, and reflects the relative proportion of 
molecules retained by filters with those pore sizes. Colloids with a low COP50/COP10 
ratio will be lost more rapidly from the intravascular space. Thus, the concentration and 
Mw of colloid molecules and hence the COP, determine the initial degree of volume 
expansion, whereas both the Mw and surface charge characteristics determine the rate 
of loss through the capillary endothelial barrier and loss into the urine by glomerular 
filtration. Therefore, the intravascular retention and half time of colloids amount to 
hours, dependent on dispersion and weight of molecules.  
Gelatins are polydisperse and in excess of 75% of the molecules are thought to be 
smaller than the renal threshold of 30 kDa. The large number of small molecules exerts 
a powerful initial COP effect making gelatins good for short-term volume expansion, but 
molecules with a Mw less than 15 kDa have a similar clearance to that of creatinine and 
will be filtered by the glomerulus. They are thus rapidly cleared from the intravascular 
space, with a half-life of 3.5-4 hours21. In sepsis, the hemodynamic effects of gelatins 
may be similar to that of isooncotic HES preparations, but gelatins may decrease gastric 
tonometric PCO2 and improve adequacy of mucosal blood flow more than HES
26,28,32,33.
If colloids are capable of expanding the plasma volume to a greater extend 
than crystalloids, then the same volume of colloids would have greater effects on 
hemodynamics than crystalloids. The volume ratio of crystalloids to colloids relative 
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to hemodynamic efficacy depends on the rate and fate of the infused fluids and the 
hemodynamic monitoring tool and endpoint utilized. The hemodynamic endpoint of 
resuscitation varies from one study to the other between clinical judgment, arterial 
and central venous pressures, to pulmonary artery occlusion pressures and cardiac 
output and variables obtained by transpulmonary thermodilution. The variety is 
likely responsible, in part, for the widely varying volume ratios during resuscitation 
as reported in the literature. For instance, the VISEP trial documented that target 
values of central venous pressure in severe sepsis were reached faster with HES (10%, 
200/0.5) loading than that with Ringer’s lactate, at an averaged volume ratio of 1:1.3, 
but 28 day mortality did not differ13. The central venous pressure and central venous O2 
saturation in the HES group were somewhat higher than in the Ringer’s lactate group, 
perhaps suggesting underestimation of crystalloids requirements or more appropriate 
infusion of HES products. Trof et al., however, demonstrated, in perhaps less severely 
ill septic patients described before26, that 90 min fluid loading with 4-6% colloids, 
either gelatins, HES or albumin, resulted in a greater linear increase in cardiac filling, 
output and left ventricular stroke work than that with saline loading both in septic and 
nonseptic patients, probably due to a larger plasma volume following increased COP 
with the former and in spite of the characteristic myocardial depression of sepsis28. 
The efficacy of isooncotic colloids, regardless of their type, was 3-fold greater than of 
saline, independent of underlying condition, even though about 17% more crystalloid 
was infused. This confirms older data suggesting a 2 to 5-fold greater fluid requirement 
with crystalloids in both hypovolemic and septic shock aiming at similar hemodynamic 
endpoints, and thus far greater interstitial volume expansion, for a given plasma volume 
expansion, than with colloids29,30,34. In children with Dengue shock syndrome, Ringer’s 
lactate administration resulted in higher hematocrits, lower arterial (pulse) pressures 
and cardiac outputs, and slower shock reversal than that of (similar volumes of) 
synthetic colloids dextrans, gelatins or HES35,36. In children with septic shock, up to 67% 
more saline than gelatin (volume ratio 1.7:1) was required to reach similar plasma volume 
and other hemodynamic targets37. In a recent study comparing HES (6%, 130/0.4) versus 
normal saline during early goal directed therapy of septic patients, the volume ratio 
was 1:2.4 for reaching similar hemodynamic endpoints after 24 hours38. Resuscitation 
with HES improved the sublingual microcirculation more than that with saline. Indeed, 
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HES 130/0.4 is an effective plasma volume expander and favorably increases global 
hemodynamics in sepsis39. 
Therefore, based on correct interpretation of the current literature, the volume 
ratio for similar hemodynamic endpoints is approximately 1 (isooncotic) colloid to 
2-3 crystalloid volume units, even in sepsis, in line with the guidelines5. The factor is 
maintained when multiplying lower ratios, when applicable, with the difference in 
hemodynamic endpoints attained. Otherwise, appropriate resuscitation (with colloids) 
may contribute, among others, to prevention of kidney injury and renal failure7,14. Taken 
together, the studies cited imply that in sepsis, unless the condition is perhaps very 
severe, increased leakage of colloids is not a major factor limiting their plasma volume 
expanding effects, in contrast to common beliefs and recent suggestions17. 
2. What are the current insights regarding renal toxicity and other adverse 
effects attributable to synthetic colloids in sepsis?
 
The most discussed adverse effects of synthetic colloids, in particular HES, is the risk of 
acute kidney injury (AKI)13-17,22. A recent systematic review examining the effects of HES 
on renal function compared to other fluid resuscitation therapies in different patient 
populations demonstrated an overall relative risk of author-defined acute renal failure (by 
serum creatinine, creatinine clearance or calculation/estimation of glomerular filtration 
rate) of 1.50, and 1.38 for requiring renal replacement therapy (RRT) as compared to 
crystalloid or non-HES colloid, whereby subgroup analyses suggested an increased risk in 
septic versus nonseptic patients15. However, the 183 randomized controlled trials (RCT) 
identified by this review evaluated the need for RRT as the primary outcome measure 
and not other renal outcomes. Second, in none of the studies, the newly developed 
and validated criteria to objectively define and stage AKI, were used. Third, despite the 
presence of probably sufficient data to suggest a difference between HES-treated sepsis 
and nonsepsis patients with respect to the risk of AKI, the studies in nonseptic patients 
were inadequately powered to confirm this difference. Finally, the variability of type and 
volume of the used HES solutions may have confounded outcome results; that type and 
volume matters is supported by some literature. For instance, the cumulative amount 
of HES administered in the largest sepsis study13 to date was considerably higher than 
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in most other studies. The mean cumulative dose of HES was 70.4 mL/kg and volume 
expansion was performed exclusively with Ringer’s lactate or HES. This volume is far 
above the manufacturer’s recommendation of 33 mL/kg on day 1, followed by 20 mL/
kg/day. Furthermore, this study used second generation (pentastarch 10%, 200/0.5) HES 
preparations instead of more modern generation tetrastarches (HES 130/0.4). Indeed, 
in 2001 already, Schortgen et al. suggested that the use of second generation HES, as 
compared to gelatin solutions was an independent risk factor for acute renal failure in 
patients with severe sepsis or septic shock40. Meanwhile, recent retrospective work 
suggests that resuscitation with (low volumes of) low Mw (130/0.4) tetrastarch HES 
(third generation) in critically ill patients (>25% sepsis) is not associated with increased 
development of AKI41,42. Also a large retrospective study involving >3000 patients (>25 
% sepsis) demonstrated that the use of HES did not influence renal function or the need 
for RRT in multivariable analysis43. Although the median amount of HES was below the 
recommended maximum dose, it did not predict the subsequent need for RRT. The type 
of HES was not reported specifically but the use of third generation HES could have 
contributed to the more favorable results. Nevertheless, there is currently inadequate 
clinical data to prove the claim that safety differences exist between different HES 
products15,22.
The mechanism of potential HES-induced AKI is not well understood. It may include 
reabsorption of the macromolecule into (proximal) renal tubular cells leading to 
osmotic nephrotic lesions or renal plugging due to hyperviscosity of the filtrate, and is 
associated with a decrease of glomerular filtration pressure by a more rapid increase 
in intracapillary oncotic than hydrostatic pressure14. Prolonged elevation of COP, 
reached by a higher Mw and a more extensive MS as accomplished by first and second 
generation HES solutions, might explain why these old generation HES products could 
be more nephrotoxic, if at all, than the third generation tetrastarches. We also do not 
know the comparative action of colloid concentrations on the kidney, since elevation of 
COP by itself may inhibit glomerular filtration14. Moreover, gelatins may increase low Mw 
proteinuria even in volunteers, probably by competitively inhibiting tubular resorption 
rather than by tubular injury44. They may, at high doses, be independently associated 
with AKI41. Unbalanced crystalloid solutions as compared to balanced or bicarbonate-
containing solutions may negatively affect renal perfusion and function, because of high 
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chloride concentrations, and the validity of infusion of these solutions as a control for 
colloid effects can therefore be doubted14.
Alleged non-renal toxicities of HES finally include long-term pruritus and 
hepatocellular injury with jaundice, but there is no literature on these side effects in 
septic patients only18,22. Two studies from the same group argue that pentastarch or 
hetastarch HES does not affect coagulation as compared to albumin during sepsis, 
even though circulating von Willebrand factor was decreased45,46. Although some 
resuscitation fluids have been suggested to modify inflammatory responses, there is 
no specific information or comparison of patient-centered outcomes in sepsis. Human-
derived albumin carries the theoretical risk of transmittable disease, but there is no 
evidence for that and natural colloids are therefore regarded as safer than synthetic 
colloids22. 
A survey on non-hyperoncotic colloids and crystalloids in France suggested that fluids 
were associated with similar incidences of overhydration and acute lung injury/acute 
respiratory distress syndrome, irrespective of sepsis47. Indeed, prospective studies in 
septic patients suggested that both crystalloid and (synthetic) colloid fluid loading does 
not aggravate pulmonary permeability-edema, provided that loading is in the steep 
part of the cardiac function curve26,32,39,47-49, whereas maintaining a fixed pulmonary 
capillary wedge pressure resulted in pulmonary overhydration with use of crystalloids 
(only)29. There is some evidence that HES may even ameliorate increased pulmonary 
permeability48. Hyperoncotic albumin solutions may50-52 or may not53,54 ameliorate 
oxygenation and perhaps edema in sepsis-induced acute lung injury (as compared to 
crystalloid or isooncotic synthetic colloid), whether or not combined with furosemide.
3. How should we interpret pooled data on mortality2 comparing colloids 
versus crystalloids for fluid resuscitation in critically ill, septic patients?
 
The Cochrane systematic reviews comparing colloids versus crystalloids and colloids 
versus colloids for fluid resuscitation in general critically ill patients demonstrated that 
resuscitation with colloids may not reduce the risk of death, in spite of their hemodynamic 
superiority2, and that colloids may not be different in this respect55. This may, among 
others relate, to poorly defined clinical or hemodynamic endpoints and monitoring 
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targeted to values proven to be associated with survival, as well as their insufficient 
application in clinical practice, so that potential benefits may not outweigh adverse 
effects. Moreover, looking more critically to the extracted and analyzed data, most 
studies were not powered for mortality nor was mortality defined as a primary outcome 
measure, as in the Wiedermann systematic review on HES in sepsis18. Table 1 shows an 
overview of the available and analyzed studies on sepsis comparing (modified) gelatin 
or HES solutions with crystalloids or natural colloids (human albumin), or comparing 
HES versus (modified) gelatin, and reporting data for mortality. Remarkably, most of the 
studies included small number of patients except two13,36 and only the VISEP trial was 
powered for mortality as primary outcome measure13. This recent German multicenter 
study was powered at 600 sepsis patients to detect a reduction in mortality from 40% 
to 30% at 28 days. However, after enrollment of 600 patients, the planned interim 
analysis showed a greater incidence of renal failure and a trend toward higher 90-day 
mortality among patients who received HES than among those who received Ringer’s 
lactate. Therefore, the study was suspended. Among the 537 patients who could be 
evaluated, the rate of death at 28 days did not differ between the HES group and the 
Ringer’s lactate group. The rate of death at 90 days was increased among patients who 
received a higher dose of HES, as compared with those who received a lower dose (58 
versus 31%). All the other studies were underpowered for mortality as primary outcome 
measure. And although most of these studies showed a tendency to higher mortality for 
synthetic colloids treated patients, displayed by higher risk ratios, it is hard to definitively 
conclude that synthetic colloids affect survival as compared to crystalloids or human 
albumin and vice versa. In septic children also, lack of evidence of an effect on mortality 
by either crystalloid or colloid fluids could be caused in part by the fact that none of the 
studies included, had mortality as the primary endpoint3. In contrast, the use of albumin 
solutions compared to crystalloids may improve mortality in sepsis56,57, and this may 
lead to the speculation that adverse effects of synthetic colloids may offset potential 
beneficial effects and thereby attenuate a potential survival benefit.
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Currently, the CHEST trial (NCT 00935168) is underway comparing HES 130/0.4 versus 
normal saline for fluid resuscitation in ICU patients with mortality as primary outcome 
measure. Also a few other RCT’s are currently performed or analyzed comparing HES 
130/0.4 with crystalloids such as Ringer’s acetate (NCT 00962156, n=800) or normal 
saline (NCT 00273728, n=250; NCT 00464204, n=200) on mortality in patients with 
sepsis. Results of these studies may also reveal whether HES 130/0.4 is safer than 
older HES preparations or not, as current evidence remains inconclusive15,22. Also new 
albumin studies (versus crystalloids) are underway such as the Italian ALBIOS study 
(NCT00707122, n=1350). The French multicenter trial (NCT00327704, n=800) on albumin 
in severe sepsis and septic shock has been completed. Preliminary results indicate lack 
of survival benefit of albumin over saline, partly due to underpowering.  
Conclusion and recommendations
Based on the current literature, there is sufficient evidence that the use of (synthetic) 
colloids results in more (rapid) plasma volume expansion and hemodynamic 
optimization than resuscitation with crystalloids, even when accompanied by presumed 
increased vasopermeability in sepsis. Although suggested otherwise17, the volume ratio 
for similar hemodynamic endpoints is approximately 1 colloid to 2-3 crystalloids. The 
factor is maintained when multiplying lower ratios, when applied, with the difference 
in hemodynamic endpoints attained. The risk of renal toxicity with the use of HES 
solutions must be qualified according to type, concentration and volume of the HES 
solution used. When it comes to outcome, there is no evidence that the use of synthetic 
colloids for resuscitation purposes negatively influences mortality in sepsis as compared 
to crystalloids or natural colloids. Large prospective studies comparing low Mw 
tetrastarches or albumin with crystalloids for fluid resuscitation in sepsis are currently 
being performed. The results are eagerly awaited. In the meantime, we suggest that 
the use of newer generations HES solutions (e.g. 130/0.4) should not be discouraged for 
resuscitation purposes in patients with sepsis or septic shock. The clinician should weigh 
benefits versus disadvantages, thereby taking the maximum recommended dose of 50 
mL/kg/day into account.  
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Abstract
Introduction 
Static cardiac filling volumes have been suggested to better predict fluid responsiveness 
than filling pressures, but this may not apply to hearts with systolic dysfunction and 
dilatation. We evaluated the relative value of cardiac filling volume and pressures for 
predicting and monitoring fluid responsiveness, according to systolic cardiac function, 
estimated by global ejection fraction (GEF, normal 25-35%) from transpulmonary 
thermodilution.
Methods 
We studied hypovolemic, mechanically ventilated patients after coronary (n=18) or major 
vascular (n=14) surgery in the intensive care unit. We evaluated 96 colloid fluid loading 
events (200-600 mL given in 3 consecutive 30 min intervals, guided by increases in filling 
pressures), divided into groups of responding events (fluid responsiveness) and non-
responding events, in patients with low GEF (<20%) or near-normal GEF (≥20%). Patients 
were monitored by transpulmonary dilution and central venous (n=9)/pulmonary artery 
(n=23) catheters to obtain CI, global end-diastolic volume index (GEDVI), central venous 
(CVP) and pulmonary artery occlusion pressure (PAOP).
Results
Fluid responsiveness occurred in 8 (≥15% increase in CI) and 17 (≥10% increase in CI) of 
36 fluid loading events when GEF was <20%, and 7 (≥15% increase in CI) and 17 (≥10% 
increase in CI) of 60 fluid loading events when GEF was ≥20%. Whereas a low baseline 
GEDVI predicted fluid responsiveness particularly when GEF ≥20% (p = .002 or lower), a 
low PAOP was of predictive value particularly when GEF <20% (p = .004 or lower). The 
baseline CVP was lower in responding events regardless of GEF. Changes in CVP and 
PAOP paralleled changes in CI particularly when GEF <20%, whereas changes in GEDVI 
paralleled CI regardless of GEF. 
Conclusion 
Regardless of GEF, CVP may be useful for predicting fluid responsiveness in patients 
after coronary and major vascular surgery provided that positive end-expiratory 
pressure is low. When GEF is low (<20%), PAOP is more useful than GEDVI for predicting 
fluid responsiveness, but when GEF is near-normal (≥20%) GEDVI is more useful than 
PAOP. This favors predicting and monitoring fluid responsiveness by pulmonary artery 
catheter-derived filling pressures in surgical patients with systolic left ventricular 
dysfunction and by transpulmonary thermodilution-derived GEDVI when systolic left 
ventricular function is relatively normal.
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Introduction
The clinical benefit of various hemodynamic monitoring techniques in the critically ill is 
still under debate1-5. Static filling volumes, such as the transpulmonary dilution-derived 
global end-diastolic volume, have been suggested to better predict fluid responsiveness 
than filling pressures such as the central venous pressure (CVP) or pulmonary artery 
occlusion pressure (PAOP) obtained from a pulmonary artery catheter6-19. Most studies, 
however, often included patients with relatively normal left ventricular systolic function, 
undergoing coronary artery surgery6-13,15,16,19. Mundigler et al. suggested that pressures 
were superior to transpulmonary thermodilution-derived volumes for monitoring 
changes in cardiac preload during fluid loading in non-surgical patients with left 
ventricular systolic dysfunction, measured by transesophageal echocardiography20. We 
also suggested this in patients with presumed left ventricular systolic dysfunction based 
on transpulmonary thermodilution-derived global ejection fraction (GEF) following 
valvular surgery21. However, others did not reach the same conclusion14,17. Nevertheless, 
according to Laplace’s Law, pressures and volumes may both contribute to end-diastolic 
wall stress as a true measure of cardiac preload. Based on the curvilinear left ventricular 
pressure-volume relationship at end-diastole, volumes may increase more than pressures 
with fluid loading at low cardiac filling, while at higher cardiac filling, pressures may 
increase more than volumes5. At low cardiac filling, volumes may thus better predict fluid 
responsiveness than pressures, while in hearts with systolic dysfunction and dilatation, 
pressures may better predict and monitor fluid responsiveness than volumes5,22.
We hypothesized that during fluid loading in patients with reduced systolic cardiac 
function as compared to those with normal function, filling pressures may be superior 
to filling volumes (i.e. global end-diastolic volume, GEDV) for predicting and monitoring 
of fluid responsiveness, and vice versa. We thus measured prospectively cardiac 
filling pressures and volumes in hypovolemic patients following cardiovascular and 
major vascular surgery, using the pulmonary artery catheter and transpulmonary 
thermodilution technique, prior to, during and following colloid fluid loading.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
90 Chapter 6
Patients and methods
This is a sub study of a prospective, non-randomized, single-center clinical trial, 
investigating the volume expanding effects of various resuscitation fluids23. The study 
was approved by the Ethics Committee of the Vrije Universiteit Medical Center. Written 
informed consent was obtained pre-operatively. We analyzed the effect of colloid fluid 
loading in patients who had undergone coronary artery (n=18) or major vascular surgery 
(n=14). Colloid fluid loading was given with modified fluid gelatin 4%, hydroxyethyl starch 
(HES) 6% or albumin 5%, all of which have similar oncotic properties and hemodynamic 
responses23. We only analyzed patients who completed fluid loading and measurements 
up to t=90 min. Inclusion criteria, at enrollment and start of the protocol, were presumed 
hypovolemia, defined as a systolic blood pressure <110 mm Hg and reduced filling 
pressures: PAOP <13 mm Hg (in the presence of a pulmonary artery catheter) or CVP <12 
mm Hg. Exclusion criteria were age >75 year, preterminal illness with a life expectancy 
of less than 24 hours, or know anaphylactic reactions to colloids. All perioperative care 
was given by attending physicians who were not involved in the study.
Study protocol. The protocol was started upon arrival of the patients in the 
intensive care unit (ICU). Demographic characteristics were recorded, including the 
acute physiology and chronic health evaluation (APACHE-II) score and transesophageal 
echocardiographic findings prior to surgery. At baseline (t=0 min), hemodynamic 
measurements were performed. Heart rate (HR) and mean arterial pressure (MAP) from 
a radial artery were recorded at t=0 and 90 min. The HR was taken from the continuously 
recorded electrocardiogram. The mean pulmonary artery pressure (MPAP) was measured 
at t=0 and 90 min. Cardiac output, GEDV, CVP and PAOP were measured every 30 min, 
from t=0 to 90 min. Pressures were measured with patients in the supine position after 
calibration, zeroing to atmospheric pressure and, for PAOP, after proper wedging, at the 
midchest level at end-expiration (Tramscope®, Marquette, GE, Milwaukee, Wisconsin). 
For the measurements of cardiac output and GEDV, the transpulmonary thermal-dye 
indicator dilution technique was used1,6. These measurements involve a central venous 
injection of 15 mL of ice-cold indocyanine green in 5% glucose solution and concomitant 
registration of the dilution curves in the femoral artery, by a 3F catheter equipped 
with a thermistor (PV 2024, Pulsion Medical Systems, Munich, Germany). This catheter 
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was inserted at the end of surgery via a 4F introducing sheath (Arrow, Reading, USA) 
and connected to a bedside computer (COLD Z-021, Pulsion Medical Systems, Munich, 
Germany. The COLD Z-021 is the precursor to the current pulse contour cardiac output 
(PiCCO™) technique. GEDV represents the volumes of the right and left heart at end-
diastole and reflects left ventricular dimensions obtained by echocardiography in the 
absence of overt right ventricular distention7,12-17. The ratio between stroke volume and 
global end-diastolic volume/4 is defined as the global ejection fraction (GEF, normal 
values 25-35%), and is an indicator of left ventricular systolic function, provided that 
there is no right ventricular dysfunction24,25. Reproducibility of these measurements is 
typically within 10%1. After baseline measurements were taken, fluids were given over 
90 min on the basis of the response within predefined limits of increases in pressures 
(CVP or - when available - PAOP), according to a previously described protocol23,26,27. Up 
to 200 mL of fluid were given every 10 min, provided that the increase in filling pressures 
with the fluid loading did not exceed critical values, and this policy has been proven safe 
in previous studies23,26,27 (i.e. not evoking pulmonary edema). The maximum amount of 
fluid infused was 1800 mL. Concomitant vasoactive and sedative drug treatment and 
ventilatory settings remained unchanged during fluid loading. Indeed, all patients were 
received volume-controlled mechanical ventilation and positive end-expiratory pressure 
(PEEP). Drainage of blood was <50 mL/hour in all patients, and no patient underwent 
repeated surgery for bleeding within 12 hours post surgery.
Statistical analysis. The groups to be analyzed were divided into low GEF (<20%) 
and near-normal GEF (≥20%). The cutoff of 20% approximately reflects a cutoff of 
40% ejection fraction of the left ventricle, the lower limit of normal, as measured by 
echocardiography, provided that there is no right ventricular dysfunction24,25. We also 
analyzed data according to a cutoff of 15%. Stroke volume, cardiac output and global end-
diastolic volume were indexed to body surface area (BSA), giving stroke volume index 
(SVI, mL/m2), cardiac index (CI, L/min/m2) and global end-diastolic volume index (GEDVI, 
n 680-800 mL/m2), respectively. Cardiac distensibility was determined as the surrogate 
for cardiac compliance and was calculated by GEDVI/(CVP+PAOP)/2 (mL/m2/mm Hg), or 
GEDVI/CVP if PAOP was not available28. Fluid responsiveness was defined as an increase 
of CI or SVI ≥10% or ≥15%, in accordance with the literature4,9,17, between t=0-30, t=30-
60 and t=60-90 min during fluid loading. For categorical data, X2 and Fisher exact tests 
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were used. Since continuous data were normally distributed (Kolmogorov-Smirnov test, 
p >.05), they were summarized by mean ± standard deviation (SD) and parametric tests 
were done. Paired and unpaired t-tests were used to compare data in time and between 
GEF groups. Generalized estimating equations were used to evaluate differences in 
baseline and changes in variables between summated responding and non-responding 
fluid loading events in each GEF group, to evaluate their predictive and monitoring 
values, respectively, taking repeated measurements in the same patients into account, 
with the amount and type of fluid infused entered as covariates to adjust for potential 
confounding. Partial correlation coefficients (r), adjusted for repeated measurements 
by entering patient number and for type and amount of fluids as covariates were 
calculated. Coefficients were compared after z transformation. Receiver operating 
characteristic curves (ROC) plotting sensitivity against 1-specificity were constructed 
to evaluate the predictors of fluid responsiveness by the areas under the curve (AUC, 
with 95% confidence intervals) for pooled data, in the absence of accepted methods 
to adjust for repeated measurements, and were compared with each other. Optimum 
cutoff values with associated combinations of highest sensitivity and specificity were 
calculated (MedCalc Software, Belgium). Exact two-sided p values >.001 are given and 
considered statistically significant when <.05. All analyses were conducted using SPSS 
version 15.0 (SPSS Inc, USA).
Results
Table 1 summarizes the demographic, hemodynamic and respiratory characteristics of 
patients. Patients underwent coronary artery or major vascular surgery (in three cases 
on the distal thoracic aorta). Surgery was uneventful in all patients. The table shows 
the differences between patient groups with a GEF <20% and ≥20% and the changes 
with fluid loading. There was no difference in the amount and type of fluids infused 
and fluid balances between the GEF groups. GEF did not change during fluid loading. 
Baseline GEDVI was higher when GEF was <20% than ≥20% suggesting cardiac dilatation. 
Preoperative echocardiography did not document severe right ventricular dysfunction 
and dilatation in any patient. There was no postoperative pulmonary hypertension and 
MPAP was 28 mm Hg at maximum in one patient. Indeed, MPAP at t=90 min in the low 
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GEF group was 23±7 and 25±2 mm Hg and in the near-normal GEF group 21±4 and 22±4 
mm Hg, in responders and non-responders, respectively (GEE: p = .44 for response, p = 
.99 for GEF). Similarly, the MAP at t=90 min in the low GEF group was 95±16 and 86±25 
mm Hg and in the near-normal GEF group 83±7 and 85±12 mm Hg, in responders and non-
responders, respectively (GEE: p = .52 for response, p = .98 for GEF).
Fluid loading events. Among the 96 fluid loading events, the proportion of responding 
events (increase in CI ≥10%) decreased from t=0 to 90 min (p = .031). The amount 
infused was somewhat lower in non-responding than in responding events when GEF 
was low (<20%), (Table 2). Baseline CI was lower in responding events, regardless of 
GEF and cutoff percentage of fluid responsiveness. When GEF was low, baseline CVP 
and PAOP were lower for responding events (≥10% increase in CI) while baseline GEDVI 
did not differ from that in non-responding events, irrespective of the amount and type 
of fluids. When GEF was near-normal (≥20%), baseline GEDVI and CVP were lower for 
responding events (≥10% increase in CI), while baseline PAOP did not differ from that in 
non-responding events.
Similar results were obtained for a GEF cutoff of 15% (Table 3). For fluid responsiveness 
defined as an increase in CI ≥15%: only baseline PAOP and not CVP predicted fluid 
responsiveness in the low GEF group (Table 4). In contrast, GEDVI particularly predicted 
fluid responsiveness when GEF was near-normal. Changes in GEDVI paralleled CI 
responses in both GEF groups, while changes in CVP paralleled CI responses only in the 
low GEF group. Changes in PAOP particularly paralleled responses in CI when GEF was 
low. 
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Table 1. Patient characteristics.
GEF <20%
(n=12)
GEF ≥20%
(n=20)
p value
Demographic variables
Age 66±7 61±7 .082
Male / female 9/3 16/4 1.000
APACHE II 9±4 9±3 .690
Coronary artery / major vascular surgery 5/7 13/7 .277
CPB yes / no 4/1 9/4 .648
Time of CPB, minutes 97±72 78±58 .564
Echocardiography (LVEF before surgery)
good (≥40%) / poor (<40%) 3/9 16/4 1.000
Hemodynamic and respiratory variables
HR, b/min
t=0 75±11 68±12 .112
t=90 72±12 72±141 .101 (for increase)
MAP, mm Hg
t=0 85±15 74±12 .034
t=90 92±19 84±102 .608 (for increase)
CVP, mm Hg
t=0 5±2 3±2 .047
t=30 7±3 5±2 N.A. 
t=60 8±3 6±2 N.A. 
t=90 8±23 7±23 .813 (for increase)
mPAP, mm Hg
t=0 17±6 15±4 .260
t=90 23±5 21±4 .627 (for increase)
PAOP, mm Hg
t=0 6±3 7±3 .477
t=30 9±2 9±2 N.A, 
t=60 11±3 10±3 N.A, 
t=90 12±23 11±23 .037 (for increase)
GEDVI, mL/m2
t=0 1049±247 830±195 .009
t=30 1132±360 840±174 N.A. 
t=60 1170±387 857±171 N.A. 
t=90 1220±476 861±189 .089 (for increase)
SVI, ml/m2
t=0 42±10 52±12 .022
t=90 47±94 56±145 .030 (for increase)
CI, mL/min/m2
t=0 3.1±0.7 3.4±0.6 .170
t=30 3.5±0.7 3.7±0.7 N.A. 
t=60 3.7±0.9 3.9±0.8 N.A.
t=90 3.9±0.93 3.9±0.63 .101 (for increase)
GEF, %
t=0 16±4 25±5 N.A.
t=90 19±3 26±4 N.A.
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Distensibility, mL/m2/mm Hg
t=0 241±167 229±124 .830
t=90 132±641 124±602 .910 (for decrease)
PEEP, cm H2O
t=0 7.5±2.0 6.7±2.7 .385
Fluid infused, mL 1466±296 1585±291 .300
Gelatin / HES / albumin 2 / 3 / 7 5 / 8 / 7 .436
Fluid balance, mL 1001±334 1034±497 .839
Mean ± SD 
LVEF left ventricular ejection fraction, CPB cardiopulmonary bypass, GEF global ejection fraction, APACHE 
II acute physiology and chronic health evaluation, LV left ventricular, HR heart rate, MAP mean arterial 
pressure, CVP central venous pressure, MPAP mean pulmonary artery pressure, PAOP pulmonary capillary 
occlusion pressure, GEDVI global end-diastolic volume index, CI cardiac index, PEEP positive end-expiratory 
pressure, HES hydroxyethyl starch. t=0 and 90 min: prior to and at completion of fluid loading; 1p < .05; 
2p = .001; 3p < .001; 4p = .017; 5p = .007 vs. t=0, N.A. not applicable.
Table 2. Summated fluid loading responsiveness (≥10% increase in cardiac index) when global ejection 
fraction is <20% or ≥20%.
                         GEF <20%
                           (n=12)
                        GEF ≥20%
                           (n=20)
R
(n=17 steps 
in 10 patients)
NR
(n=19 steps 
in 11 patients)
p value R
(n=17 steps 
in 14 patients)
NR
(n=43 steps
in 20 patients)
p value
CI, L/min/m2
baseline 3.3±0.9 3.6±0.8 .095 3.3±0.5 3.8±0.8 .028
after 3.9±0.9 3.6±0.8 3.9±0.7 3.8±0.7
change 0.6±0.2 0.0±0.1 N.A. 0.6±0.6 0.0±0.3 N.A. 
GEDVI, mL/m2
baseline 1254±518 1102±246 .506 812±163 869±179 .011
after 1123±422 1111±234 754±176 877±167
change 130±175 -8±73 <.001 586±3 -8±62 .003
CVP, mm Hg
baseline 5±3 8±3 .004 3±2 5±2 .027
after 6±2 9±2 5±2 6±2
change 1±1 1±2 .013 1±1 1±1 .468
PAOP, mm Hg
baseline 8±3 11±3 .003 8±2 9±3 .150
after 10±2 13±4 10±3 11±3
change 2±1 1±2 .083 1±1 1±2 .563
Fluid input per step, mL 541±100 442±135 .019 541±123 523±113 .377
Mean ± SD 
GEF global ejection fraction, R responding fluid loading step (≥10% increase in CI), NR non-responding 
fluid loading step, CI cardiac index, GEDVI global end diastolic volume index, CVP central venous pressure, 
PAOP pulmonary capillary occlusion pressure: n=13, n=10, n=11 and n=21, in R and NR at GEF <20% and ≥20%, 
respectively, N.A. not applicable. p values adjusted for amount and type of fluid.
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Table 3. Summated fluid loading responsiveness, defined as ≥10% increase in cardiac index, when global 
ejection fraction (GEF) is ≤15% or >15%.
                        GEF <20%
                           (n=4)
                        GEF ≥20%
                           (n=28)
R
(n=6 steps 
in 4 patients)
NR
(n=6 steps 
in 3 patients)
p value R
(n=28 steps 
in 19 patients)
NR
(n=56 steps
in 28 patients)
p value
CI, L/min/m2
baseline 3.0±0.7 3.4±0.8 .068 3.4±0.7 3.8±0.8 .037
after 3.6±0.7 3.4±0.9 4.0±0.8 3.8±0.7
change 0.6±0.3 0.0±0.2 N.A. 0.6±0.5 0.0±0.3 N.A.
GEDVI, mL/m2
baseline 1531±458 1275±329 .114 811±182 915±172 .014
after 1746±587 1270±362 880±187 904±180
change 215±270 -5±104 .775 68±69 -9±61 .008
CVP, mm Hg
baseline 5±2 9±2 .002 3±2 6±3 .042
after 6±3 9±2 5±2 7±3
change 1±1 1±1 .277 1±1 1±1 .975
PAOP, mm Hg
baseline 8±3 12±3 .039 8±2 9±3 .488
after 11±2 14±2 10±3 14±4
change 2±2 2±2 .639 1±1 1±2 .137
Mean ± SD
GEF global ejection fraction, R responding fluid loading step (≥10% increase in CI), NR non-responding 
fluid loading step, CI cardiac index, GEDVI global end diastolic volume index, CVP central venous pressure, 
PAOP pulmonary capillary occlusion pressure: n=13, n=10, n=11 and n=21, in R and NR at GEF ≤15% and >15%, 
respectively, N.A. not applicable. P values adjusted for amount and type of fluid.
Correlations. For the low GEF group, baseline PAOP and CVP inversely correlated to 
changes in CI, irrespective of amount and type of fluids (r = -.57 and -.44, p = .008 and 
.010, respectively; Figure 1). In the near-normal GEF group, only baseline CVP inversely 
correlated to CI changes (r = -.35, p = .009) and PAOP did not (Figure 2). Baseline 
GEDVI inversely correlated to changes in CI in the near-normal GEF group (r = -.29, p = 
.03; Figure 3). Changes in CI were paralleled by changes in GEDVI (r = .74, p <.001) in the 
low GEF group. Changes in CI correlated to changes in both CVP and GEDVI in the near-
normal GEF group (r = .36 and r = .72, p = .007 and <.001, respectively). Changes in PAOP 
correlated better to CVP in the near-normal GEF group (r = .67, p <.001) than in the low 
GEF group (r = .21, p = .404). 
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Table 4. Summated fluid loading responsiveness, defined as ≥15% increase in cardiac index, when global 
ejection fraction (GEF) is <20% or ≥20%.
                        GEF <20%
                           (n=12)
                         GEF ≥20%
                           (n=20)
R
(n=8 steps 
in 6 patients)
NR
(n=28 steps 
in 10 patients)
p value R
(n=7 steps 
in 6 patients)
NR
(n=53 steps
in 20 patients)
p value
CI, L/min/m2
baseline 3.2±0.6 3.5±0.9 .009 3.1±0.5 3.8±0.7 .024
after 3.9±0.6 3.7±0.9 4.0±0.9 3.8±0.7
change 0.7±0.2 0.0±0.2 N.A. 0.9±0.8 0.1±0.3 N.A. 
GEDVI, mL/m2
baseline 1328±532 1057±227 .027 644±104 869±169 <.001
after 1536±633 1070±231 730±84 869±178
change 209±228 13±77 <.001 85±88 0±60 .010
CVP, mm Hg
baseline 4±3 7±3 .269 3±1 5±2 .169
after 5±2 8±2 5±2 6±2
change 1±2 1±1 .020 2±2 1±1 .575
PAOP, mm Hg
baseline 6±3 11±3 <.001 9±2 9±3 .604
after 9±2 12±4 12±3 11±4
change 3±1 1±1 .004 2±0 1±1 .022
Fluid input per step, mL 563±106 468±128 .025 549±151 526±111 .498
Mean ± SD
GEF global ejection fraction, R responding fluid loading step (≥10% increase in CI), NR non-responding fluid 
loading step, CI cardiac index, GEDVI global end diastolic volume index, CVP central venous pressure, PAOP 
pulmonary capillary occlusion pressure, N.A. not applicable. p values adjusted for amount and type of fluid.
Predictors	of	fluid	responsiveness	in	ROC	curves. In the near-normal GEF group, baseline 
GEDVI and CVP predicted fluid responsiveness (increase in both CI ≥10% and ≥15%), while 
in the low GEF group baseline PAOP and CVP had predictive value (Table 5). This table 
also shows the optimum cutoff values and associated sensitivities and specificities for 
fluid responsiveness. Table 6 shows identical results for cutoffs of SVI responses (0-90 
min) rather than of CI responses.
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Figure 1. Baseline filling pressures (PAOP, CVP) versus change in cardiac index (CI) when global ejection 
fraction (GEF) is low (<20%): r = -.57, p = .008 and r = -0.44, p = .010, respectively.
Figure 2. Baseline filling pressures (PAOP, CVP) versus change in cardiac index (CI) when global 
ejection fraction (GEF) is near-normal (≥20%): r = -.01, p = .951 and r = -.35, p = .009, respectively. For 
difference between r: p = .023.
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Figure 3. Baseline global end-diastolic volume (GEDVI) versus change in cardiac index (CI) according to 
global ejection fraction (GEF). In ≥20% GEF group r = -.29, p = .03, in <20% GEF group r = .17, p = .33. For 
difference between r: p = .048.
Table 5. Areas under the receiver operating characteristic curve (AUC’s, 95% confidence intervals) for 
prediction of fluid responsiveness (increase in cardiac index ≥10% (A) or ≥15% (B)) by baseline values, 
according to global ejection fraction (GEF).
GEF <20% GEF≥20%
AUC p value Cutoff AUC p value Cutoff
A
GEDVI 0.56 (0.39-0.73) .511 902 0.72 (0.58-0.83) .002 890
CVP 0.76 (0.59-0.88) .001 6 0.73 (0.60-0.84) <.001 2
PAOP 0.79 (0.57-0.93) .004 10 0.65 (0.46-0.81) .129 9
B
GEDVI 0.62 (0.44-0.77) .330 1279 0.89 (0.78-0.95) <.001 623
CVP 0.77 (0.60-0.89) .002 5 0.73 (0.60-0.84) .013 4
PAOP 0.84 (0.63-0.96) <.001 9 0.50 (0.32-0.69)* .98 9
GEF global ejection fraction, GEDVI global end diastolic volume index (mL/m2), CVP central venous pressure 
(mm Hg), PAOP pulmonary capillary occlusion pressure (mm Hg) 
*p = .008 vs. AUC GEDVI; for A and low GEF: PAOP sensitivity 92%, specificity 60%, positive predictive 
value 75%, negative predictive value 86%; for normal GEF: GEDVI sensitivity 82%, specificity 56%, positive 
predictive value 42%, negative predictive value 89%; for B and low GEF: PAOP sensitivity 86%, specificity 
69%, positive predictive value 55%, negative predictive value 92%; for normal GEF: GEDVI sensitivity 71%, 
specificity 94%, positive predictive value 63%, negative predictive value 93%.
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Table 6. Areas under the receiver operating characteristic curve (AUC’s, 95% confidence intervals) for 
prediction of fluid responsiveness (increase in SVI ≥10% from t=0-90 min (A) or ≥15% (B)) by baseline values 
at t=0, according to global ejection fraction (GEF).
GEF <20% GEF≥20%
AUC p value AUC p value
A
GEDVI 0.53 (0.17-0.89) .865 0.88 (0.72-1.03) .005
CVP 0.89 (0.70-1.08) .034 0.67 (0.42-0.92) .203
PAOP 1.00 (1.00-1.00) .020 0.72 (0.45-0.99) .175
B
GEDVI 0.49 (0.14-0.83) .935 0.74 (0.52-0.96) .099
CVP 0.80 (0.54-1.06) .088 0.74 (0.53-0.96) .091
PAOP 1.00 (1.00-1.00) .020 0.75 (0.48-1.03) .157
GEF global ejection fraction, GEDVI global end diastolic volume index (mL/m2), CVP central venous pressure 
(mm Hg), PAOP pulmonary artery occlusion pressure (mm Hg).
Discussion
Our study suggests that in patients after coronary and major vascular surgery the 
predictive value of cardiac filling pressures and volumes for fluid responsiveness 
depends on GEF, as calculated by transpulmonary dilution-derived parameters. 
In patients with low GEF indicating systolic cardiac dysfunction, PAOP has a greater 
predictive value than GEDVI for fluid responsiveness, whereas in patients with near-
normal GEF, GEDVI is superior to PAOP. This suggests the increasing value of filling 
pressures over volumes for predicting fluid responsiveness in patients with left ventricular 
systolic dysfunction. Indeed, the suggestion that a low GEF reflects systolic dysfunction 
of the left ventricle is supported by the fact that changes in PAOP did not correlate with 
changes in CVP, as reported by others29-31. Furthermore, our data suggest that PAOP 
relates to systolic and not to diastolic function since distensibility did not differ between 
the low and near-normal GEF groups, both prior to and after fluid loading. There was 
no sign of pulmonary hypertension or difference in MPAP according to fluid responses, 
thus diminishing the likelihood for right ventricular dysfunction confounding GEDVI as a 
reflection of left ventricular end-diastolic volume. Hence, the low GEF was likely caused 
by postoperative left ventricular dysfunction, as the preoperative echocardiographic 
left ventricular function did not differ among GEF groups. Hence, the greater predictive 
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value of PAOP than of CVP, according to GEF, can be explained by greater effect 
of left than of right ventricular loading on fluid responsiveness, although we did not 
directly assess postoperative biventricular function, for instance by echocardiography. 
Conversely, the predictive value of CVP for fluid responsiveness regardless of GEF may 
indicate the importance of venous return for augmenting cardiac output, rather than 
right ventricular dysfunction following increased afterload limiting a rise in cardiac 
output with fluids when CVP is relatively high as suggested recently32. Finally, the similar 
course of MAP according to fluid responses disfavors alterations in systemic vascular 
tone confounding the effect of preload augmentation and its assessment during fluid 
loading.
The frequency of fluid responsiveness generally agrees with the literature, utilizing 
various loading protocols, and also involving variable amounts of fluid, in cardiac surgery 
patients9,10,12,14-17,19,20. That both CVP and PAOP were of predictive and monitoring value in 
our study can be attributed in part to the fact that a relatively low PEEP was applied, so 
that atmospheric pressure-referenced filling pressures may have approached transmural 
values. That fluid responsiveness was not uniformly observed in spite of clinical signs of 
hypovolemia can be attributed to the relatively poor predictive value of the latter, as 
commonly described33. Our study does not address the effect of mathematical coupling 
of GEDVI to CI, when volumes are derived from the same transpulmonary dilution curve as 
cardiac output. The often observed superiority of cardiac volumes over filling pressures 
in predicting and monitoring cardiac output responses, i.e. fluid responsiveness, may 
indeed be overestimated by the phenomenon, as recently described by our group also1,6-
8,10-16,18,19,27. In hearts with systolic dysfunction and dilatation, a right- and downward shift 
on the Frank-Starling curve and along the curvilinear pressure-volume relationship at 
end-diastole, preload recruitability may be more dependent on and thus predicted and 
monitored by pressures than by volumes5,22. Indeed, GEDVI was higher in patients with 
a low versus a near-normal GEF, suggesting cardiac dilatation. Cardiac distensibility did 
not differ among GEF groups, favoring a similar position of the diastolic pressure-volume 
relation and diastolic function. Our data, obtained in surgical patients, thus confirms the 
Mundigler et al. data in non-surgical patients with reduced left ventricular systolic function 
due to dilated and ischemic cardiomyopathy20. The authors showed that in patients 
with left ventricular systolic dysfunction, the value of transpulmonary thermodilution-
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derived total end-diastolic volume is particularly insensitive for monitoring the effects of 
fluid administration on cardiac preload when compared to filling pressures. On the other 
hand, in patients with normal left ventricular systolic function, volumes and pressures 
were of equal value20. 
Reuter et al. and Preisman et al.14,17 did not observe different monitoring values of 
filling volumes or pressures according to left ventricular ejection fraction and this can 
be attributed, in part, to the small number of patients in their studies and their (varying) 
definitions of left ventricular systolic dysfunction (ejection fraction <35% in the former 
and <40% in the latter). Nevertheless, the trend was for the increasing value of pressure 
monitoring in patients with low versus those with normal GEF in the study by Reuter 
et al.14. The current data also agree with our previous study in a cohort of valvular and 
coronary artery surgery patients21, showing the superior value of the pulmonary artery 
catheter-derived pressures over transpulmonary dilution-derived volumes for assessing 
fluid responsiveness in the former with a low GEF and presumed left ventricular 
systolic dysfunction. The current study thus suggests that systolic cardiac function 
and the degree of cardiac dilatation, rather than underlying disease (type of surgery), 
determines the relative value of pressures and volumes for predicting and monitoring 
fluid responsiveness, as suggested previously5. 
Our study has some limitations. Since our analyses adjusted for amount and 
type of fluids, it is unlikely that small differences in the amounts of fluids (mean 100 
mL when GEF <20%, for instance) rather than differences in cardiac preloading, were 
responsible for different increases in CI (of 0.6 L/min/m² when GEF <20%) in responding 
versus non-responding fluid loading events. The fluid loading protocol guided by 
changes in filling pressures was used to prevent deleterious fluid overloading rather 
than to guide treatment on the basis of fluid responsiveness, as recently advocated 
to ensure safety23,26,27. By virtue of its design, the study did not address the potential 
clinical benefits of one hemodynamic monitoring technique over the other. Although 
our results were obtained by thermal-dye dilution, the current standard is single 
transpulmonary thermodilution (PiCCO™ technique)10,34, because double and single 
dilution methods yield similar values for GEDVI. Hence, our results should also be applied 
to single transpulmonary thermodilution. Although dynamic indices (e.g. pulse pressure 
or stroke volume variation) are better predictors of fluid responsiveness (provided that 
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they are interpreted properly)32,33, we did not include these indices, since the aim was 
to study the value of static cardiac preload indicators. That static filling pressures were 
of predictive value for fluid responsiveness in our study can be explained by the low 
PEEP used in our patients, and this may not apply when higher PEEP is needed. Finally, 
predictors and monitors of fluid responsiveness were independent of the definition of 
the latter, even though most commonly CI responses >10% are used33.
Conclusions
Our study suggests that, after coronary artery and major vascular surgery, prediction 
and monitoring of fluid responsiveness by pressures or transpulmonary thermodilution-
derived volumes depends on systolic cardiac function and the degree of cardiac 
dilatation. Whereas CVP may be useful for predicting fluid responsiveness in patients 
after coronary and major vascular surgery regardless of GEF, GEDVI is less and PAOP is 
more useful for predicting fluid responsiveness when GEF is low than when it is near-
normal, respectively, provided that positive end-expiratory pressure is low. In practice, 
our data may imply use of the pulmonary artery catheter and derived filling pressures 
in hemodynamic monitoring of patients with impaired left ventricular systolic function 
and dilatation, and use of transpulmonary thermodilution and derived filling volumes in 
cases of relatively normal left ventricular systolic function. This may help in refining fluid 
therapy and preventing harmful fluid overloading.
Key Messages
•	 In patients after coronary artery or major vascular surgery, the relative 
predictive value of filling pressures and volumes for fluid responsiveness 
depends on left ventricular systolic function as measured by GEF
•	 Whereas, CVP may be useful for predicting fluid responsiveness regardless 
of GEF, in patients with low GEF, PAOP has a greater predictive value than 
GEDVI for fluid responsiveness
•	 In patients with near-normal GEF, GEDVI is superior to PAOP for predicting 
fluid responsiveness
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•	 This study argues in favor of using pulmonary artery catheter-derived 
filling pressures in hemodynamic monitoring of patients with impaired left 
ventricular systolic function and of using transpulmonary thermodilution-
derived volumes in relatively normal left ventricular systolic function
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Abstract
Background
Sepsis-induced cardiac dysfunction may limit fluid responsiveness and the mechanism 
thereof remains unclear. Since cardiac function may affect the relative value of cardiac 
filling pressures, such as the recommended central venous pressure (CVP), versus filling 
volumes in guiding fluid loading, we studied these parameters as determinants of fluid 
responsiveness, according to cardiac function. 
Methods 
A delta CVP-guided, 90 min colloid fluid loading protocol was performed in 16 
mechanically ventilated patients with sepsis-induced hypotension and three 30 min 
consecutive fluid loading steps of about 450 mL per patient were evaluated. Global 
end-diastolic volume index (GEDVI), cardiac index (CI) and global ejection fraction (GEF) 
were assessed from transpulmonary dilution. Baseline and changes in CVP and GEDVI 
were compared among responding (CI increase ≥10% and ≥15%) and non-responding 
fluid loading steps, in patient with low (<20%, n=9) and near-normal (≥20%) GEF (n=7) at 
baseline.
Results
A low GEF was in line with other indices of impaired cardiac (left ventricular) function, 
prior to and after fluid loading. Of 48 fluid loading steps, 9 (of 27) were responding 
when GEF <20% and 6 (of 21) when GEF ≥20. Prior to fluid loading, CVP did not differ 
between responding and non-responding steps and levels attained were higher in the 
former, regardless of GEF (p = .004). Prior to fluid loading, GEDVI (and CI) was higher 
in responding (1007±306 mL/m2) than non-responding steps (870±236 mL/m2) when 
GEF was low (p = .002), but did not differ when GEF was near-normal. Increases in 
GEDVI were associated with increases in CI and fluid responsiveness, regardless of GEF 
(p <.001).
Conclusions 
As estimated from transpulmonary dilution, about half of patients with sepsis-induced 
hypotension have systolic cardiac dysfunction. During dysfunction, cardiac dilation with 
a relatively high baseline GEDVI maintains fluid responsiveness by further dilatation 
(increase in GEDVI rather than of CVP) as in patients without dysfunction. Absence of 
fluid responsiveness during systolic cardiac dysfunction may be caused by diastolic 
dysfunction and/or right ventricular dysfunction. 
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Introduction
 
Patients with severe sepsis or septic shock commonly develop cardiac dysfunction, 
even in the absence of cardiac ischemia1-3. These abnormalities may include depression 
of left and/or right ventricular systolic function and/or diastolic dysfunction and may 
be accompanied by ventricular dilatation, as estimated from echocardiography or 
radionuclide cineangiography4,5. This cardiac dysfunction is usually reversible and 
returns to normal in 7 to 10 days in survivors6-8. Systolic dysfunction-induced ventricular 
dilatation is suggested to be an adaptive mechanism to maintain a high cardiac output 
which is associated with survival4,9, while other investigators denied such a dilatory 
response arguing in favor of impaired relaxation and diastolic (often upon systolic) 
dysfunction contributing to non-survival8,10-16. 
Fluid loading is often the initial treatment of sepsis-induced hypotension and the 
response may be diminished in sepsis-induced cardiac depression associated with 
severe disease and non-survival5,13,14. On the other hand, fluid overloading when the 
heart is non-responsive and the central venous pressure (CVP) is inadvertently elevated 
is potentially harmful and also associated with mortality, emphasizing the value of 
appropriate hemodynamic monitoring17. By optimizing preload and assessing fluid 
responsiveness, deleterious hypoperfusion and fluid overloading may be prevented. 
Traditionally, filling pressure, like CVP, have been used to guide fluid loading in sepsis-
induced hypotension17-20, even though its predictive value for fluid responsiveness 
during mechanical ventilation and altered cardiac function is doubtful21-23. Alternatively, 
the transpulmonary dilution technique estimates the global end-diastolic volume index 
(GEDV), and pulmonary blood volume index (PBVI) as a superior and global measures 
of cardiac preload11,23,24. The GEDVI represents the volumes of the right and left heart at 
the end of diastole and often reflects left ventricular end-diastolic volume estimated by 
echocardiography provided that right ventricular dilatation is absent25. 
A relatively low GEDVI may predict fluid responsiveness (and a relatively high GEDVI 
absence thereof), but the role of systolic and/or diastolic dysfunction with respect to 
interpretation of absolute values remains unclear, even though changes in stroke 
volume or cardiac output correlate to changes in GEDVI21,23,26. Indeed, the relative value 
of GEDVI and filling pressures in determining fluid responsiveness depends on systolic 
cardiac function, at least in non-septic patients27. Conversely, echocardiographic end-
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diastolic left ventricular dimensions poorly predicted fluid responsiveness but changes 
were superior to filling pressures in monitoring changes in cardiac output upon fluid 
loading in some studies on sepsis9,23. In contrast, fluid responsiveness was found to be 
associated with biventricular dilatation by nuclear angiography and non-responsiveness 
appeared attributable to right ventricular systolic dysfunction following mild pulmonary 
hypertension in other studies on sepsis6,9. 
In view of the above controversies on mechanisms and predictive values, we 
evaluated and compared filling volumes to pressures in determining the cardiac response 
to fluid loading according to systolic cardiac function in sepsis-induced hypotension, 
in the hypothesis that, even in dysfunctional hearts, cardiac dilatation is required to 
increase cardiac output upon fluid loading. 
Patients and methods
 
This was a sub-study of a prospective, non-randomized, single-center clinical trial, 
investigating the cardiorespiratory effects of various resuscitation fluids in presumed 
hypovolemia during sepsis and non-sepsis, in mechanically ventilated patients in the 
intensive care unit (ICU)24,28. We analyzed, retrospectively, 16 patients with sepsis 
monitored by both CVP and the transpulmonary dilution technique. These patients 
were divided in two groups according to a low GEF (<20%) and near-normal GEF (≥20%). 
The cutoff of 20% approximately reflects a cutoff of 40% ejection fraction of the left 
ventricle as measured by echocardiography, provided that there is no right ventricular 
dysfunction29-31. The original study was approved by the Ethics Committee of the Vrije 
Universiteit Medical Center and written informed consent was obtained. We analyzed 
the effect of colloid fluid loading in patients with sepsis-induced hypotension. Colloid 
fluid loading was given with modified fluid gelatin 4%, hydroxyethyl starch (HES) 6% or 
albumin 5%, all of which have similar oncotic properties and hemodynamic responses24,28. 
We only analyzed patients who completed fluid loading and measurements up to 
t=90 min. Inclusion criteria, at enrollment and start of the protocol, were presumed 
hypovolemia, defined as a systolic blood pressure <110 mmHg and a relatively low CVP 
taking positive end-expiratory pressure (PEEP) into account (Table 1). Exclusion criteria 
were age >75 year, preterminal illness with a life expectancy of less than 24 hours, or 
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known anaphylactic reactions to colloids. Sepsis was defined according to international 
guidelines32. The origin of sepsis was defined by clinical signs and symptoms, imaging 
techniques and positive local and/or blood cultures32. All patients were on controlled 
mechanical ventilation and positive end-expiratory pressure (PEEP).
Study protocol. The protocol was started in the ICU when patients met the inclusion 
criteria. Demographic characteristics were recorded, including the acute physiology 
and chronic health evaluation (APACHE-II). After baseline measurements were taken, 
fluids were given over 90 min on the basis of the response within predefined limits of 
increases in CVP, according to a previously described protocol16,28 (Table 1). Up to 200 mL 
of fluid were given every 10 min, provided that the increase in CVP upon fluid loading did 
not exceed critical values, and this policy has been proven safe in previous studies24,28 
(i.e. not evoking pulmonary edema). The maximum amount of fluid infused was 1800 
mL. Fluid responsiveness was defined as an increase of CI ≥10 and 15%, in accordance 
with the literature22,23, between t=0-30, t=30-60 and t=60-90 min upon fluid loading. 
Concomitant vasoactive and sedative drug treatment and ventilatory settings remained 
unchanged during fluid loading. 
Measurements. Heart rate (HR) and mean arterial pressure (MAP) were recorded at 
t=0 and 90 min. MAP and CVP were measured in the supine position after calibration, 
zeroing to atmospheric pressure at the midchest level at end-expiration (TramscopeR, 
Marquette GE, Milwaukee, Wisconsin). Cardiac output, GEDVI, PBVI and CVP were 
measured every 30 min, from t=0 to 90 min. Relevant measurements were indexed to 
body surface area (BSA), giving stroke volume index (SVI, mL/m2), cardiac index (CI, L/
min/m2), GEDVI (n 680-800 mL/m2) and PBVI (n 150-250 mL/m2), respectively. For these 
measurements, the transpulmonary thermal-dye indicator dilution technique was used11. 
These measurements involve averages obtained from 2-3 central venous injections of 15 
mL of ice-cold indocyanine green in 5% glucose solution and concomitant registration of 
the dilution curves in the femoral artery, by a 3F catheter equipped with a thermistor (PV 
2024, Pulsion Medical Systems, Munich, Germany). This catheter was inserted via a 4F 
introducing sheath (Arrow, Reading, USA) and connected to a bedside computer (COLD 
Z-021, Pulsion Medical Systems, Munich, Germany. The COLD Z-021 is the precursor to 
the current transpulmonary thermodilution pulse contour cardiac output (PiCCO™) 
technique and yields the same cardiac parameters. Reproducibility of measurements 
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is typically within 10%11. GEDVI represents the volumes of the right and left heart at end-
diastole and reflects left ventricular dimensions obtained by echocardiography in the 
absence of overt right ventricular distention25. The ratio between stroke volume index 
(cardiac index/HR) and GEDVI/4 is defined as the global ejection fraction (GEF, normal 
values 25-35%), and is an indicator of left ventricular systolic function, provided that 
there is no right ventricular dysfunction29-31. Left ventricular stroke work index (LVSWI, 
gm/m2) was calculated from SVI x (MAP-CVP) x 0.0136 and cardiac function index (CFI, 
n 18.0-26.0 1/min) from CI/(GEDVI/4)30,31. Preload-recruitable stroke work was defined 
by LVSWI/GEDVI24. CFI, LVSWI and LVSWI/GEDVI were used to assess cardiac (e.g. left 
ventricular) systolic function. The lung injury score was calculated from radiographic 
densities, oxygenation ratio PaO2/FIO2, PEEP and dynamic compliance and ranges 
between 0-4. Mortality refers to death in the ICU.
Statistical analysis. For categorical data, Fisher exact tests were used. Since 
continuous data were normally distributed (Kolmogorov-Smirnov test, p >.05), they 
were summarized by mean±standard deviation (SD) and parametric tests were done. 
Paired and unpaired t-tests were used to compare data in time and between GEF 
groups, respectively generalized estimating equations (GEE) were used to evaluate 
differences in baseline and changes in variables between summated responding and 
non-responding fluid loading steps in each GEF group, to evaluate their determining 
values, respectively, taking repeated measurements in the same patients and type and 
volume of fluid administered (as covariates) into account. Exact two-sided p values >.001 
are given and considered statistically significant when <.05. All analyses were conducted 
using SPSS version 15.0 (SPSS Chicago, Ill, USA).
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Table 1. Fluid challenge protocol.
CVP at start: ≤ 8  if PEEP ≤15 200 mL/10 min
≤ 12 if PEEP >15 200 mL/10 min
≤ 10 if PEEP ≤15  100 mL/10 min
≤ 14 if PEEP >15 100 mL/10 min
≤ 12 if PEEP ≤15 50 mL/10 min
≤ 16 if PEEP >15 50 mL/10 min
CVP during infusion: increase >5 stop
CVP after 10 min waiting: increase ≤2 continue
2< increase ≤5 wait 10 min
increase >5 stop
CVP after 10 min waiting: increase >2 stop
increase ≤2 repeat
CVP central venous pressure (mm Hg), PEEP positive end-expiratory pressure (cm H2O).
Results
 
Table 2 summarizes the characteristics of patients. The hemodynamic variables differ 
according to GEF and changes upon fluid loading. There was no difference in the amount 
and type of fluids infused between the GEF groups. GEF did not change during fluid 
loading. In the low GEF group, other function indices also pointed to systolic cardiac 
dysfunction, prior to and after fluid loading, even though the CI attained with fluid 
loading did not differ among the groups. The number of fluid loading responses did not 
differ according to GEF, but the increase in CI decreased with increasing fluid loading 
steps only when GEF was low (p =.04). The increases with fluids in CVP, GEDVI, MAP, 
LVSWI and CI did not differ among GEF groups, even though SVI, PBVI and LVSWI/GEDVI 
increased in the low GEF group only. 
Fluid loading steps in GEF groups. Responses were independent of the type of colloid 
fluid, regardless of GEF and cutoff for fluid responsiveness. CI prior to each fluid loading 
step was higher in responding than non-responding steps in the low GEF group, but 
lower in the near-normal GEF group (Table 3). CVP did not differ between responding 
and non-responding steps in both GEF groups but attained higher values after fluid 
loading in non-responding than in responding steps, regardless of GEF. 
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Table 2. Patient characteristics.
GEF <20%
(n=9)
GEF ≥20%
(n=7) p value
Age 62±9 57±9 .32
Male/female 7/2 4/3 .60
APACHE II 16±4 12±5 .08
Cardiac premorbidity 4 1 .31
Sepsis origin .38
Pulmonary 4 3
Abdominal 2 0
CNS 0 1
Urogenital 1 0
Unknown 2 3
Bloodstream infection .41
Gram - 2
Gram + 2
Fungi 2
PEEP, cm H2O 14±6 12±3 .17
Tidal volume, mL/kg 8.0±0.8 9.0±1.6 .08
PaO2/FIO2 209±54 193±62 .60
Lung injury score 2.2±0.8 2.5±0.8 .60
ICU mortality 4 2 .37
Hemodynamics
HR, min
t=0 106±18 90±25 .15
t=90 103±16 95±22 .42
MAP, mm Hg
t=0 73±12 74±9 .84
t=90 88±191 89±131 .87
CVP, mm Hg
t=0 9±5 8±3 .61
t=90 12±52 12±32 .83
CI, L/min/m2
t=0 3.3±0.6 4.3±1.5 .06
t=90 3.9±1.02 5.0±1.43 .09
SVI, ml/m2
t=0 31±6 49±12 .002
t=90 38±91 53±11 .01
LVSWI, gm/m2
t=0 27±5 43±8 <.001
t=90 39±111 55±111 .01
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GEDVI, mL/m2
t=0 891±257 787±140 .35
t=90 963±2731 866±1701 .43
GEF, %
t=0 15±2 25±5 N.A.
t=90 16±4 25±7 .005
CFI, 1/min
t=0 15.2±2.9 22.1±6.2 .01
t=90 16.8±4.0 23.4±5.5 .01
LVSWI/GEDVI, gm/mL
t=0 0.13±0.04 0.22±0.04 <.001
t=90 0.17±0.073 0.26±0.07 .02
Dopamine, µg/kg/min 5.6±3.4 4.9±4.3 .92
Norepinephrine, µg/kg/min 0.09±0.11 0.06±0.12 .25
Fluid, mL 1456±296 1271±269 .22
Gelatin / HES / albumin 3 / 2 / 4 2 / 3 / 2 .66
Mean±SD or number of patients, where appropriate.  
GEF global ejection fraction, APACHE II acute physiology and chronic health evaluation, CNS central nervous 
system, PEEP positive end-expiratory pressure, ICU intensive care unit, PaO2/FIO2 arterial partial pressure of 
O2 over inspiratory O2 fraction, HR heart rate, MAP mean arterial pressure, CVP	central venous pressure, 
CI cardiac index, SVI	stroke volume index, LVSWI	left ventricular stroke volume index, GEDVI global end-
diastolic volume, CFI cardiac function index, HES hydroxyethyl starch. 1p = .02 , 2p = .002, 3p = .009, vs. t=0, 
N.A. not applicable.
When GEF was low, GEDVI was higher prior to responding than non-responding fluid 
loading steps, while GEDVI in the near-normal GEF group did not differ prior to fluid 
loading steps. GEDVI and PBVI increased in responding fluid loading steps regardless of 
GEF. Hence, baseline CVP and GEDVI were poor predictors of fluid responsiveness in both 
GEF groups. When fluid responsiveness was defined as an increase in CI ≥15%, changes in 
CO were also directly associated with changes in GEDVI, but not in PBVI. Otherwise there 
were only 4 out of 9 responding steps remaining when defining fluid responsiveness by 
15 vs. 10% CI increases, in patients with low GEF needing relatively large amounts of fluid. 
Baseline GEDVI was not lower in responders than non-responders. 
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Table 3. Summated fluid loading steps, with responsiveness defined as ≥10% and ≥15% increase in cardiac 
index (CI), when systolic cardiac function is reduced or near-normal at 20% cutoff of global ejection fraction 
(GEF).
GEF <20%
(n=9)
GEF ≥20%
(n=7)
Increase CI ≥10% R
(n=9 steps 
in 6 patients)
NR
(n=18 steps 
in 9 patients)
p value R
(n=6 steps 
in 5 patients)
NR
(n=15 steps
 in 7 patients)
p value
CI, L/min/m2
baseline 3.7±0.7 3.5±0.7 .04 3.6±1.2 5.0±1.5 .008
after 4.4±0.8 3.4±0.6 4.3±1.4 5.0±1.5
change 0.7±0.3 0.0±0.3 N.A. 0.7±0.3 0.0±0.2 N.A. 
GEDVI, mL/m2
baseline 1007±306 870±236 .002 801±186 834±163 .83
after 1102±313 858±208 872±199 843±167
change 96±59 -12±54 <.001 70±85 8±38 <.001
CVP, mm Hg
baseline 9±6 11±5 .41 10±3 10±3 .68
after 10±6 12±4 10±2 11±3
change 1±1 1±2 <.001 1±2 2±1 .004
PBVI, mL/m2
baseline 215±95 203±64 .25 212±51 225±50 .86
after 250±54 204±52 224±40 227±50
change 34±63 16±9 <.001 11±52 2±53 <.001
Fluid input per step, mL 522±120 467±161 .07 450±176 467±145 .75
Gelatin / HES / Albumin 3 / 1 / 5 6 / 5 / 7 .65 5 / 6 / 4 1 / 3 / 2 .24
Increase CI ≥15% R
(n=9 steps 
in 6 patients)
NR
(n=23 steps 
in 9 patients)
p value R
(n=5 steps 
in 4 patients)
NR
(n=16 steps
 in 7 patients)
p value
CI, L/min/m2
baseline 3.6±1.0 3.6±0.7 .50 3.6±1.3 4.9±1.5 .001
after 4.4±1.1 3.7±0.7 4.4±1.5 5.0±1.5
change 0.90.3 0.0±0.3 N.A. 0.8±0.3 0±0.0 N.A.
GEDVI, mL/m2
baseline 802±214 935±271 .26 814±205 829±160 .83
after 935±254 940±277 886±219 841±162
change 133±42 5±63 <.001 73±96 12±39 <.001
CVP, mm Hg
baseline 10±4 11±5 .59 9±3 10±3 .61
after 11±4 12±5 10±3 11±3
change 1±1 1±1 .76 1±2 1±1 .05
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
119Global end-diastolic volume and sepsis-induced systolic dysfunction
7
PBVI, mL/m2
baseline 159±105 216±67 .17 213±57 224±48 .68
after 218±26 220±60 215±38 230±50
change 59±87 4±63 .56 1±51 6±53 <.001
Fluid input per step, mL 600± 465±153 < .001 460±195 462±140 .84
Gelatin / HES / Albumin 1 / 1 / 2 8 / 5 / 10 .67 1 / 3 / 1 5 / 6 / 5 1.0
Mean±SD or number of patients where appropriate
CI cardiac index, GEF global ejection fraction, R responding fluid loading step, NR non-responding fluid 
loading step, CVP central venous pressure, GEDVI global end-diastolic volume index, PBVI pulmonary blood 
volume index, HES hydroxyethylstarch, N.A. not applicable.
Correlations. Changes in PBVI did not correlate to changes in GEDVI and only the latter 
related to changes in CI, regardless of GEF (r=0.56, p <.001; Figure 1). Changes between 
0-90 min in SVI correlated to changes in GEDVI in the low GEF group only (r=0.70, p =.03, 
n=9).
Figure 1. Similar changes in cardiac index (CI, %) versus changes in global end-diastolic volume index 
(GEDVI, mL/m2) upon fluid loading steps in patients with low global ejection fraction (open circles, 
r = .65 p < .001) and those with near-normal global ejection fraction (closed circles, r = .42 p = .05) 
during severe sepsis or septic shock.
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Discussion
 
Our study suggests that systolic cardiac dysfunction evidenced by a low GEF29,30 is 
common in patients with severe sepsis or septic shock. This dysfunction occurring in 
56% of our patients, independent of cardiac premorbidity, agrees with the literature1-3,31. 
Although this phenomenon might impair fluid responsiveness9,18,24, our study suggests 
that fluid responsiveness can be maintained when the heart dilates, even during 
myocardial depression. In contrast, the optimum GEDVI in patients after cardiovascular 
surgery34-36 ranges from 680-800 mL/m2, and these values may therefore not apply 
in sepsis. Maintaining fluid responsiveness at higher GEDVI conforms to the idea 
that dilatation during sepsis-induced systolic dysfunction is as an adaptive response 
associated with survival by maintaining a relatively high CI1-3,6,7,9,37. Indeed, GEDVI was 
higher prior to responding than to non-responding steps according to CI ≥10% increases 
when GEF was low (7 of 9 (77%) responding steps had a baseline GEDVI >850 mL/m2). 
Also, it was not lower in responding than non-responding steps according to CI ≥15% 
increases, in contrast to the observations that a low baseline GEDVI, albeit dependent on 
GEF25, is more often associated with fluid responsiveness than a relatively high GEDVI21,26. 
This confirms that the predictive value for fluid responsiveness of baseline GEDVI or end-
diastolic dimensions, rather than changes, is imperfect by its dependency of systolic 
function, also in sepsis21,26,27,38,39. That the GEDVI prior to responding fluid loading steps 
was not lower compared to non-responding steps when GEF ≥20%, can be attributed to 
a difference in systolic function26, since CI was lower in the latter. Finally, baseline GEDVI 
may depend on age and gender40.
In contrast, we observed that patients with both systolic dysfunction and inability to 
dilate, were not fluid responsive. The inability to dilate upon systolic dysfunction could 
comply with the impaired relaxation and diastolic dysfunction found on echocardiography 
either as an isolated phenomenon or concomitant with systolic dysfunction in 20-60% 
of patients with severe sepsis or septic shock10-16,25. The phenomenon appeared was 
associated with non-survival and was often transient and reversible in survivors. An 
additional hypothesis may be the presence of right ventricular dysfunction, in view 
of the increase in CVP. It cannot be excluded that the presence of predominant right 
ventricular dysfunction and dilatation limiting left ventricular filling though pericardial 
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constraint may contribute to the lack of fluid responsiveness. Indeed, right ventricular 
dysfunction caused by moderate pulmonary hypertension (which was not monitored 
in this study) has been described to limit fluid responsiveness before6,39. Out data show 
that CVP increases upon fluid loading were slightly greater in non-responding than in 
responding steps which may also point to right ventricular dysfunction and dilatation 
in some of our patients with low GEF. However, in our study, the increase in CVP was 
also greater in non-responding than in responding fluid loading steps when GEF was 
near-normal, which may argue against predominant right ventricular dysfunction in non-
responding fluid loading steps of low GEF patients. Since we did not perform operator-
dependent, bedside echocardiography simultaneously, to differentiate between right 
or left ventricular dilatation, we cannot definitively decide on diastolic and/or right 
ventricular dysfunction in non-responding steps when GEF is low.
Patients with near-normal systolic function were also fluid-responsive by dilatation 
when operating in the steep part of the cardiac function curve. The dilatation associated 
with fluid responsiveness, as measured by an increase in GEDVI, is thus independent 
of systolic cardiac function. Our study partially agrees with data obtained by others 
suggesting that changes in filling pressures are less helpful in this respect than changes in 
GEDVI21-23,26. Apparently, the phenomenon that impaired systolic function renders filling 
pressures more important than volumes in the predictive and monitoring value of fluid 
responsiveness, while the opposite is true when systolic function is relatively normal, 
after cardiovascular surgery33, may not apply to sepsis-induced cardiac dysfunction. 
Otherwise, a higher PEEP level applied in this series than in the previous one27, may have 
contributed to the poor predictive value of CVP at low GEF.  
Our study has some limitations. The number of patients is relatively small but the 
study was undertaken to improve interpretation of transpulmonary dilution data with 
fluid loading in severe sepsis and septic shock rather than to prove benefits thereof. The 
correlation between changes in GEDVI and CI, regardless of GEF, can be overestimated 
by mathematical coupling when both are derived from the same thermodilution curve, 
as argued before41. Since both PBVI and GEDVI are also derived, among others, from the 
same thermodilution curve, mathematical coupling with CI would affect both variables. 
That PBVI differed from GEDVI in responding to fluid loading and a rise in CI ≥15% and, in 
contrast to GEDVI, did not correlate to CI changes may, however, disfavor mathematical 
coupling. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
122 Chapter 7
In conclusion, our study suggests that in patients with sepsis-induced hypotension and 
systolic cardiac dysfunction, occurring in about half of patients, fluid responsiveness is 
maintained by global cardiac dilatation, as measured by transpulmonary dilution-derived 
GEDVI, rather than by an increase in CVP. Absence of fluid responsiveness in systolic 
cardiac dysfunction may be explained by diastolic dysfunction and/or concomitant 
right ventricular dysfunction. Transpulmonary (thermo)dilution-derived GEDVI is more 
helpful than CVP in monitoring fluid responsiveness and non-responsiveness and their 
mechanisms in sepsis-induced hypotension, but normal or targeted levels of preload 
(GEDVI 680-800 mL/m2) may not be applied in this condition.
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Abstract
Purpose of review
This review highlights current insights concerning the (measurement of) extravascular 
lung water as an index of pulmonary edema, by transpulmonary dilution techniques. 
The focus is on the applicability of the technique at the bedside in monitoring critically 
ill patients.
Recent findings 
Several (animal) studies have been performed to validate the technique by postmortem 
gravimetry in different conditions. Moreover, recent clinical data emphasize the utility 
of the thermodilution-derived extravascular lung water, its contribution to the clinical 
manifestations of acute lung injury/acute respiratory distress syndrome, its response 
to treatment aimed at edema prevention or resolution, and as a prognostic parameter.
Summary
The thermodilution-derived extravascular lung water is a useful adjunct to assess 
lung vascular injury, cardiogenic edema and overhydration and to guide treatment in 
critically ill patients. The effects on morbidity and mortality of this approach need to 
be studied further.
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Introduction
Impaired gas exchange, reduced pulmonary compliance and pulmonary opacities 
on chest radiography are, either alone or together, poor indicators of the amount 
and course of pulmonary edema, of various causes, while positive fluid balances 
and pulmonary edema are associated with worse outcomes in critically ill patients1-4. 
Therefore, investigators have searched for methods to directly quantify pulmonary 
edema. The bedside method to directly assess the amount of extravascular lung 
water (EVLW) as a measure of pulmonary edema in critically ill patients, which has 
been applied most often, is the assessment of extravascular thermal volume with 
the help of transpulmonary thermal-dye indicator dilution, formerly involving a dye 
and a cold solution, central venous bolus infection and detection in the aorta via a 
femoral artery catheter of the respective dilution curves2. The differences in dilution 
curves between the intravascular dye and the cold, of which some dissipates into the 
pulmonary structures, dependent on their hydration status, and thus the difference 
in mean transit times multiplied by cardiac output, yield an extravascular thermal 
distribution volume as a rough indicator of EVLW – pulmonary edema. Using the 
Edwards densitometer technique, Mihm et al.5 and others already noted that the EVLW 
overestimated gravimetric EVLW at a postmortem examination – the gold standard in 
dogs and human organ donors, regardless of the cause of edema, that is hydrostatic 
forces or increased permeability. Nevertheless, the correlation, over a wide range of 
volumes, between the two was high5.
The technique was revived in the 1980s and 1990s by a German company, utilizing a 
similar approach with a fiberoptic and thermistor-equipped 4F femoral artery catheter 
and thermal-dye dilution, to assess the EVLW with the help of the so-called COLD 
machine6-26. The technique was later on further simplified into a single thermodilution 
measurement (PiCCO, Pulsion Medical Systems, Munich, FRG)12,19,27-36. The mean transit 
time of the thermal signal multiplied by cardiac output yields the intrathoracic thermal 
volume. The intrathoracic blood volume (ITBV) is derived from multiplication of the 
global end diastolic volume (GEDV), determined from cardiac output and down-slope 
time of the thermodilution curve, by a factor of 1.25, at least in humans27. Subtracting 
ITBV from intrathoracic thermal volume gives the extravascular thermal volume – 
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EVLW (upper limit of normal about 7–10 mL/kg body weight; Table 1)9. The correlation 
in studies between ITBV and GEDV is high, even though coefficients of the regression 
equation relating ITBV to GEDV vary among species and, perhaps, conditions12,27,36,37. 
The correlation is relatively high between EVLWs measured by single or double 
indicator dilution techniques12,19,27.
Table 1. Principles and calculations involved in thermodilution-derived extravascular lung water (EVLW). 
Intrathoracic thermal volume (ITTV, mL) = cardiac output (CO) x mean transit time of the thermal 
indicator
Pulmonary thermal volume (PTV, mL) = CO x exponential downslope time of the thermodilution curve
Global end-diastolic volume (GEDV, mL) = ITTV – PTV 
Intrathoracic blood volume (ITBV, normal 850-1000 mL/m2) = 1.25x GEDV (-28.4)
Extravascular lung water (EVLW, normal EVLW 3-7 mL/kg body weight) = ITTV – ITBV 
Another parameter evolving is the permeability index – the ratio of EVLW to ITBV 
or pulmonary blood volume15,22-25,33,34. Pulmonary blood volume is determined from the 
difference between pulmonary thermal volume (intrathoracic thermal volume minus 
GEDV) and EVLW. Indeed, congestive heart failure leading to a rise in pulmonary blood 
volume and edema is expected to increase the ratio less than an increase in permeability 
in the course of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). 
Hence, the ratio is critically dependent upon a steady state between blood volumes 
and EVLW, so that changes in cardiac size upon treatment or fluid loading can confound 
the ratio independently of permeability changes. Moreover, an increase in EVLW to 
blood volume ratios can be evoked by low colloid osmotic pressures’ increasing the 
propensity for pulmonary edema formation, even in the absence of increased protein 
permeability22. The correlation in septic ALI/ARDS between protein permeability in the 
lungs and EVLW to blood volume ratios is imperfect. Figure 1 shows the relationship 
between pulmonary leak index (PLI, as measured from 68Ga transferrin uptake in the 
lungs as a measure of protein permeability) and the ratio between EVLW and ITBV, 
which is normally 0.2–0.3, in patients with pneumonia or extrapulmonary sepsis 
(rs = 0.46, p = .032). A similar direct relation was observed for PLI compared with EVLW/
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pulmonary blood volume24. Hence, the clinical value of the ratio in differentiating 
cardiogenic from permeability edema associated with ALI/ARDS and in guiding 
therapy remains unclear. Similarly, the EVLW may not help in differentiating between 
ALI/ARDS and overhydration38. The amount of alveolar edema is not only dependent 
on hydrostatic and colloid osmotic forces, permeability and lymph flow, but also on 
active, ß-receptor-mediated alveolar water resorption, and the EVLW measurements 
may be able to track the development and resorption of lung edema in animal and 
clinical studies35.
Figure 1. Relationship between pulmonary leak index and extravascular lung water/intrathoracic 
blood volume.
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Animal studies
The gold standard for EVLW measured by (single thermo) dilution is postmortem 
gravimetry in animal models of lung edema and high correlations have been observed, 
even though some systematic (positive) bias may be present5,8,21,29,30,36,39-41. Kirov et 
al.30 induced pulmonary edema with either oleic acid or lipopolysaccharide in awake 
and spontaneously breathing sheep and EVLW measured by single transpulmonary 
thermodilution correlated closely with postmortem gravimetric EVLW measurements. 
Despite similar relative increases, the absolute values of EVLW were overestimated 
by single transpulmonary thermodilution, with greater overestimation at more 
severe lung injury30. This was accounted for in part by physical factors and the 
varying relationship between ITBV and GEDV in experimental and clinical settings. 
These findings have been confirmed in other studies21,36,39. In toxic pulmonary edema, 
mimicking ALI/ARDS in humans, EVLW has also been shown to highly correlate with 
gravimetric measurements.
Clinical studies
Pulmonary thermal volume was shown to highly correlate with estimated lung 
weight on computer tomography scans in ARDS patients20. There was a weaker 
correlation between EVLW and computer tomography-derived lung weight. Other 
studies addressed clinically relevant correlates and determinants of EVLW. Bindels 
et al.10 analyzed pulmonary capillary wedge pressure and EVLW in patients with 
acute cardiogenic pulmonary edema requiring mechanical ventilation. There was no 
correlation between the two variables, while EVLW decreased when cardiac function 
increased with treatment. This was confirmed by Boussat et al.14 in septic patients, 
who observed a direct relation between EVLW and ITBV, rather than with pressures. 
EVLW and ITBV may vary independently even though mathematically coupled22,24,29,33. 
After cardiac surgery, however, a rise in (thermal-dye) EVLW may better relate to 
Starling forces than to increased permeability, cardiac output or ITBV22. Other clinically 
relevant counterparts of EVLW measurements include a negative correlation between 
oxygenation, compliance and EVLW, which is reported in several studies7,31,33,34,42. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
133Transpulmonary dilution-derived extravascular lung water as a measure of lung edema 
8
In other studies on ALI/ARDS15,20,22,23,31,39, however, EVLW only poorly related to 
oxygenation, suggesting that edema itself only partially contributes to gas exchange 
abnormalities. Authors showed increased EVLW in ALI/ARDS, and more so when ARDS 
was severe, which was associated, paradoxically, with survival in one study but not in 
others16,33,34,42. The fact that increased EVLW can be demonstrated in only about 70% of 
patients with ALI/ARDS according to the consensus criteria can be taken as evidence 
of the contribution of consolidation or atelectasis to the syndrome, rather than as 
a failure of the technique to measure edema in poorly perfused or atelectatic areas 
(see below)22-24,31,33. EVLW may indicate that portion of the lung that is not immediately 
accessible to the tidal volume and may fall during recruitment of collapsed alveoli, 
although this is controversial7,8,11,17,20,31.
A study16 utilizing the double dilution technique demonstrated the prognostically 
adverse effect of a high EVLW, regardless of the type and severity of underlying disease, 
in 373 critically ill patients, having sepsis, ARDS or other conditions. The authors 
showed an increased EVLW in nonsurvivors compared with survivors (15.6 compared 
with 12.2 mL/kg, respectively): the mortality was 65% in patients with EVLW of more 
than 15 mL/kg compared with 33% in patients with EVLW of less than 10 mL/kg. Also, 
patients with ARDS had higher EVLW (14.9 mL/kg) compared with other patients (11.9 
mL/kg). Mortality varied by diagnosis and was 67, 45 and 27% in septic, ARDS and all 
other patients, respectively, and the relation of the EVLW with mortality tended to be 
maintained in the subgroups. Martin et al.33 studied EVLW in severely septic patients, 
with and without ARDS, with the help of the PiCCO. EVLW was higher in nonsurvivors 
(n = 12) compared with survivors (n = 17): 14.0 compared with 8.0 mL/kg, respectively. 
Furthermore, 57% of the patients without ARDS had an increased EVLW, possibly as 
a consequence of overhydration, while, conversely, four of 15 ARDS patients had 
normal EVLW. The median EVLW in the ARDS group compared with the non-ARDS 
group was 12.0 and 7.7 mL/kg, respectively. In both ARDS/non-ARDS subgroups, chest 
radiographs and lung injury scores did not differ when EVLW was low or high. Finally, 
Kuzkov et al.34 recently demonstrated the clinical and prognostic significance of single 
thermodilution-derived EVLW in septic patients.
Preliminary clinical data show that EVLW monitoring may guide treatment24-26,35. 
The (old) thermal-dye EVLW measurement has been compared with pulmonary artery 
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catheter-based pressure monitoring for the treatment of patients with ALI43. Indeed, 
(fluid) therapy based on this EVLW rather than on a pulmonary wedge pressure after 
pulmonary artery catheterization was associated, in critically ill patients with ALI and 
pulmonary edema, with an increase in ventilator-free days and decreased morbidity43. 
No new diagnostic therapeutic studies, however, utilize the (relatively new) single 
thermodilution technique, aimed at preventing or ameliorating an increase in EVLW 
and subsequent morbidity and mortality, thereby confirming and extending the 
Mitchell et al.43 study. Pressure support ventilation proved more effective when EVLW 
was low than when it was high7.
Confounding factors
Despite its potential, there are some drawbacks of the dilution EVLW method, 
inherent to the technique. Obviously, the thermodilution assessment is hampered 
by systemic and accidental errors. Even though reproducibility is within 10%9, EVLW 
may be underestimated in underperfused areas, such as after pulmonary resection, 
embolism and pulmonary arterial occlusion, but less so after tracheal instillation of 
fluid21,28,32,36. Obstructing pulmonary arteries in a pig model, mimicking pulmonary 
arterial embolization, lowered thermal-dye EVLW13. As alluded to above, some 
types of pulmonary edema, in animal studies18,39-41, are less well reflected by EVLW 
measurements than others, partly associated with redistribution of intrapulmonary 
blood flow. Cardiac output may also be too high for thermal equilibration with the 
extravascular distribution volume, and positive end-expiratory pressure (PEEP) may 
increase the distribution of the thermal indicator and increase EVLW, although this 
is controversial and opposite observations have been made, dependent on models, 
techniques and effects of PEEP on cardiac output and ventilator-associated lung 
injury6,8,17,31,40,41. Boldt et al.44 observed that altering cardiac output after cardiac surgery 
in humans did not affect the (old) thermal-dye EVLW (densitometer technique). 
The effect of atelectasis, and thus of tidal volumes, on EVLW assessment is still not 
completely understood8,17,19,22,23,31,36.
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Conclusion
The thermodilution technique for assessing extravascular thermal volume in the 
thorax as a bedside measure of EVLW is a promising technique to evaluate the severity 
and course of both permeability and cardiogenic/hydrostatic pulmonary edema, and 
may serve as a guide to treatment. Hence, the method can be easily integrated with 
the hemodynamic assessments to achieve an optimal balance between intra and 
extravascular hydration in patients with (impending) shock, hypotension or oliguria. 
The time constant for changes in EVLW upon changes in pulmonary capillary wedge 
pressure, the value in decision making, morbidity and mortality of the critically ill 
patient remain some of the unresolved issues. Potential areas of clinical evaluation 
of the EVLW measurements include drug treatment for ARDS and resorption of 
pulmonary edema25,35, strategies to prevent or limit ventilator-associated lung injury, 
monitoring fluid resuscitation26 and manipulating fluid balances38.
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Abstract
Objectives 
To evaluate the effect of hemodynamic management guided by upper limits of cardiac 
filling volumes or pressures on durations of mechanical ventilation and lengths of stay 
in critically ill patients with shock.
Design 
Prospective, randomized, clinical trial.
Setting 
Mixed intensive care unit of a large teaching hospital and mixed intensive care unit of 
a tertiary care, academic medical center.
Patients: A total 120 septic (n=72) and nonseptic (n=48) shock patients, randomized 
(after stratification) to transpulmonary thermodilution (n=60) or pulmonary artery 
catheter (n=60) between February 2007 and July 2009.
Interventions 
Hemodynamic management was guided by algorithms including upper limits for fluid 
resuscitation of extravascular lung water (<10 mL/kg) and global end-diastolic volume 
index (<850 mL/m2) in the transpulmonary thermodilution group and pulmonary 
artery occlusion pressure (<18–20 mm Hg) in the pulmonary artery catheter group for 
72 hrs after enrollment.
Measurements and main results 
Primary outcomes were ventilator-free days and lengths of stay in the intensive care 
unit and the hospital. Secondary outcomes included organ failures and mortality. 
Cardiac comorbidity was more frequent in nonseptic than in septic shock. Ventilator-
free days, lengths of stay, organ failures, and 28-day mortality (overall 33.3%) were 
similar between monitoring groups. Transpulmonary thermodilution (versus pulmo-
nary artery catheter) monitoring was associated with more days on mechanical 
ventilation and longer intensive care unit and hospital lengths of stay in nonseptic 
(p=.001) but not in septic shock. In both conditions, fewer patients met the upper limit 
of volume than of pressure criteria at baseline and transpulmonary thermodilution 
(versus pulmonary artery catheter) monitoring was associated with a more positive 
fluid balance at 24 hrs.
Conclusions 
Hemodynamic management guided by transpulmonary thermodilution versus 
pulmonary artery catheter in shock did not affect ventilator-free days, lengths of 
stay, organ failures, and mortality of critically ill patients. Use of the a transpulmonary 
thermodilution algorithm resulted in more days on mechanical ventilation and intensive 
care unit length of stay compared with the pulmonary artery catheter algorithm in 
nonseptic shock but not in septic shock. This may relate to cardiac comorbidity and a 
more positive fluid balance with use of transpulmonary thermodilution in nonseptic 
shock.
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Introduction
In critically ill patients, fluid resuscitation is the first step in the treatment of 
hypovolemia and shock. Both under- and overtreatment may be detrimental because 
of inadequate tissue oxygenation or development of pulmonary edema, which may 
prolong mechanical ventilation, respectively1-10.
Traditionally, the pulmonary artery catheter (PAC) has been used to guide 
hemodynamic management. In mechanically ventilated patients, however, 
atmospheric pressure-referenced filling pressures such as the pulmonary artery 
occlusion pressure (PAOP) may be confounded by airway pressures and may thereby 
poorly predict cardiac preload, fluid responsiveness, and pulmonary capillary 
filtration1-3,6,9,11-13. New, less invasive techniques such as transpulmonary thermodilution 
(TPTD) may provide better indicators of cardiac preload and fluid responsiveness such 
as the global end-diastolic volume3,11,14. The TPTD-derived extravascular lung water 
(EVLW) accurately reflects interstitial, alveolar, and clinically manifest lung edema if 
>10 mL/kg15-18.
While we enter an era of less liberal fluid therapy4,19, fluid overloading with 
increased EVLW (above the normal 7 mL/kg) was already suggested in the past to 
prolong mechanical ventilation and to be preventable by monitoring of EVLW 
(versus PAOP)1. Hence, the combined use of global end-diastolic volume and EVLW 
may allow fine-tuning of hemodynamic management, because fluid loading in the 
steep (as opposed to the flat) part of the cardiac function curve may prevent rapid 
formation of pulmonary edema17. However, nonrandomized studies suggest that the 
use of volume monitoring by TPTD (up to EVLW of 10 mL/kg) is associated with higher 
fluid requirements, more complete resuscitation, and less need of vasopressors as 
compared with pressure-based monitoring, although the effects on ventilator-free 
days (VFDs) remain undetermined3,14. Finally, hemodynamic management and its 
outcome may differ among shock etiologies6,8-10,19,20. In septic shock, volume-based 
prediction of cardiac output responses to fluid loading may be superior to pressure-
based prediction, whereas the reverse may be true in nonseptic shock in patients with 
relatively poor cardiac function after cardiovascular surgery, for instance11,21,22.
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Therefore, we hypothesized that the risk of fluid overloading is less when fluid 
administration is restricted by upper limits of volumes by TPTD than of pressures by 
PAC and translates into more VFDs while safeguarding adequate resuscitation. We 
conducted a prospective, randomized, two-center trial comparing volume-guided 
hemodynamic management by TPTD- versus PAC-guided management in critically ill 
patients and explored whether septic and nonseptic shock differ in this respect. 
Material and methods
Study Design. This prospective, randomized, nonblinded clinical trial was conducted in 
intensive care units (ICUs) of a university hospital and a large teaching hospital in The 
Netherlands from February 2007 to July 2009. Patients meeting inclusion criteria were 
randomly assigned to receive either a TPTD or PAC catheter when inclusion criteria for 
advanced hemodynamic monitoring were met (see subsequently). The medical ethics 
committee at each study center had approved the protocol.
Eligibility. Patients were eligible when they were on mechanical ventilation with 
an expected stay in the ICU >48 hrs together with the presence of shock, indicating a 
clinical reason for invasive hemodynamic monitoring as determined by the attending 
physicians. Shock was defined by acute circulatory failure characterized by persistent 
arterial hypotension defined as a mean arterial pressure <65 mm Hg (or <80 mm 
Hg with previous hypertension) despite assumingly adequate volume resuscitation 
and/or the need for vasopressors to maintain a mean arterial pressure ≥65 mm Hg 
(or ≥80 mm Hg in case of known hypertension)7. We consecutively included patients 
in two major groups, septic and nonseptic shock until the predefined number of 120 
was reached. Septic shock was defined by shock plus two or more of the following 
for systemic inflammatory response syndrome criteria: abnormal body temperature 
(>38°C, <36°C), tachycardia (>90 beats/min), mechanical ventilation, and abnormal 
white blood cell counts (≤4 or ≥12 x 109/L or >10% immature bands) plus a clinically 
evident and/or microbiologically proven focus on infection7. The nonseptic shock 
group consisted of patients in shock after 1) (surgery for) major trauma (Injury Severity 
Score >25, without documented traumatic brain injury); 2) elective and emergency 
major abdominal surgery (including esophageal resection, gastric resection, liver 
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surgery, pancreatic surgery, colorectal surgery); 3) cardiac surgery (coronary bypass 
surgery, aortic root and/or valvular surgery); 4) major vascular surgery (thoracic 
aorta, abdominal aorta, and iliac/mesenteric reconstructions); and 5) a group with 
miscellaneous conditions (e.g., cardiogenic, obstructive, or unclassified shock).
Randomization. Randomization was done by the sealed envelope method after 
meeting eligibility criteria. The randomization was stratified per center for sepsis 
versus nonsepsis (no blocks were used). Written informed consent (by proxy) was 
obtained before randomization or, for reasons of urgency, delayed and obtained 
within 24 hrs after enrollment. In case of rejected consent by proxy, the allocation 
code was reused in new envelopes. Patients were included as soon as possible after 
randomization.
Exclusion Criteria. Exclusion criteria were age <18 or >80 yrs, pregnancy, preterminal 
illness with life expectancy <24 hrs, therapeutic hypothermia after cardiac arrest, 
traumatic brain injury, absence of mechanical ventilation, known (unrepaired) cardiac 
or vascular aneurysms, bifemoral vascular surgery, known pulmonary hypertension 
(defined as mean pulmonary artery pressure >50 mm Hg), or absence of informed 
consent.
Outcomes. Primary outcome measures were VFDs from enrollment to extubation 
until day 28 survival23, days on mechanical ventilation, and lengths of stay in the 
ICU and in the hospital, including ICU- and hospital-free days. Secondary outcome 
measures were Sequential Organ Failure Assessment scores during the first 72 hrs after 
enrollment; 72-hr, 28-day, and hospital mortality (up to 100 days after enrollment); 
and protocol adherence for fluid administration, defined by the percentage of 
fluid challenges within the predefined upper limits and complications associated 
with catheter insertion or use. The latter was defined by technical failures such as 
pneumothorax, bleeding, suspected femoral artery obstruction and poor wedging, 
or defective central venous oxygen saturation or cardiac output measurements. 
We finally evaluated daily fluid intake and balances, lung injury score, hemodynamic 
measurements, and vasopressor requirements during the first 72 hrs after enrollment 
to determine adequacy of hemodynamic resuscitation.
Study Protocol. The ICU staff (doctors and nurses) underwent training in the conduct 
of the protocol. The assigned catheter was inserted as soon as possible after inclusion. 
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Fluid resuscitation and hemodynamic management was guided by either TPTD or PAC-
derived parameters according to a predefined algorithm (Figure 1 and 2) for up to 72 hrs 
after enrollment, after which PACs are routinely removed in our ICUs. Fluid challenges 
were performed by colloids (gelatin 4% or hydroxyethyl starch solutions 6%, 130/0.4) 
at a dose of 250–500 mL per 30 minutes7 when indicated clinically and according to 
the TPTD or PAC parameters defining upper limits of safe infusion (see subsequently). 
Clinical indications for a fluid challenge were, among others, mean arterial pressure 
<65 mm Hg (or <80 mm Hg in case of known hypertension), tachycardia >110 beats/min 
suggestive for hypovolemia, mixed venous oxygen saturation (SvO2) <65% or central 
venous oxygen saturation (ScvO2) <70%, oliguria <0.5 mL/kg/hr (suspected prerenal 
cause), peripheral perfusion deficits such as cold extremities and skin discolorations, 
and hyperlactatemia (>2.0 mmol/L). Fluid challenges were withheld when the safety 
limits by TPTD or PAC monitoring had been reached (see subsequently) and when 
there was <10% rise in cardiac output. End points of resuscitation, reflecting adequacy 
of fluid and hemodynamic management, were mean arterial pressure ≥65 mm Hg 
(or ≥80 mm Hg in case of known hypertension), ScvO2 ≥70% or SvO2 ≥65%, lactate 
clearance, diuresis ≥0.5 mL/kg/hr (unless development of intrinsic renal failure), and 
restoration of peripheral perfusion deficits.
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Indication for fluid challenge 
 
 
              PAOP<18mmHg (PEEP<10cmH2O)                PAOP≥18mmHg (PEEP<10cmH2O) 
              PAOP<20mmHg (PEEP≥10cmH2O)                PAOP≥20mmHg (PEEP≥10cmH2O) 
 
 
         Colloids 250-500 mL (in 30 min)   CI<2.0 L/min/m²  CI≥2.0 L/min/m² 
 
 
Increase in CI (>10%)           No increase CI         Inotropic agents          Vasopressors 
 
 
Reassess hemodynamics          Inotropic agents and/or vasopressors 
 
 
Figure 2.  Algorithm for hemodynamic management according to PAC pulmonary artery catheter derived data. CI cardiac index, PAOP 
pulmonary artery occlusion pressure, PEEP positive end-expiratory pressure 
 
 
 
 
 
Figure 2. Algorithm for hemodynamic management according to PAC pulmonary artery catheter derived 
data. CI cardiac index, PAOP pulmonary artery occlusion pressure, PEEP positive end-expiratory pressure.
TPTD Protocol. The TPTD catheter (PiCCO; Pulsion Medical Systems AG, Munich, 
Germany) was inserted in the femoral artery and measurements were performed 
through an injection of a 20-mL ice-cold (4°C) saline bolus through a central venous 
catheter (different sizes were used: 16 cm for right subclavian or internal jugular vein, 
20 cm for left subclavian or internal jugular vein). Measurements were obtained in 
triplicate and averaged. Fluid resuscitation and hemodynamic management was done 
according to a predefined algorithm (Figure 1). Upper limits of EVLW and global end-
diastolic volume index (GEDVI) were 10 mL/kg predicted body weight and 850 mL/m2, 
respectively1,11,14-18. Variables were obtained both before and following a fluid challenge 
and when clinically indicated on other grounds, but at least every 4 hrs.
PAC Protocol. Fluid resuscitation and hemodynamic management in this group were 
guided by clinical parameters and by baseline values and responses to fluid loading 
within upper safety limits of PAOP of 18 mm Hg at positive end-expiratory pressure 
<10 cm H2O and 20 mm Hg at positive end-expiratory pressure ≥10 cm H2O (Figure 2). 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
147Volume-limited versus pressure-limited hemodynamic management in septic and nonseptic shock
9
These PAOP limits may relate to the development of hydrostatic pulmonary edema12. 
Filling pressures and cardiac output were measured when clinically indicated, but at 
least every 4 hrs, and before and after fluid challenges, after calibration, zeroing to 
atmospheric level, proper wedging (for PAOP), and at the end of expiration (indicated 
by the ventilation curve) with patients in supine position (Marquette, Milwaukee, WI). 
Thermodilution cardiac output measurements were done in triplicate, irrespective 
of the ventilatory cycle, and averaged after central venous bolus injections of 10 mL 
normal saline.
Therapeutic Protocol. Fluid losses were supplemented by infusion of normal or 
half-normal saline. After 72 hrs, vasopressors and inotropic drugs were administered 
and dosed on clinical grounds in case of, but not limited to, persistent and fluid-
refractory hypotension, suspected impairment of tissue O2 delivery, lactic acidosis, 
and oliguria. Norepinephrine was the vasopressor drug of first choice in our ICUs, 
which was continuously infused and dosed on the basis of hemodynamic responses. 
Dobutamine was the inotropic drug of choice followed by enoximone. All patients 
were pressure-controlled ventilated (Servo-i; Maquette or Evita 4; Dräger, Lübeck, 
Germany), aiming at tidal volumes <8 mL/kg predicted body weight and positive end-
expiratory pressure was dosed (≤20 cm H2O) to maintain arterial PO2 >65 mm Hg at 
an inspiratory O2 fraction of at least 40%. Pressure-controlled ventilation was changed 
into pressure-support ventilation when clinically justified. Weaning was attempted 
through clinical protocols. Sedatives, analgesics, and antibiotics were prescribed by 
attending physicians according to strict clinical guidelines. Systemic corticosteroids 
were initialized in case of persistent vasopressor-dependent septic shock, defined as 
a norepinephrine dose ≥1 mg/hr. After the initial 72-hr period of the protocol, when 
the PACs were removed, patients in both groups were treated at the discretion of the 
attending physicians.
Data Collection. Hemodynamic measurements were done and arterial and central 
venous (in TPTD group) or mixed venous (in PAC group) blood samples were taken 
every 4 hrs, at baseline, and up to 72 hrs after enrollment. Partial gas pressures, O2 
saturations, and lactate levels were determined (ABL Radiometer, Copenhagen, 
Denmark, and i-STAT 1, Abbott, Abbott Park, IL). Cardiac output was indexed to 
body surface area, calculated from gender, weight, and height, and yielding cardiac 
index (CI) like the GEDVI, whereas the EVLW was indexed to predicted body weight. 
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The amount and type of fluid infusion, drainage, and diuresis to calculate 24-hr fluid 
balances were recorded together with doses and types of inotropic/vasopressor drugs. 
Daily measured clinical and laboratory variables allowed calculation of Sequential 
Organ Failure Assessment. Daily chest x-rays were made and scored by independent 
radiologists for quadrants of alveolar consolidations to calculate, together with the 
level of positive end-expiratory pressure, the arterial PO2/inspiratory O2 fraction, and 
total respiratory dynamic (tot.respir.dyn.) compliance, the lung injury score. To this 
end, relevant variables were taken from the ventilators. The compliance
tot.respir.dyn. 
was 
calculated from tidal volume/(Pinsp - positive end-expiratory pressure), where Pinsp is 
end-inspiratory airway pressure (cm H2O). The acute respiratory distress syndrome 
was defined using the consensus conference criteria24. Patients were followed until 
death or hospital discharge up to 100 days after enrollment.
Statistical Analysis. A prestudy power analysis by t-test showed that at least 
50 evaluable patients would be needed per monitoring group to demonstrate a 
difference of mean 2 VFDs (9 versus 7 days), assuming a sd of 50% (at α = 0.05 and 
β = 0.80). Analysis was done on an intention-to-treat basis in the absence of premature 
study discontinuations and, as anticipated, stratification was taken into account. After 
logarithmic conversion of nonnormally distributed data (Kolmogorov-Smirnov test 
p < .05) to normalize distributions where appropriate, generalized estimating 
equations were done to evaluate the contribution of monitoring (TPTD versus 
PAC) and underlying condition (septic versus nonseptic shock) and their first-order 
interaction on differences in categorical and continuous variables. The interaction 
yields the effect of monitoring dependent on underlying condition. For evaluation of 
changes in time, repeated measures in the same patients were taken into account after 
entering baseline variables as covariates. Multiple Cox proportional hazard regression 
modeling with backward elimination on the basis of statistical significance was done 
to evaluate determinants (hazard ratios) of duration of mechanical ventilation and 
hospital stays. Kaplan-Meier curves were made to evaluate, in septic and nonseptic 
shock, the likelihood of mechanical ventilation in the ICU (until day 28). The log-rank 
test was used. Fisher’s exact test was used to compare categorical data. Two-sided p 
values < .05 were considered statistically significant. Values are summarized as median 
(interquartile range = 75th–25th percentile) or as box and whisker plots in figures. All 
analyses were conducted using SPSS version 16.0 (SPSS, Chicago, IL).
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Results
In the study period, 192 patients with septic and nonseptic shock were screened (Figure 
3). Finally, 120 patients were randomized; 60 patients received a TPTD and 60 a PAC 
catheter (Table 1). The study was started within 24 hrs of ICU admission in 63% of TPTD- 
and 67% of PAC-assigned patients. There were no premature study discontinuations. 
TPTD and PAC groups were comparable at baseline (Table 1), except for an interaction 
for Acute Physiology and Chronic Health Evaluation II scores between monitoring 
groups and underlying condition.
 192 patients screened  
 
66 patients excluded 
24.2 % underwent induced hypothermia for               
cardiac arrest 
18.2 %  age > 80 years 
15.1 %  inclusion in other trials  
12.1 %  vascular insertion risk 
10.7 %  known pulmonary hypertension 
9.1   %  preterminal illness (life expectancy <24h) 
9.1   %  known aortic aneurysms  
1.5   %  pregnancy 
 
      randomization     6 patients withdrawn (no consent by proxy) 
 
 120 patients included 
 
 
60 received TPD and were analyzed    60 received PAC and were analyzed  
 
Figure 3. Consort diagram. TPTD transpulmonary thermodilution, PAC pulmonary artery catheter. 
  
Figure 3. Consort diagram. TPTD transpulmonary thermodilution, PAC pulmonary artery catheter.
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Table 1. Patient and baseline characteristics for monitoring by pulmonary artery catheter (PAC) or 
transpulmonary thermodilution (TPTD), according to shock etiology.
sepsis nonsepsis p value
PAC
(n=34)
TPTD
(n=38)
PAC
(n=26)
TPTD
(n=22)
M U U*M
Age, year 67 (15) 67 (19) 69 (15) 69 (13) .83 .55 .79
Male/female sex, n (%) 18(53)/16(47) 20(53)/18(47) 19(73)/7(27) 15(68)/7(32) .75 .05 .78
APACHE II 26 (15) 27 (13) 29 (12) 24 (11) .39 .21 .02
SOFA 9 (5) 10 (6) 10 (4) 10 (4) .72 .87 .75
Inclusion <24 h admission, n (%) 24 (71) 25 (74) 14 (54) 12 (55) .82 .05 .87
Comorbidity, n (%)
Cardiovascular 7 (21) 11 (29) 16 (62) 16 (73) .25 <.001 .94
Respiratory 2 (6) 3 (8) 2 (8) 0 .65 .50 N.A.
Renal 1 (3) 4 (11) 3 (12) 2 (9) .47 .39 .28
Neurological 4 (12) 3 (8) 1 (1) 1 (1) .87 .28 .71
Diagnostic group
Sepsis, n (%) .56 N.A. .95
Respiratory 11 (32) 13 (34) - -
Abdominal 12 (35) 17 (45) - -
Other 11 (32) 8 (21)
Nonsepsis, n (%)
Nonsurgical - - 10 (38) 7 (32)
Cardiac surgery - - 7 (27) 6 (27)
Vascular surgery - - 4 (15) 4 (18)
Trauma - - 1 (1) 1 (1)
Other surgery - - 4 (15) 4 (18)
Associated microorganisms in 
sepsis, n (%)
.72 N.A. N.A.
Gram positive 8 (24) 6 (16) - -
Gram negative 10 (29) 14 (37) - -
Other 1 (3) 12 (31) - -
Bacteremia, n (%) 13 (39) 12 (31) .33 N.A. N.A.
Hemodynamics
Heart rate, b/min 112 (27) 105 (27) 89(29) 93(31) .72 <.001 .96
MAP, mm Hg 77 (15) 77 (15) 78 (19) 78 (29) .29 .32 .53
Cardiac index, mL/min/m2 3.7 (1.7) 3.2 (1.7) 2.8 (1.5) 2.8 (1.2) .26 <.001 .27
CVP, mm Hg 13 (7) 12 (5) 10 (7) 10 (7) .23 .38 .47
MPAP, mm Hg 29 (11) - 26 (8) - N.A. .16 N.A.
PAOP, mm Hg 18 (1) - 12 (8) - N.A. .02 N.A.
GEDVI, mL/m2 - 752 (217) - 818 (295) N.A. .33 N.A.
S
(c)v
O2 0.74 (0.21) 0.75 (0.17) 0.69 (0.13) 0.74 (0.17) .01 .38 .63
Lactate, mmol/L 3.3 (4.2) 3.7 (4.2) 2.1 (1.9) 2.4 (4.2) .67 .08 .68
Norepinephrine, μg/kg/min 0.50 (0.55) 0.48 (0.63) 0.29 (0.21) 0.24 (0.34) .57 .007 .91
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Respiration
PaO2/FIO2 178 (91) 170 (123) 189 (98) 188 (110) .32 .85 .72
Tidal volume, mL/kg PBW 7.8 (1.9) 7.4 (1.9) 7.3 (2.5) 7.4 (1.2) .10 .23 .69
Pinsp, cmH2O 33 (11) 31 (10) 29 (9) 28 (9) .23 .009 .36
PEEP, cmH2O 13 (6) 12 (6) 10 (7) 12 (6) .19 .16 .28
Compliance, mL/cm H2O 28 (10) 27 (12) 32 (15) 30 (11) .27 .13 .55
Radiographic score 1 (2) 2 (2) 0 (0) 0 (1) .27 .001 .97
Lung injury score 2.4 (1.0) 2.5 (1.0) 1.9 (1.0) 2.2 (1.0) .19 .06 .69
ARDS at inclusion, n (%) 11 (32) 11 (29) 2 (8) 2 (9) .96 .007 .77
EVLW, mL/kg PBW - 11.0 (7.0) - 11.0 (6.0) N.A. .12 N.A.
Median (interquartile range) or number (percentage), where appropriate PAC pulmonary artery catheter, 
TPTD transpulmonary thermodilution, APACHE II acute physiology and chronic health evaluation, SOFA 
sequential organ failure assessment score, MAP mean arterial pressure, CVP central venous pressure, 
PAOP pulmonary artery occlusion pressure, GEDVI global end-diastolic volume index, S(c)vO2 central or 
mixed venous O2 saturation, PaO2 partial pressure of O2 in arterial blood, FIO2 inspiratory O2 fraction, PBW 
predicted body weight, Pinsp, end-inspiratory pressure, PEEP positive end-expiratory pressure, ARDS acute 
respiratory distress syndrome,	EVLW extravascular lung water, M monitoring, U underlying condition, U*M 
interaction, N.A. not applicable.
Septic versus nonseptic shock. There were more males and cardiovascular comorbidities 
among nonseptic than septic shock patients (Table 1). At baseline, septic shock patients 
had more often acute respiratory distress syndrome and had higher radiographic 
scores and ventilatory pressures than nonseptic shock patients. At baseline, patients 
with septic shock had higher heart rate, CI, and PAOP, whereas central venous 
pressure and GEDVI did not differ from those in nonseptic shock patients. Patients 
with septic shock had less improvement in Sequential Organ Failure Assessment 
scores, shorter length of stay in the hospital, higher inhospital mortality, and greater 
fluid and vasopressor requirements than nonseptic shock patients (Table 2 and 3). The 
course of hemodynamic variables guiding treatment was similar between septic and 
nonseptic shock except for the GEDVI, which was higher in the latter (Figure 4). The 
fall in lactate was greater in septic shock.
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Figure 4. Course of guiding variables (A. EVLW extravascular lung water; B. GEDVI  global end-diastolic 
volume index, C. PAOP pulmonary artery occlusion pressure, ) in the septic shock (closed symbols) and 
nonseptic shock (open symbols); box and whisker plots. The mean daily EVLW and GEDVI decreased in 
the TPTD group (p = .027 or lower), while PAOP decreased in the PAC group (p = .034). Only for GEDVI: 
P=0.05 between septic and nonseptic shock groups.
Primary Outcome. The number of VFDs did not differ between monitoring groups 
(Table 2; Figures 5,6,7). Although overall not differing between monitoring groups, the 
duration of mechanical ventilation (including patients who died within 28 days) and 
length of stay in the ICU were longer in TPTD than in PAC-monitored nonseptic shock 
but not in septic shock patients (p = .001 for interaction). The number of ventilation 
days directly related to the EVLW and lung injury score at 72 hrs (p ≤ .05) regardless of 
underlying condition. When lung injury score at 72 hrs was entered as a covariate, the 
number of ventilation days and days in the ICU was similar among groups (p = .30 for 
monitoring, p = .69 for underlying condition, and p = .29 for interaction of monitoring 
with underlying condition). The hospital length of stay was also prolonged in nonseptic 
shock patients in the TPTD group. For the prediction of time on the ventilator until day 
28, in Cox regression analysis, there was no contribution of both monitoring group, 
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underlying condition, and their interaction. Nevertheless, there was a tendency 
toward greater ventilator dependency until day 28 in the nonseptic shock patients 
randomized to TPTD than to PAC (p = .06) (Figures 8 and 9), which reached statistical 
significance (p = .01) when considering the entire mechanical ventilation period (up to 
day 100).
Table 2. Primary and secondary outcomes.
sepsis nonsepsis p value
PAC
(n=34)
TPTD
(n=38)
PAC
(n=26)
TPTD
(n=22)
M U U*M
Primary
VFDs 0 (16) 0 (16) 6 (22) 0 (19) .44 .34 .71
VFDs=0 18 (53) 23 (61) 11 (42) 12 (55) .29 .37 .81
VFDs=0 and MV>day 28 5 (15) 7 (18) 4 (15) 7 (32) .69 .05 .58
Ventilation days† 13 (14) 10 (15) 8 (15) 21 (34) .38 .15 .001
LOS ICU, days 15 (15) 11 (17) 9 (13) 22 (34) .39 .07 .001
ICU free days# 0 (13) 0 (14) 9 (20) 0 (15) .29 .27 .35
LOS hospital, days 25 (25) 27 (42) 29 (25) 34 (55) .60 .01 .04
Hospital free days# 0 (0) 0 (0) 0 (0) 0 (1) .71 .18 .82
Secondary
Correct / total fluid challenges, n (%) 152 / 175(85) 209 / 242 (84) 87 / 94 (92) 84 / 104 (75) .002 .59 .06
Protocol non-adherence, n (%) 10 (30) 12 (32) 6 (23) 11 (50) .11 .58 .18
Catheter dysfunction, n (%) 4 (12) 3 (8) 4 (15) 2 (9) .39 .70 .90
SOFA,$  
at baseline 9 (5) 10 (6) 10 (4) 10 (4) .49 .02 .89
at 24 h 10 (6) 9 (6) 9 (4) 10 (5)
at 48 h 9 (6) 10 (7) 9 (7) 10 (8)
at 72 h 9 (6) 10 (8) 8 (6) 8 (7)
Mortality until 72 h, n (%) 4 (12) 10 (26) 3 (12) 0 .51 .05 .13
Mortality until day 28, n (%) 13 (38) 16 (42) 6 (23) 5 (23) .87 .05 .83
Mortality in ICU, n (%) 13 (38) 17 (45) 6 (23) 5 (23) .77 .04 .73
Mortality in hospital, n (%) 15 (44) 21 (55) 8 (31) 5 (23) .97 .01 .29
Median (interquartile range) or number (percentage), where appropriate PAC pulmonary artery catheter, 
TPTD transpulmonary thermodilution, VFDs ventilator free days, MV mechanical ventilation, LOS length of 
stay, ICU intensive care unit, SOFA sequential organ failure assessment score, M monitoring, U underlying 
condition, U*M interaction. †including all patients; # ICU-free days / Hospital-free days = 0 if patient dies 
before day 28, = (28-x) if patient is successfully discharged from the ICU / hospital, where x is the 
number of days spent in the ICU / hospital, = 0 if the patient stays in the ICU / hospital for 28 days or 
more; $ for change vs. baseline.
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Figure 5. A plot of primary outcome measures in all patients for TPTD transpulmonary thermodilution and PAC pulmonary artery 
catheter. VFDs ventilator-free days, LOS length of stay, ICU intensive care unit 
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Figure 5. A plot of primary outcome measures in all patients for TPTD transpulmonary thermodilution 
and PAC pulmonary artery catheter. VFDs ventilator-free days, LOS length of stay, ICU intensive care 
unit.
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Figure 6. A plot of primary outcome measures in patients with septic shock for TPTD transpulmonary thermodilution and PAC 
pulmonary artery catheter. VFDs ventilator-free days, LOS length of stay, ICU intensive care unit. 
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Figure 6. A plot of primary outcome measures in patients with septic shock for TPTD transpulmonary 
thermodilution and PAC pulmonary artery catheter. VFDs ventilator-free days, LOS length of stay, ICU 
intensive care unit.
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Figure 7. A plot of primary outcome measures in patients with nonseptic shock patients, for TPTD transpulmonary thermodilution and 
PAC pulmonary artery catheter. VFDs ventilator-free days, LOS length of stay, ICU intensive care unit. 
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Figure 8. Likelihood of ventilator-dependency in septic shock (log-rank test p = .68), in TPTD transpulmonary thermodilution and PAC 
pulmonary artery catheter groups, until day 28 in the ICU. Crosses are censored data. 
  
Figure 8. Likelihood of ventilator-dependency in septic shock (log-rank test p = .68), in TPTD 
transpulmonary thermodilution and PAC pulmonary artery catheter groups, until day 28 in the ICU. 
Cross s are censore  data.
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Figure 9. Likelihood of ventilator-dependency in nonseptic shock (log-rank test p = .06), in TPTD transpulmonary thermodilution and PAC 
pulmonary artery catheter groups, until day 28 in the ICU. Crosses are censored data 
  
Figure 9. Likelihood of ventilator-dependency in nonseptic shock (log-rank test p = .06), in TPTD 
transpulmonary thermodilution and PAC pulmonary artery catheter groups, until day 28 in the ICU. 
Cross s are c nsored data.
Secondary Outcomes. There was no difference in mortality between monitoring 
groups. Overall, 21 patients (35%) died in the TPTD group before day 28 and 19 (32%) in 
the PAC group (p = .85). This 3% difference had 95% confidence intervals between 0.4% 
and 11%. Age, Acute Physiology and Chronic Health Evaluation II score, and underlying 
condition predicted both survival duration to day 28 in either the ICU or in the hospital 
(p = .01 or lower), whereas monitoring groups (and first-order interactions) did not 
contribute (Figures 10 and 11, represent Kaplan-Meier curves for likelihood of survival 
as a function of days inhospital for the study groups). Protocol adherence was higher 
in the PAC group as compared with the TPTD group independent of underlying 
condition (Table 2). In the subgroup of patients with full protocol adherence, VFDs did 
not depend on monitoring group, underlying condition, and interaction. The number 
of catheter-related complications and Sequential Organ Failure Assessment scores did 
not differ among monitoring groups. In the TPTD group, the femoral artery catheter 
was removed in two patients because of fear for vascular occlusion, although without 
further adverse consequences. In one patient, the thermistor was defective and in 
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another one, central venous blood sampling was not feasible after 48 hrs. In the PAC 
group, no catheter-related complications occurred. In six patients, the PAOP could not 
be measured and in another patient, mixed venous blood sampling was not possible 
after 48 hrs.
Efficacy	of	Resuscitation. Baseline hemodynamics were similar among monitoring 
groups, but baseline ScvO2 in the TPTD group was higher than the SvO2 in the PAC 
group (Table 3). The CI and ScvO2 increased more with time in the TPTD than the CI 
and SvO2 in the PAC group. The decrease in norepinephrine requirements tended to 
favor the TPTD group (p = .06). Forty-six percent of patients in the PAC group already 
had reached the upper limit (PAOP ≥18 mm Hg) of fluid administration at baseline 
compared with 25% of patients in the TPTD group (GEDVI ≥850 mL/m2 plus EVLW ≥10 
mL/kg predicted body weight, p = .047). Fluid volume infusions per day inversely 
related in time to the mean daily GEDVI in the TPTD group (p = .004) and the mean 
daily PAOP in the PAC group (p = .003). Fluid infusions and balances were greater at 
24 hrs and less so at 48 and 72 hrs (p < .001 for time), so that at 24 hrs, the TPTD group 
had a more positive balance than the PAC group (p = .044) independent of underlying 
condition.
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Figure 10. Likelihood of survival in septic shock (log-rank test p = .59) in TPTD transpulmonary 
thermodilution and PAC pulmonary artery catheter groups, as a function of (up to 100) hospital days. 
Vertical lines are censored data.
Figure 11. Likelihood of survival in nonseptic shock (log-rank test p = .50) in TPTD transpulmonary 
thermodilution and PAC pulmonary artery catheter groups, as a function of (up to 100) hospital days. 
Vertical lines are censored data.
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Figure 11. Likelihood of survival in nonseptic shock (log-rank test p = .50) in TPTD transpulmonary thermodilution and PAC pulmonary artery catheter groups, as a function of 
(up to 100) hospital days. Vertical lines are censored data. 
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Table 3. Cardiorespiratory parameters.
sepsis nonsepsis p value
(for change)
PAC
(n=34)
TPTD
(n=38)
PAC
(n=26)
TPTD
(n=22)
M U U*M
CVP, mm Hg
at baseline 13 (7) 12 (5) 10 (7) 10 (7) .65 .22 .13
at 24 h 10 (5) 10 (5) 10 (6) 10 (7)
at 48 h 10 (5) 12 (6) 10 (6) 11 (4)
at 72 h 10 (8) 8 (6) 10 (6) 11 (4)
MAP, mm Hg
at baseline 77 (15) 77 (15) 78 (19) 78 (29) .31 .97 .17
at 24 h 80 (18) 75 (12) 80 (15) 81 (19)
at 48 h 79 (16) 77 (15) 81 (18) 83 (16)
at 72 h 83 (14) 88 (19) 76 (25) 88 (27)
CI, L/min/m2
at baseline 3.7 (1.7) 3.2 (1.7) 2.8 (1.5) 2.8 (1.2) .21 .008 .87
at 24 h 3.2 (1.5) 3.6 (1.3) 3.4 (1.5) 3.6 (1.2)
at 48 h 3.1 (1.5) 3.5 (1.2) 3.6 (1.8) 3.0 (1.1)
at 72 h 3.2 (1.1) 3.7 (1.9) 2.6 (2.0) 3.2 (0.9)
S
(c)v
O2 
at baseline 0.74 (0.21) 0.75 (0.17) 0.69 (0.13) 0.74 (0.17) .15 .02 .13
at 24 h 0.72 (0.09) 0.80 (0.08) 0.72 (0.13) 0.78 (0.16)
at 48 h 0.74 (0.21) 0.77 (0.13) 0.76 (0.12) 0.77 (0.08)
at 72 h 0.69 (0.12) 0.79 (0.09) 0.71 (0.16) 0.76 (0.11)
Lactate, mmol/L
at baseline 3.3 (4.2) 3.7 (4.2) 2.1 (1.9 ) 2.4 (4.2) .003 .52 .27
at 24 h 2.3 (2.0) 2.1 (2.2) 1.5 (1.5) 1.7 (1.9)
at 48 h 2.2 (1.2) 1.6 (1.7) 1.3 (1.5) 1.2 (0.8)
at 72 h 1.7 (1.4) 1.5 (1.0) 1.1 (1.2) 1.2 (0.8)
Fluids in, mL
at 24 h 5793 (2293) 5608 (3240) 4495 (2040) 4852 (2105) .002 .31 .98
at 48 h 4531 (2538) 4598 (2022) 3931 (1671) 4187 (1929)
at 72 h 4130 (1804) 3741 (1961) 3258 (1318) 3577 (1440)
Fluid balance, mL
at 24 h 3159 (2993) 4506 (3880) 2699 (2238) 3221 (2355) .005 .31 .46
at 48 h 2229 (2226) 2655 (2268) 2450 (2016) 2023 (2468)
at 72 h 1979 (1435) 1641 (2490) 827 (2747) 1526 (2974)
Norepinephrine, μg/kg/min
at baseline 0.50 (0.55) 0.48 (0.63) 0.29 (0.21) 0.24 (0.34) .15 .06 .13
at 24 h 0.21 (0.39) 0.34 (0.62) 0.19 (0.24) 0.17 (0.47)
at 48 h 0.11 (0.26) 0.15 (0.42) 0.13 (0.22) 0.09 (0.28)
at 72 h 0.10 (0.23) 0.08 (0.25) 0.01 (0.10) 0 (0.11)
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PaO2/FIO2, 
at baseline 178 (91) 170 (123) 189 (98) 1188 (110) .81 .77 .29
at 24 h 218 (97) 245 (125) 210 (58) 212 (83)
at 48 h 240(90) 225 (93) 237 (104) 204 (66)
at 72 h 213 (90) 239 (102) 272 (95) 209 (67)
PEEP, cm H2O
at baseline 13 (6) 12 (6) 10 (7) 12 (6) .72 .40 .48
at 24 h 12 (5) 12 (4) 12 (7) 12 (5)
at 48 h 10 (6) 12 (6) 10 (7) 12 (5)
at 72 h 10 (6) 10 (6) 8 (6) 11 (6)
Lung injury score
at baseline 2.4 (1.0) 2.5 (1.0) 1.9 (1.0) 2.2 (1.0) .15 .60 .42
at 24 h 2.0 (1.0) 2.0 (1.0) 1.7 (1.0) 2.0 (1.0)
at 48 h 1.9 (1.0) 2.0 (1.0) 1.5 (1.0) 2.0 (1.0)
at 72 h 1.7 (1.0) 1.7 (1.0) 1.0 (1.0) 1.7 (1.0)
Median (interquartile range) PAC Pulmonary Artery Catheter, TPTD Transpulmonary Thermodilution, CVP 
central venous pressure, MAP mean arterial pressure, CI cardiac index, S(c)vO2 central or mixed venous 
O2 saturation, PaO2 partial pressure in arterial blood of O2, FIO2 inspiratory O2 fraction, PEEP positive end-
expiratory pressure, U underlying condition, M monitoring arm, U*M interaction.
Discussion
As far as we know, this is the first prospective randomized clinical trial of TPTD versus 
PAC using predefined algorithms recommending upper limits for fluid loading and 
guiding hemodynamic management of critically ill patients with shock of various 
etiologies.
The main finding of our study is that the major primary end point, VFDs, did 
not differ among monitoring techniques. Also, the total number of ventilation 
days (including all patients) and length of stay in the ICU and hospital did not differ 
between TPTD and PAC. Approximately 50% of patients had 0 VFDs because of early 
death before day 28. Although our patients had higher mortality rates than in other 
reports5, disease severities were also higher. It might be suggested that, in retrospect, 
this study was underpowered for detecting a difference in VFDs as a result of relatively 
high 28-day mortality and resultant low VFDs and high range. In any case, monitoring 
groups of the study did not differ with respect to 28-day and hospital mortality, which 
is in line with the absence of a demonstrated survival benefit of many hemodynamic 
monitoring tools25. The current study was not powered to demonstrate such effect, 
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although it was large enough to show an expected higher mortality in septic than in 
nonseptic shock patients.
The trial was conceived with the idea that volume monitoring may limit 
potentially harmful pulmonary fluid overloading that may occur with pressure-guided 
management. In this hypothesis, we thus favored goal-directed and thus individualized 
therapy over fixed restricted fluid regimens, as argued before6,8-10,13,14. However, by 
defining upper limits for fluid administration of both volumes and pressures, the 
ultimate fluid infusions and balances (after 24 hrs) were roughly similar between 
the monitoring groups. Nevertheless, pulmonary fluid overloading could likely be 
prevented by using either EVLW/GEDVI or PAOP, because the EVLW/PAOP, which 
were elevated at baseline, decreased in time despite fluid loading. This conforms to 
our earlier observations that fluid loading in the steep part of the cardiac function 
curve does not aggravate or induce pulmonary edema both in septic and nonseptic 
patients17. However, patients with nonseptic shock had more days on the ventilator 
and longer length of stay when they were monitored by TPTD, whereas this was not 
the case in septic shock. We cannot exclude that fluid restriction (with an upper limit 
of EVLW ≥7 rather than the 10 mL/kg predicted body weight in the current study) might 
have resulted in less prolonged ventilation in these patients, as suggested before1. The 
difference in study results according to etiology may be attributable, in part, to greater 
cardiovascular comorbidity in the nonseptic shock patients, suggesting that the 
upper limits of GEDVI and EVLW for fluid administration may have been too high and 
interfered with weaning of the ventilator through intermittent hydrostatic pulmonary 
edema26. Indeed, the GEDVI was higher in nonseptic than septic shock patients, at 
similar CI, suggesting diminished cardiac performance in the former. Filling volumes 
may be superior to pressures for assessing cardiac preload and predicting fluid 
responsiveness in patients with sepsis and relatively normal cardiac function, whereas 
pressures may be superior in postsurgical patients with relatively poor systolic 
cardiac function11,21,22. This may have contributed to the different effect of monitoring 
techniques between underlying conditions. Nevertheless, the course of EVLW did 
not differ between septic and nonseptic shock patients, but the frequency of acute 
respiratory distress syndrome was much higher in septic shock so that hydrostatic 
pulmonary edema may have been more frequent in patients with nonseptic shock. 
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Finally, incorporation EVLW or lung injury score at 72 hrs abrogated the association 
between monitoring by TPTD and prolonged mechanical ventilation in nonseptic 
shock patients, suggesting that monitoring by TPTD resulted in a too high EVLW in 
nonseptic patients to promote weaning. Thus, our study confirms that septic shock 
patients have different cardiorespiratory physiology than nonseptic shock patients 
and that combining these conditions for the evaluation of protocols for hemodynamic 
management may conceal differences. This justifies our stratified randomization and 
analysis. That our results are not in line with the shortened duration of mechanical 
ventilation during volume-guided treatment of cardiac surgery patients14 can be 
explained by a difference in inclusion criteria requiring the presence of shock and thus 
greater severity of illness and fluid requirements accompanied by longer stays and 
higher mortality of our nonseptic patients. Furthermore, we used higher cutoff values 
for GEDVI (850 versus 800 mL/m2).
EVLW/GEDVI monitoring by TPTD was associated with a greater increase in CI and 
ScvO2 in time with a tendency for a more rapid decrease in vasopressor requirements. 
This was probably related to a greater 24-hr fluid balance with TPTD than with PAC 
in agreement with the literature3,14. The greater 24-hr fluid balance in turn might be 
explained by the fact that upper limits for fluid administration were less often met in 
the TPTD than in the PAC group. Indeed, fluid infusion inversely related to PAOP in the 
PAC and GEDVI in the TPTD group, so that these preload indices were indeed used to 
help dosing fluids. Otherwise, the opposing course of GEDVI and PAOP and CI over 
days may imply an increase in cardiac function in many patients, possibly because of 
transient myocardial stunning in cardiovascular surgery and amelioration of myocardial 
depression in septic shock patients, thereby contributing to less vasopressor 
requirements over days. In our study, the course of lactate and organ failure did, 
however, not differ between the monitoring groups, so that the increase in CI and 
ScvO2/SvO2 suggesting increased tissue oxygenation, claimed to be associated with 
improved survival in previous studies on septic shock6-8,10,17 and in nonseptic surgical 
patients8,13,14 probably did not benefit organ oxygenation or function. Our results 
agree with data obtained in a nonrandomized study after cardiac surgery14 and with 
observations involving a mixed population3, suggesting that volume monitoring may 
result in greater fluid and less vasopressor requirements than standard monitoring.
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Our study has advantages compared with other studies by its prospective, two-
center, and randomized nature. A limitation of this study is its relatively small size. 
The baseline characteristics were largely similar among monitoring groups, except for 
a lower SvO2 in the PAC compared with the ScvO2 in the TPTD group, which is in line 
with the well-known differences among the sampling sites27,28. Also, using dynamic 
indices of preload responsiveness generated by the PiCCO technique such as stroke 
volume variation or pulse pressure variation may be valuable for guiding fluid therapy, 
but these indices are strongly dependent on heart rhythm, full ventilatory support, 
and settings and their use was therefore not considered for the current study. 
With monitoring by TPTD, more protocol nonadherence for fluid loading occurred, 
particularly in nonseptic shock, but this did not affect the results, because the number 
of patients with nonadherence was not increased and results did not change after 
eliminating those with nonadherence. We finally cannot exclude that the relatively 
high upper limits for indicators of cardiac preload and pulmonary edema we used may 
need refinement in the future, particularly for nonseptic shock.
Conclusions
 
This prospective, two-center, randomized clinical trial suggests that fluid resuscitation 
and hemodynamic management guided by TPTD versus PAC monitoring, using 
algorithms with predefined upper limits for fluid loading, results in similar VFDs and 
mortality in patients with septic or nonseptic shock while safeguarding resuscitation.
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Letters to the editor
Results of questionable management protocols are inherently 
questionable
Sir,
We read with interest the paper1 by Trof et al. published in a recent issue of this 
journal, which concluded that hemodynamic management in nonseptic shock guided 
by the PiCCO resulted in more days on mechanical ventilation and ICU length of stay 
compared with a pulmonary artery catheter (PAC) algorithm, and that this difference 
may be attributed to a more positive fluid balance with use of transpulmonary 
thermodilution. The authors merit praise for conducting a randomized outcome 
study, which is a challenging task. However, the interpretation of the results of this 
study is not simple and should be done with caution. The authors often state that they 
have compared two hemodynamic monitoring devices, the PiCCO and the PAC, while 
in effect, this study compared two very different management protocols (volume 
vs. pressure guided), which employed some questionable end-points. Because of 
this major limitation, it may well be that opposite results could have been obtained 
if different endpoints were chosen. For example, the algorithm chosen for patients 
managed with the PiCCO uses extravascular lung water (EVLW) as the first-line variable 
for deciding whether to infuse fluid in septic and non-septic shock, which is quite 
unusual. Moreover, the authors considered that fluid loading was mandatory if EVLW 
was <10 ml/kg whether preload responsiveness was a present or not. Regrettably, 
preload responsiveness was not assessed in this study, the reason given by the 
authors being that pulse pressure variation and/or stroke volume variation could not 
be used for assessing preload responsiveness in this patient population. The authors 
should be reminded however, that alternatives to these variability indices have been 
developed2 and can easily be used with the PiCCO system. What we find to be an 
even more significant flaw in the aforementioned algorithm is that patients with high 
lung water (EVLW ≥10 ml/kg) received fluid loading when the global diastolic volume 
index (GEDVI) was below 850 mL/m2. No clear reason was given for choosing such 
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a threshold value, which, at best, is the highest GEDVI value that can be considered 
“normal”. It seems therefore, that this protocol has led to the administration of 
fluids in patients who would not have received them in “real world” conditions. This 
is further supported by the fact that, at baseline, 46% of patients of the pulmonary 
artery catheter group had already reached the upper limit of fluid resuscitation (PAOP 
≥18 mmHg) compared with only 25% of the patients of the PiCCO group who have 
reached the respective limits (GEDVI ≥850 ml/m2 plus EVLW ≥10 ml/kg). This finding 
strongly suggests that the results of this study and the differences found in outcome 
were a result of the arbitrary (and questionable) end-points chosen for each protocol 
and not the monitoring technology that was used. What can be learned from this 
study is simply that fluid administration in patients with high lung water in order to 
achieve higher-than-normal preload values is associated with worse outcome.
Jean-Louis Teboul1, Xavier Monnet2, Azriel Perel3
1AP-HP, Hôpitaux Universitaires Paris-Sud, service de réanimation médicale, Le 
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Authors reply
We appreciate the comments on our paper1 by Teboul, Monnet and Perel, participating 
in the advisory board of the manufacturer of the PiCCO device, yielding variables which 
we compared to those derived from a pulmonary artery catheter (PAC), in guiding 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
169Volume-limited versus pressure-limited hemodynamic management in septic and nonseptic shock
9
treatment of critically ill patients with septic or non-septic shock. First, the authors 
suggest that the hemodynamic management protocols that we compared employed 
questionable end-points which may explain the somewhat longer need for mechanical 
ventilation in non-septic (in contrast to septic) patients treated as guided by PiCCO 
(transpulmonary thermodilution) rather than by PAC (pressure and right-sided 
thermodilution) based algorithms, and they suggest that opposite results had been 
obtained if different end-points had been chosen. We must emphasize that we did not 
conduct a fluid resuscitation study. The purpose of our study was to find out whether 
the risk of fluid overloading can be diminished if upper limits of EVLW and GEDVI are 
taken into account to limit fluid loading, when otherwise indicated, compared to a 
strategy limited by pulmonary arterial occlusion pressure (PAOP) obtained via a PAC, 
while safeguarding adequate resuscitation. The latter was certainly the case for the 
PiCCO group (greater increase in cardiac index and venous oxygenation and more 
rapid tapering of vasoconstrictors suggestive of shock reversal than with PAC). To 
this end, we defined upper limits of each of these parameters, which, again, were 
not taken as targets but as limits. We only gave fluids in these shock patients, when 
clinically indicated on the basis of the criteria mentioned in the paper (including but not 
limited to hypotension, low venous oxygenation, hyperlactatemia, oliguria) and did 
not apply any described predictors of fluid responsiveness in a formal manner, since 
patients in shock can be expected to be in need of fluid and to be, as volunteers, often 
fluid responsive, at least initially. Moreover, many indicators of fluid responsiveness 
remain highly controversial in clinical practice, the use of these indicators have not 
been proven to individualize (and restrict) fluid management resulting in better 
outcomes and less ventilator requirements (issues of safety and efficacy), and some of 
them even have relative contraindications, such as passive leg raising that may be less 
practical in patients with femoral artery catheters for renal replacement therapy, etc2. 
Evaluating their patient-centered benefit would require a different study. In any case, 
patients in our study were ventilated with tidal volumes mostly below 8 ml/kg, often in 
a pressure support modus, and at least 10% in the PiCCO group had atrial fibrillation or 
other rhythm disturbances precluding meaningful interpretation of dynamic indices 
derived from (ventilator-induced) variations in arterial blood pressure2. Moreover, fluid 
administration with the PiCCO algorithm was not greater, even on the first day, than 
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in the PAC group, although fluid balance was, unexpectedly, somewhat higher. The 
EVLW declined similarly in both septic and non-septic patients in the PiCCO group in 
the course of shock treatment, and cardiac index indeed increased upon fluids (in the 
first day of PiCCO monitoring), confirming our previous observations3 that, regardless 
of initial EVLW, patients increasing their cardiac index with fluid administration mostly 
do not increase their EVLW. In non-septic patients, the number reaching upper limits 
of PAOP and EVLW/GEDVI in the two arms of the study, respectively, was 35 and 27% 
(not different), respectively, suggesting equal chances for limiting fluids. Hence, 
the suggestion that these patients had received fluids in an unrealistic manner is 
questionable, as well as the suggestion that this may have increased their EVLW, which 
is simply not true. Our study thus reflects the real life practice of fluid resuscitation. 
This is not to say that if we would have chosen a lower EVLW limit, as explained in the 
discussion, a more rapid resolution of pulmonary edema, at the expensive of more 
(rather than less, as in the current study) vasopressor treatment, would have resulted 
in more rapid (rather than retarded) liberation from mechanical ventilation in non-
septic shock patients. We therefore intend to repeat the study at a lower EVLW upper 
limit. Otherwise the EVLW of 10 ml/kg was chosen since this limit has been shown 
to be associated with development of clinically manifest pulmonary edema and has 
been used before4. The less different effect of PiCCO vs. PAC monitoring in septic 
shock patients again can be explained, among others, by their greater propensity for 
non-cardiogenic pulmonary edema that is less rapidly cleared as cardiogenic edema. 
The latter presumably predominated over non-cardiogenic edema in our non-septic 
patients with cardiac premorbidity, and possibly recurred in the course of weaning 
when the latter were not ‘dry’ enough, explaining the difference in duration of 
ventilation between the monitoring groups. Conversely, the relatively high upper limit 
of GEDVI we have chosen, based upon our own observations as well as other studies, 
does not yet completely exclude (particularly in septic shock) an increase in CI with 
fluid loading when needed in the treatment of shock5-8. Again, it may well turn out in 
a future study that a lower upper limit would result in a more restricted fluid regimen, 
of which the safety and efficacy for critically ill patients with shock remains to be 
proven. In any case, our study suggests that the evaluated PiCCO algorithm is safe 
and non-inferior to PAC-guided management (with similar mortality as a secondary 
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endpoint), although in need of refinement to enhance (rather than delay) resolving 
of cardiogenic edema and liberation from mechanical ventilation in non-septic shock 
patients.
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Hemodynamic treatment algorithms should follow physiology – or they 
fail to improve outcome
Dear Sir,
Trof et al. are to be congratulated for having performed this trial on the use of 
extravascular lung water index (EVLWI) in critically ill patients. Contradictory to 
earlier work, they could not find any significant differences in outcome between 
patients, in which hemodynamic management was guided by an algorithm based 
on transpulmonary thermodilution (TPTD) leading to a more positive fluid balance, 
compared to those guided by PAOP1,2. 
In the TPTD group, an EVLWI < 10ml/kg was used as primary criterion to initiate 
a fluid challenge. Although the suggested threshold of EVLWI is reasonable for 
the detection of pulmonary edema and acute lung injury3, it does not indicate, if a 
patient is fluid responsive or not. It is simply not understandable, why this parameter, 
serving as an indicator for exceeding vascular capacity in the lungs should serve as 
an entrance decision for fluid loading. In other words, an EVLWI < 10 ml/kg cannot 
initiate, only an EVLWI> 10 ml/kg can lead to an abdiction of fluid loading. This is a 
fundamental, conceptional flaw of this investigation, since unnecessary fluid boluses 
seem to increase morbidity and mortality3-5. Further, when stepping down the TPTD 
algorithm for patients with an already elevated EVLWI, the decision for fluid loading (in 
spite of this elevated EVLWI!) was determined by GEDVI. The authors predetermined 
a GEDVI < 850ml/m² as a sign for fluid responsiveness. This second major criterion for 
fluid loading needs to be discussed thoroughly. First, predetermined and arbitrarily 
defined ranges of static parameters of preload, i.e. CVP, PAOP or GEDVI will always be 
insufficient to determine fluid responsiveness in a heterogeneous patient population 
– which is by nature the group of critically ill patients5,6. The reason is simple – because 
of interindividual heterogeneity of “optimal” preload values, which are already seen 
in hemodynamically compensated patients: “Normal” GEDVI values are dependent 
not only on patient anthropomorphy but also age and gender7. A recent data 
analysis in critically ill patients underlined this heterogeneity8. Second, if, despite 
the knowledge of the insufficiency of generalized target values for a static preload 
parameter, for practical reasons a target zone is chosen for patients already showing 
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signs of developing pulmonary edema (EVLWI>10 ml/kg), then this target zone should 
surely be based on the lower margin of published clinical findings. But the here chosen 
target of <= 850 ml/m² is far above a) the recommended target values given by the 
manufacturers of TPTD devices (lower margin 640 ml/m²), b) the median GEDVI values 
of cardiocirculatory healthy patients at discharge from the ICU (693ml/m2), and 
c) the median values in septic (788 ml/m²) and surgical ICU patients (694 ml/m²)7,8. 
Thus, not to determine fluid responsiveness, but instead to use GEDVI with a clearly 
too high target in patients already on the edge of pulmonary edema is simply not 
comprehensible. The result: additional fluid boluses (TPTD: 242; PAC: 175) resulting in a 
higher fluid balance. Further, looking at the baseline characteristics, both groups had 
higher values of PAOP and GEDVI as normally seen. The sepsis group had even higher 
PAOP compared to the non-sepsis group (18 vs. 12 mmHg), and S(c)vO2 was normal 
indicating that these patients were not in need of extra fluids. The authors claim that 
152/175 (PAC) and 209/242 (TPTD) fluid challenges in the septic group were identified 
post factum as correct, since those resulted in an increase in cardiac index of >10%. 
But a 10% variation is in the range of the precision of thermodilution measurements9. 
So this claimed 10% increase may have been even no increase at all. With the accepted 
threshold of 15%, the number of correct fluid challenges would have been much less.
In summary, a fundamental mistake in this study was the misuse of EVLWI. EVLWI 
can be used as a safety guide during fluid therapy10, as a prognostic factor for ALI3, or 
to guide treatment decisions in the presence of the therapeutic conflict “low preload, 
wet lungs”, but certainly not as a primary trigger for fluid loading. No single parameter 
can change outcome. This can only be achieved by a good treatment strategy using 
the right parameters. The present study is an excellent counterexample for this.
Manu L Malbrain1, Daniel A. Reuter2
1ICU and High Care Burn Unit, ZNA Stuivenberg, Antwerp, Belgium
2Deparment of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, 
Eppendorf University Medical Center, Hamburg, Germany
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Authors reply
We appreciate the comments on our paper1 by Malbrain and Reuter, participating in 
the medical advisory board of the manufacturer of the transpulmonary thermodilution 
device (PiCCO™, Pulsion Medical Systems, Munich, Germany). We have received 
similar comments from a similar direction before, to which we recently replied, in this 
journal2. 
First the authors comment that using a threshold for 15% (instead of 10%) increase in 
cardiac index (CI) for defining fluid responsiveness would have decreased the number 
of correct fluid challenges suggesting the administration of an unnecessary amount 
of fluids. A 15% cutoff however can be considered as arbitrary, and largely determined 
by statistical (measurement error) rather than clinical considerations3. A 10% threshold 
is more commonly used than a 15% threshold4,5, and it is completely unclear what the 
appropriate level to benefit patients is. 
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Second, the authors erroneously assume (as others have done before2, that 
we used the extravascular lung water (EVLW) and the global end-diastolic volume 
index (GEDVI) parameters as indicators of fluid responsiveness and targets for fluid 
administration, which was not done, as explained previously2. The authors should 
read the algorithms that go with this study clearly and appropriately defining fluid 
responsiveness by CI increases. The relatively higher pulmonary artery occlusion 
pressure (PAOP) in sepsis than in non-sepsis can be explained by a higher PEEP level, 
among others. The relatively high upper limit of GEDVI we have chosen, based upon 
our own observations as well as other studies (by the authors of the letter), does 
not yet completely exclude (particularly in septic shock) an increase in CI with fluid 
loading when needed in the treatment of shock6-9. Moreover, the extravascular lung 
water (EVLW) declined similarly in both septic and non-septic patients in the PiCCO 
group in the course of shock treatment, and CI indeed increased upon fluids (in the 
first day of PiCCO monitoring), confirming our previous observations10 that, regardless 
of initial EVLW, patients increasing their CI with fluid administration mostly do not 
increase their EVLW. Again, if we would have chosen a lower EVLW limit for safe fluid 
administration in case it is needed and the patient is predicted to be fluid responsive, 
as explained in the discussion, a more rapid resolution of pulmonary edema, at the 
expensive of more (rather than less, as in the current study) vasopressor treatment, 
would have resulted in more rapid (rather than retarded) liberation from mechanical 
ventilation in non-septic shock patients. Again, the EVLW was thus used and should be 
used as an upper safety limit for fluid loading when indicated, as correctly suggested 
by the authors of the letter, a statement with which we fully agree. 
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Transpulmonary thermodilution: The jury is out
To the Editor,
We read “Volume-limited versus pressure-limited hemodynamic management in septic 
and nonseptic shock” by Trof et al. with great interest. Early resuscitation of patients 
with shock is widely discussed and differing opinions have led to a large variation in 
practice patterns among clinicians. Recent data suggesting that overzealous fluid 
resuscitation may lead to poor outcomes has intensified the debate of this topic1-3. 
Trof et al. provide additional data on which to refine our strategies. 
The study provides us with a comparison between a tool which has been 
largely abandoned (the PA catheter) and a tool which has not been widely adopted 
(Transpulmonary thermodilution or TPTD) within a heterogeneous group of critically 
ill patients. 
The heterogeneous population is particularly troublesome as this was not only 
a comparison of specific medical devices, but also of the algorithms dictating care. 
As the authors suggest in their discussion, the use of these algorithms (particularly 
the TPTD algorithm) may not be appropriate for patients with any type of shock. The 
study was not powered to show improvement in patients with septic shock and the 
algorithm was not designed to care fro patients with other types of shock. 
The more commonly used goals for early resuscitation (CVP, MAP, UOP) were 
included in both arms of the trial, but a control arm with an algorithm based on these 
routine measurements was not included. Thus the trial does not clarify whether or not 
PA catheter or TPTD based algorithms are superior to a noninvasive approach. 
A third criticism of the trial is the management of patients following resolution 
of shock. Details regarding volume management after resolution of shock are scarce 
and may substantially alter the outcomes. A conservative fluid management strategy 
is recommended in most patients after resolution of shock and it is not clear that this 
strategy was maintained in either arm of this study.
In summary, we feel that the study by Trof et al. does not provide support for 
widespread use of TPTD in patients with shock. However, it certainly does not support 
abandonment of the tool. We anticipate further studies with refined algorithms in 
more homogenous populations of shock patients will help define the role of advanced 
hemodynamic monitoring in patients with shock. 
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Authors reply
We appreciate the comments on our manuscript1 by Hooper and Marik. In their 
commentary they discuss, based on the results of our study, whether the use of the 
transpulmonary thermodilution technique (TPTD) in patients with shock may be 
beneficial or not. 
First, we agree with the authors that overzealous fluid resuscitation may lead to 
poor outcomes. That is why we conducted a study yielding algorithms defining upper 
limits of fluid loading, in which we compared upper limits of pressures (pulmonary 
artery occlusion pressure, PAOP) by the pulmonary artery catheter (PAC) versus 
volumes (extravascular lung water, EVLW / global end-diastolic volume, GEDVI) 
by the TPTD technique. We hypothesized that incorporation of extravascular lung 
water in the TPTD algorithm (versus the PAC algorithm) would limit or prevent fluid 
overloading, translating into an increase in ventilator-free days. A cut off of 10 ml/kg 
for EVLW was chosen because exceeding this limit has been shown to be associated 
with development of clinically manifest pulmonary edema and has been used before2. 
Since hemodynamic management and outcome may differ among shock etiologies3-6, 
we stratified patients into septic and non-septic shock. The authors however suggest 
that the heterogeneous population is particularly troublesome as this study was not 
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only a comparison of specific medical devices, but also of the algorithms dictating care. 
In retrospect, we have to admit that different algorithms for septic versus nonseptic 
shock patients would have been better, since our results demonstrated differences 
between these groups, to the detriment of the TPTD monitored nonseptic shock 
patients. However by using the same algorithm for both groups, our study revealed 
and confirmed the differences in cardiorespiratory (patho)physiology between septic 
and nonseptic shock, which seems to be an important observation. Future studies 
using the TPTD technique should take this observation into account; indeed, we intend 
to repeat the study at lower EVLW upper limits in patients with nonseptic shock.
Second, the authors suggest that incorporating a control arm in the original study 
protocol may have clarified whether or not “device-based algorithms” are superior to 
a non-invasive approach. We agree that this conception is quite interesting since other, 
less invasive, parameters such as lactate clearance may have additional benefit for 
resuscitation purposes7. However, the goal of our study was to compare upper limits 
of pressures (PAOP) by PAC versus volumes (EVLW/GEDVI) by TPTD, hypothesizing 
that a volume-based algorithm would be superior to a pressure-based algorithm in 
preventing fluid overloading. 
Third, the authors question whether a conservative fluid management strategy 
was applied after resolution of shock in either arm of the study. Since our study 
protocol was only directive during the first 72 hours after inclusion we did not focus on 
a conservative fluid management approach after shock resolution. Fluid management 
after 72 hours occurred at the discretion of the attending physician. However, fluid 
balances in all groups of patients were increasingly less positive (table 3 supplemental 
digital content) during three consecutive days, suggesting a well considered fluid 
management strategy. Nevertheless, as recently stated in our reply to Teboul et al.8, 
it may well turn out in a future study that a lower upper limit of EVLW would result 
in a more restricted fluid regimen, of which the safety and efficacy for critically ill 
patients with shock remains to be proven. In any case, our study suggests that the 
evaluated TPTD algorithm is safe and non-inferior to PAC-guided management (with 
similar mortality as a secondary endpoint), although in need of refinement to enhance 
(rather than delay) resolving of cardiogenic edema and liberation from mechanical 
ventilation in non-septic shock patients.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
180 Chapter 9
References
1. Trof RJ, Beishuizen A, Cornet AD, et al: Volume-limited versus pressure-limited hemodynamic 
management in septic and nonseptic shock. Crit Care Med 2012;40:1177-1185.
2. Goepfert MSG, Reuter DA, Akyol D, et al. Goal-directed fluid management reduces vasopressor and 
catecholamine use in cardiac surgery patients. Intensive Care Med 2007;33:96-103
3. Sevransky JE, Nour S, Susla GM, et al. Hemodynamic goals in randomized clinical trials in patients with 
sepsis: a systematic review of the literature. Crit Care 2007;11:R67.
4. Jones AE, Brown MD, Treciak S, et al. The effect of a quantitative resuscitation strategy on mortality in 
patients with sepsis: a meta-analysis. Crit Care Med 2008;36:2734-2739.
5. Lees N, Hamilton M, Rhodes A. Goal-directed therapy in high risk surgical patients. Clinical review. Crit 
Care 2009;13:231.
6. Stewart RM, Park PK, Hunt JP, et al. Less is more: improved outcome in surgical patients with 
conservative fluid administration and central venous monitoring. J Am Coll Surg 2009;208:725-737.
7. Jansen TC, van Bommel J, Schoonderbeek FJ, et al. LACTATE study group. Early lactate-guided therapy 
in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir 
Crit Care Med 201015;182:752-61.
8. Teboul J-L, Monnet X, Perel A. Results of questionable management protocols are inherently 
questionable. Crit Care Med 2012;40:2536-7.
  
10
Summary, 
general discussion 
and future perspectives
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
182 Chapter 10
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
183Summary, general discussion and future perspectives
10
In the first part of this thesis we focused on the benefits and detriments of (synthetic) 
colloids versus crystalloids for fluid resuscitation in circulatory shock. We explored 
whether cardiac response depends on the type of fluid administered, and critically 
reviewed the literature on the crystalloid-colloid volume ratio in determining 
hemodynamic effects and discussed current views on the potential hazards of 
synthetic colloids in sepsis. The second part of this thesis was aimed at monitoring 
of fluid therapy. We compared the transpulmonary (thermo)dilution technique 
with filling pressure based hemodynamic monitoring in critically ill patients with 
different disease etiologies in order to improve understanding and interpretation of 
transpulmonary (thermo)dilution derived indices versus filling pressures, which is of 
importance because of its potential diagnostic and therapeutic implications. 
 
PART I   
Fluids: type, dosing and timing
Chapter 2
In chapter 2 we hypothesized that fluid loading with colloids results in a greater 
increase in preload-recruitable cardiac output and stroke work than saline loading. 
We assumed that this effect would be more pronounced in nonseptic than in septic 
patients because of differences in cardiac function and vascular permeability. Indeed 
we demonstrated that fluid loading with colloids resulted in a greater increase in 
cardiac filling, cardiac output and stroke work than with saline. However, we also 
found that the hemodynamic response to fluid loading in sepsis was similar to that 
in nonsepsis. This may suggest that myocardial depression and presumably increased 
vasopermeability, as seen in sepsis, are subordinate to the effect of colloids, at 
least within the time window of 90 minutes we used for our study. The most likely 
explanation for this mechanism is maintaining or even increasing the plasma colloid 
oncotic pressure (COP), even when accompanied by increased vasopermeability, as 
often seen in sepsis. We found that the volume ratio for reaching similar hemodynamic 
endpoints was approximately 1 colloid to 3 crystalloids, based on the difference in 
cardiac output increase multiplied by the difference in volume infused. 
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Chapter 3
In this chapter we performed an in-depth exploration of the crystalloid-colloid volume 
ratio and reviewed the available clinical data order to determine the differences in 
hemodynamic effects. The increase in cardiac output after fluid loading is commonly 
believed to be caused by increasing the plasma volume. However, this relationship 
may not be as straightforward when infused fluids are differently partitioned in 
stressed and unstressed volume compartments. Fluid loading may also affect 
blood viscosity and may thereby lower cardiac afterload and increase contractility. 
Furthermore, baseline cardiac loading and the function of both ventricles may affect 
mechanisms of cardiac output increase upon fluid loading. Based on the reviewed 
data, we found that the volume ratio is approximately 1 colloid to 2-3 crystalloids, 
provided that similar hemodynamic endpoints had been reached. We suggested 
that this factor is maintained when multiplying lower ratios with the difference 
in hemodynamic endpoints attained, which is an important observation since 
the hemodynamic endpoints of the reviewed studies were not defined similarly. 
Endpoints of resuscitation varied between studies; from clinical judgment, arterial 
and central venous pressures, to pulmonary artery occlusion pressures and cardiac 
output as well as variables obtained by transpulmonary thermodilution. This variety in 
study endpoints is likely to be responsible, in part, for the widely varying volume ratios 
during fluid resuscitation. 
Chapter 4
In chapter 4 we discussed the timing, dosing and choice of the type of fluid in patients 
with, or at risk for, acute lung injury (ALI) or acute respiratory distress syndrome 
(ARDS). Since extravasation of fluids is assumed to be determined by pericapillary 
hydrostatic pressure, colloid oncotic pressure (COP), and vascular permeability, the 
restraint of fluid loading in ALI/ARDS is based on the assumption that fluid therapy 
may worsen pulmonary edema, leading to increased respiratory deterioration. 
However, fluid loading does not necessarily lead to edema formation if increased 
lymph flow may offset increased fluid filtration. Additionally, the effect of plasma 
COP to attenuate filtration, or a low COP to increase filtration, is expected to increase 
when the hydrostatic pressure increases and drives fluids out of the bloodstream. 
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If hydrostatic pressure does not exceed pulmonary interstitial pressures, then fluid 
loading related increase in pulmonary edema will probably not occur. In the steep 
part of the cardiac function curve, the type (and dose) of fluid used for resuscitation, 
i.e. colloid or crystalloid, probably does not have a major impact on fluid accumulation 
in the lungs, regardless of permeability. Therefore, fluid resuscitation remains the 
treatment of choice, provided that the patient is likely to be fluid responsive, as is the 
case in hypotension and impaired tissue oxygenation, accompanied by clinical signs of 
hypoperfusion. After initial resuscitation, fluid restriction may ameliorate pulmonary 
edema formation and shorten ventilator days, particularly when permeability is 
increased, as is seen in ALI/ARDS. However, this is only likely to be of benefit if 
hemodynamically tolerated and when tissue oxygenation and renal perfusion are not 
severely compromised. 
Chapter 5
We critically reviewed the safety of synthetic colloids in patients with sepsis. We 
focused on synthetic colloid associated mortality and risk of acute kidney injury. When 
comparing colloids versus crystalloids for fluid resuscitation in critically ill patients it 
has been suggested in systematic reviews that resuscitation with colloids may not 
reduce the risk of death, in spite of their hemodynamic superiority. This observation 
may however partially relate to poorly defined clinical or hemodynamic endpoints 
and monitoring targeted to values proven to be associated with survival, as well as 
their insufficient application in clinical practice, so that potential benefits may not 
outweigh adverse effects. Moreover, looking critically at the extracted and analyzed 
data, most studies were not powered for mortality nor was mortality defined as a 
primary outcome measure. To date, there is no strong evidence that the use of 
synthetic colloids for resuscitation purposes negatively influences mortality in sepsis 
as compared to crystalloids. The risk of renal toxicity with the use of HES solutions 
must be qualified according to type, concentration and volume of the HES solution. 
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General discussion
Despite current guidelines and expert opinions1-6, there is still no widespread consensus 
on the preferred type of fluid to be used for resuscitation purposes in general. Since 
this part of the thesis was mainly focused on the use of synthetic colloids, in particular 
HES solutions, versus crystalloids, we will discuss the latest insights regarding pros 
and cons of HES.    
Hydroxyethyl starches: PRO
Currently, there is sufficient evidence that in a variety of conditions the use of colloids 
results in more (rapid) plasma volume expansion and hemodynamic optimization than 
resuscitation with crystalloids, and based on the available data the volume ratio is 
approximately 1 colloid to 2 crystalloids, provided that similar hemodynamic endpoints 
will be achieved (this thesis). As a result, administering less volume of colloidal fluids 
compared to crystalloids for reaching the same hemodynamic endpoint(s) may prevent 
deleterious overhydration and perhaps prolongation of mechanical ventilation and 
ICU stay. This insight may be beneficial for patients at risk for pulmonary edema, in 
particular patients with ALI/ARDS. Indeed, it has been suggested that HES solutions 
may protect or ameliorate ischemia-reperfusion, sepsis induced lung injury and 
pulmonary capillary leakage7-15. Biophysiologically, medium molecular weight HES may 
plug leaks in injured endothelium and reduce interstitial edema16,17. Biochemically, 
HES may decrease sepsis or ischemia-reperfusion induced inflammatory responses 
and neutrophil recruitment, and thus attenuates endothelial dysfunction and reduces 
pulmonary capillary permeability while crystalloid solutions cause more hemodilution, 
which in turn causes endothelial and red blood cell edema, decreases the surface 
area for tissue oxygen exchange, and worsens tissue and pulmonary edema18. 
In patients with ALI/ARDS, the use of HES significantly improved hemodynamics 
without worsening pulmonary edema, and it even attenuated pulmonary vascular 
permeability19. It may be suggested that modulation of the oncotic pressure by 
administration of colloids may influence development of pulmonary edema. However, 
the importance of oncotic pressure in the limitation of flux is only conceivable if the 
barrier is intact. In case of endothelial lesions, interstitial fluid composition will contain 
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more proteins than plasma, theoretically limiting the contribution of increasing the 
plasma entotic pressure20. In a small series of mechanically ventilated patients with 
ALI/ARDS with hypoproteinemia and presumably a low COP, albumin and furosemide 
versus furosemide alone ameliorated gas exchange and other surrogate indices of 
pulmonary edema21. In hypoalbuminemic critically ill patients with a presumably 
low COP, albumin administration was associated with less positive fluid balances 
and improved pulmonary function22. This effect may also be true for HES solutions. 
However, at present convincing evidence that albumin or HES treatment is justified 
for limitation of pulmonary edema or respiratory morbidity in patients with ALI/ARDS 
is lacking. 
Hydroxyethyl starches: CON
With regard to harmful side effects, the comparative safety of (synthetic) colloids has 
recently been extensively reviewed3,23. Potentially detrimental effects are focused on 
the HES solutions and consist mainly of renal toxicity and impaired coagulation. 
Acute Kidney Injury
The mechanism of potential HES-induced acute kidney injury (AKI) is poorly understood. 
It may include reabsorption of the macromolecule into (proximal) renal tubular cells 
leading to osmotic nephrotic lesions24 or renal plugging due to hyperviscosity of 
the filtrate, and is associated with a decrease of glomerular filtration pressure by a 
more rapid increase in intracapillary oncotic pressure than hydrostatic pressure25. The 
prolonged elevation of COP, reached by a higher molecular weight (Mw) and a more 
extensive molar substitution (MS) as accomplished by first and second generation 
HES solutions, might explain why these old generation HES products could be more 
nephrotoxic, than the third generation tetrastarches. Indeed, older generations of 
HES (Mw ≥200 kDa) have been shown to be an independent risk factor for acute 
kidney injury (AKI) in patients with severe sepsis or septic shock26 and their use should 
therefore be discouraged, while recent work suggest that resuscitation with third 
generation tetrastarches is not associated with increased development of AKI27-30 or 
may even preserve renal function and attenuate tubular damage31. The underlying 
disease may play a distinctive role; the risk of AKI may be greater during severe sepsis32 
than in trauma or in an elective surgical setting3,32. 
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Coagulopathy
The risk of potential adverse effects of HES solvents on coagulation is still under 
debate. The mechanism of impaired coagulation is only partially explained by the 
observation that the hydroxyethylated glucose polymer may reduce von Willebrand 
factor and interferes with fibrinogen polymerization and platelet function33,34. It has 
been suggested that the degree of coagulopathy depends on the pharmacokinetic 
properties of the HES molecules, such as molecular weight or the degree of substitution 
of carbon atoms with hydroxyl moieties34. To date, there is only circumstantial 
evidence that low molecular weight HES is associated with hypocoagulation35. Data 
from randomized controlled trials have so far not revealed any coagulation differences 
attributable to HES solvent or source material23. Nevertheless, it seems reasonable 
that administration of HES products should be discouraged in patients with massive 
bleeding. 
Recent studies 
Very recently, two large multicenter studies (the Scandinavian Starch for Severe 
Sepsis/Septic Shock (6S) trial36 and the CRYSTMAS study37) comparing HES 130/0.4 
versus crystalloids (Ringer’s acetate and 0.9% NaCl respectively) in patients with 
severe sepsis/septic shock have been published. The 6S trial group randomly assigned 
patients with severe sepsis to fluid resuscitation in the ICU with either 6% HES 130/0.4 or 
Ringer’s acetate at a dose of up to 33 ml per kilogram of ideal body weight per day. The 
primary outcome measure was either death or end-stage kidney failure (dependence 
on dialysis) at 90 days after randomization. Fluid administration occurred when ICU 
clinicians judged that volume expansion was needed, in other words, there was no 
predefined fluid loading protocol. The results of this study demonstrated an increased 
risk of death at day 90 with the use of HES 130/0.4 compared to Ringer’s acetate in 
patients with severe sepsis/septic shock. In addition, patients receiving HES were more 
likely to require renal-replacement therapy (RRT), as compared with those receiving 
Ringer’s acetate. The authors suggest that long-term toxic effects of HES deposition 
in tissues / organs may be responsible for the increased mortality; a high fraction of 
HES is taken up and deposited in tissues, where it can not be metabolized and acts as 
a foreign body, inducing potential toxicity. However, their explanation may be refuted 
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since only one patient (of 87) in the HES group was still dependent on RRT after 90 
days, which may thus suggest potential reversibility of HES induced AKI. Furthermore, 
it cannot be excluded that other (confounding) factors may have influenced the 
increased mortality in the HES group. For instance, the amount of blood transfusions 
was significant higher in the HES group; already in the past is has been demonstrated 
that red blood cell transfusions are independently associated with increased morbidity 
and mortality in ICU patients38. Moreover, the results of this study are contradicted by 
the results of the other large, multicenter trial, the CHRYSTMAS study. This French-
German study compared the hemodynamic efficacy and safety of HES 130/0.4 versus 
NaCl 0.9% for hemodynamic stabilization in patients with severe sepsis. The maximum 
allowed dose for both treatment groups was 50 mL/k/day on the first day and 25 mL/
kg/day from the second to the fourth day. Primary endpoint was the amount of study 
drug (mL) required to achieve initial hemodynamic stability. Hemodynamic stability 
was defined as a mean arterial pressure ≥65 mm Hg and at least two of the following 
three parameters maintained for four hours: central venous pressure 8-12 mm Hg, 
urine output >2 mL/kg, and central venous oxygen saturation ≥70%. Safety objective 
was to assess the occurrence of kidney dysfunction, coagulation disorders, and 
pruritis. The results of this study demonstrated that significantly less HES (mean 1379 
mL) compared to NaCl (mean 1709 mL) was required to reach hemodynamic stability. 
Furthermore, HES had no negative effects on kidney function, coagulation, or pruritis. 
It may be suggested that the presence of a predefined fluid loading protocol in the 
CHRYSTMAS study may have explained, at least in part, the differences in outcome 
compared to the 6S trial. Fluid administration based on predefined hemodynamic 
goals may limit the possible deleterious effects of synthetic colloids on renal function; 
in the 6S trial, the median cumulative volume of HES was 3000 mL compared to 
the mean 1379 mL in the CRYSTMAS study, while resuscitation in both studies was 
assumed to be adequate. This suggestion may be confirmed by a German study32 
showing that fluid resuscitation by HES 130/0.4 in patients with severe sepsis was 
associated with a greater incidence of acute kidney injury. In this study a median of 46 
mL/kg of HES 130/0.4 was administered, which corresponds with approximately 3000 
mL. The indication for colloid administration was left to the discretion of the attending 
physician and also here, no predefined resuscitation protocols were used. It can be 
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hypothesized that the administration of lower, or more precisely, effective volumes of 
HES would have reduced the incidence of acute kidney injury. In summary, the results 
of these very recent studies may well suggest that HES induced kidney injury is not 
only particularly dose-dependent but also potentially reversible. 
 
Future perspectives
In future randomized trials comparing (synthetic) colloids with crystalloids for fluid 
resuscitation that deviate from the ratio, the accuracy of hemodynamic monitoring 
and guiding fluid therapy should be evaluated since potential dissimilar resuscitation 
between groups may confound interpretation of relative benefits and detriments 
of solution types. The use of predefined resuscitation algorithms - to minimize 
inter-physician variability - based on cardiac output responses upon fluid loading 
may answer the question whether indeed two times less colloids (compared to 
crystalloids) are needed to reach similar resuscitation endpoints, and if so, whether 
potential harmful side effects of synthetic colloids will be minimized. Furthermore, 
whether randomization implies administration of only colloids versus only crystalloids 
is debatable, particularly when the study period is longer than 24 hours; in daily 
practice patients usually do not receive exclusively colloids or exclusively crystalloids 
for resuscitation purposes30,39. Therefore, future studies should preferably be 
performed on a “real life” basis, combining the administration of both colloids and 
crystalloids. Currently, some other large prospective trials comparing new generation 
tetrastarches or albumin with crystalloids for fluid resuscitation in the critically ill are 
ongoing. In the Australian-New Zealand Crystalloid Versus Hydroxyethyl Starch Trial 
(CHEST), all-cause mortality at 90 days will be compared after infusion of low molecular 
weight HES or saline (www.clinicaltrials.gov NCT00935168). Once treatment has been 
assigned, the participant will continue to receive either starch or saline only for all fluid 
resuscitation requirements in intensive care. The treating clinical team will decide the 
amount and frequency of the fluid given for resuscitation. A French multicenter trial 
is currently recruiting and comparing all types of colloids, including albumin versus 
all types of crystalloids on efficacy and safety by 28-day mortality and need for renal 
replacement therapy (NCT00318942). The amount and speed of fluid loading will 
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be at the physicians’ discretion and the amount of starch should not exceed 30 mL/
kg/24 hours. Throughout the whole ICU stay, patients will receive only crystalloids or 
only colloids for fluid resuscitation, according to randomization. However, in both 
studies, a predefined fluid loading protocol is lacking, and patients will receive either 
crystalloids or colloids during resuscitation. So, also here, the question concerning the 
colloid-crystalloid controversy will probably not be answered. 
Final conclusion
To date there is still no widespread consensus on the preferred type of fluid to be used 
for resuscitation purposes in critically ill patients, although the use of older generations 
of HES solutions (medium or high molecular weight) should be discouraged, at least 
in patients with sepsis (grade 1B). That in a variety of conditions the use of (synthetic) 
colloids results in more (rapid) plasma volume expansion and hemodynamic 
optimization than resuscitation with crystalloids may argue in favor for the use of 
colloids, thereby taking the maximum recommended dose of synthetic colloids into 
account. The discussion of low molecular weight HES solutions on mortality and on 
the potential detrimental effects on kidney function is currently very topical, but has 
not been settled yet. A most recently updated systematic review and meta-analysis 
on 6% HES 130/0.4 versus other resuscitation fluids demonstrated no difference 
in the relative risk of death in acutely ill patients40, while the European Society of 
Intensive Care Medicine (ESICM) task force41 on colloid volume therapy in critically 
ill patients recommend not to use newer generations of HES solutions (130/0.4) in 
patients with severe sepsis or those at risk for acute kidney injury, unless applied in 
the context of clinical trials (level of evidence grade 2C). Grade 2C evidence however, 
constitutes a weak recommendation based on low or very low quality evidence42,43, 
and is therefore not very persuasive. New trials comparing low molecular weight HES 
versus crystalloids for fluid resuscitation in critically ill patients are urgently required 
to address the safety and efficacy of such a fundamental intervention in intensive 
care medicine, provided that they are adequately performed based on predefined 
hemodynamic goals. 
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PART II   
Monitoring fluid therapy
Chapter 6
In chapter 6 we hypothesized that during fluid loading, in patients after cardiovascular 
surgery with reduced systolic cardiac function (reflected by global ejection fraction, 
GEF) as compared to those with normal function, filling pressures may be superior 
to filling volumes for predicting and monitoring fluid responsiveness, and vice versa. 
Indeed, we found that pulmonary artery occlusion pressure (PAOP) is more useful 
than global end-diastolic volume (GEDV) for predicting fluid responsiveness in patients 
with impaired systolic function (and subsequent cardiac dilatation), while GEDV is 
more useful in patients with normal systolic function. This finding can be explained 
by the assumption that in hearts with systolic dysfunction and dilatation, a right- 
and downward shift on the cardiac function curve and a left- and upward shift along 
the curvilinear pressure-volume curve at end-diastole (when there is a concomitant 
decrease in ventricular compliance), preload recruitability may be more dependent 
on and thus better predicted and monitored by pressures than by volumes. These 
data argue in favor of using PAC derived filling pressures for guiding fluid therapy in 
patients with reduced systolic cardiac function after cardiovascular surgery.
Chapter 7
In this chapter we evaluated and compared filling volumes to pressures, in determining 
the cardiac response upon fluid loading according to systolic cardiac function 
(reflected by GEF) in patients with sepsis induced hypotension and hypothesized that 
sepsis-induced cardiac dilatation is pivotal to maintain fluid responsiveness, even in 
the dysfunctional heart. Our main finding was that fluid responsiveness is maintained 
by cardiac dilatation, as measured by increased values of GEDVI. In contrast, patients 
with both systolic dysfunction and inability to dilate were not fluid responsive, 
possibly due to systolic right ventricular or diastolic dysfunction, in view of their 
increase in CVP. Patients with near-normal systolic function are fluid non-responsive 
when operating in the plateau phase of the cardiac function curve or, again, are 
responsive through cardiac dilatation when operating in the steep part of the cardiac 
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function curve. The dilatation associated with fluid responsiveness, as measured by an 
increase in GEDV is thus independent of systolic cardiac function. Our study suggests 
that transpulmonary (thermo)dilution-derived GEDVI is more helpful than CVP, in 
monitoring fluid responsiveness and non-responsiveness and their mechanisms in 
sepsis induced hypotension, but normal or target levels of preload (GEDVI 680-800 
mL/m2) may not apply in this condition.   
Chapter 8
In chapter 8 we reviewed current insights concerning the measurement of extra 
vascular lung water (EVLW) as an index of pulmonary edema and suggested that 
this parameter is a useful adjunct to assess lung injury, cardiogenic edema and 
overhydration, and to guide treatment in critically ill patients since fluid resuscitation, 
if not carefully monitored, may induce harmful fluid overloading and subsequent 
pulmonary edema. The ability to measure the amount of pulmonary edema at the 
bedside, using the transpulmonary (thermo)dilution technique may allow the clinician 
to hopefully prevent pulmonary overhydration by detecting changes in EVLW upon 
fluid loading. The gold standard for EVLW measurement by (thermo)dilution is 
postmortem gravimetry in animal models of lung edema and high correlations have 
been observed even in toxic pulmonary edema, which mimics ALI/ARDS in humans. 
Preliminary data show that EVLW monitoring may guide treatment. Despite its 
potential there are some drawbacks which are inherent to the technique. EVLW may 
be underestimated in underperfused lung areas. Some types of pulmonary edema are 
less well reflected in EVLW measurements than others, which is partly associated with 
redistribution of intrapulmonary blood flow. Furthermore, cardiac output may also 
be too high for thermal equilibration with the extravascular distribution volume, and 
positive end-expiratory pressure may increase the distribution of the thermal indicator 
and increase EVLW. Potential areas of clinical evaluation of the EVLW measurements 
include treatment for ARDS and resorption of pulmonary edema, strategies to 
prevent or limit ventilator-associated lung injury, monitoring fluid resuscitation and 
manipulating fluid balances.
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Chapter 9
In chapter 9, we conducted a two-center prospective, randomized controlled trial 
in order to assess superiority of EVLW-guided versus PAOP-guided fluid therapy for 
limiting fluid overloading. We hypothesized that the risk of fluid overloading will be less 
when fluid administration is restricted by upper limits of EVLW and GEDV than using 
upper limits of PAOP, which could be translated into more ventilator free days while 
safeguarding adequate resuscitation. Furthermore, we explored whether disease 
etiology, i.e. septic and nonseptic shock may differ in this respect. We randomized a 
total number of 120 patients; 60 patients received a transpulmonary thermodilution 
technique (TPTD) catheter and 60 patients a pulmonary artery catheter (PAC). 
Randomization was stratified per center for sepsis versus nonsepsis. Fluid therapy 
together with the need for vasopressor and/or inotropic agents was aimed at well-
known endpoints of resuscitation (MAP>65 mm Hg, S
cv
O2>70% or SvO2>65%, lactate 
clearance, diuresis >0.5 mL/kg/hr). Fluid therapy was discouraged when upper limits 
of EVLW (10 mL/kg PBW) and GEDV (850 mL/m2) were reached in the TPTD group 
and PAOP (18-20 mm Hg) in the PAC group. The main finding of this study was that 
the primary endpoint, ventilator-free days, did not differ between monitoring with 
the TPTD versus PAC. However, the use of the TPTD algorithm compared to the PAC 
algorithm resulted in more days on the ventilator and increased length of ICU stay in 
patients with nonseptic shock (in contrast to septic shock patients), which may relate 
to cardiac comorbidity and a more positive fluid balance with the use of the TPTD in 
the nonseptic shock group. This may suggest that the upper limits of GEDV and EVLW 
for fluid administration may have been too high, and thus interfered with ventilator 
weaning through intermittent hydrostatic pulmonary edema. It may be hypothesized 
that fluid restriction (with an upper limit of 7 mL/kg rather than 10 mL/kg) might have 
resulted in less prolonged ventilation in these patients.
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General discussion
That fluid resuscitation guided by hemodynamic monitoring may be helpful and may 
influence outcome was recently suggested in a cohort of over 3000 children with severe 
sepsis in a resource-limited setting (casu quo without monitoring). Administration of 
fixed volume of fluid boluses significantly increased 48-hour mortality compared to 
no bolus-fluid resuscitation44. This finding suggests that fluid resuscitation should be 
assessed on individual needs, aimed on the prevention or restoration of (impending) 
tissue hypo-oxygenation. The use of a hemodynamic monitoring tool may help the 
clinician to guide this patient-tailored fluid therapy. The pulmonary artery catheter 
(PAC) has been used for decades for monitoring hemodynamics in the perioperative 
setting or in critically ill patients. However, the use of the PAC in general has rapidly 
decreased over the last decade, mainly due to negative results of prospective, 
randomized trials that failed to show any associated clinical benefit while its use was 
associated with more complications, in particular cardiac arrhythmias45-47. Newer, less 
invasive techniques as the transpulmonary thermodilution may decrease the risk of 
adverse events and the use of volumetric parameters have been suggested to reflect 
cardiac preload better than filling pressures48,49. In addition, the TPTD technique has 
demonstrated to be able to display the amount of pulmonary edema, which may 
improve the efficacy and safety of fluid therapy. 
Pulmonary artery catheter 
Over the last decade, a more than 50% reduction in the use of the pulmonary artery 
catheter has been observed50, particularly due to an alleged lack of evidence for any 
clinical benefit associated with this technique. The apparent lack of benefit of the PAC 
may relate in part to adverse effects of insertion, improper use, poor interpretation 
of hemodynamic data, and inadequate treatment decisions based on the collected 
variables. Importantly, the use of a PAC has to comply with three conditions. First, 
correct measurement (zeroing, calibration, elimination of artifacts and proper reading 
of the values), second, correct interpretation (pressures, cardiac output and S
Vo2
 and 
their interaction), and third, correct application of the values obtained51. 
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In the Fluid and Catheter Treatment trial (FACTT)47, a pivotal study that may be partly 
responsible for the declining use of the PAC, patients were only included 36 hours after 
admission, at a time when further invasive monitoring probably would not be useful. 
It is of interest to note that this study used PAC-derived filling pressures not to guide 
resuscitation but to limit it, to consider the issue whether limited resuscitation to avoid 
increasing pulmonary edema in ARDS can improve outcome. This study suggested 
that the use of this protocol together with routine monitoring of the circulation with 
the PAC in ARDS, once it is stabilized, cannot be justified. That this tool may be of use 
in other critically ill patients has recently been demonstrated in a systematic review 
and meta-analysis of the use of preemptive hemodynamic intervention to improve 
postoperative outcomes in moderate and high-risk surgical patients. Half of the 
reviewed studies concerned PAC monitoring with hemodynamic objectives of oxygen 
delivery, cardiac index, and SvO2
52 Overall, preemptive hemodynamic intervention 
significantly reduced mortality and surgical complications. In addition, subgroup 
analysis showed a significant reduction in mortality in studies using PACs. Of course, 
probably not the PAC itself, but rather the use of predefined treatment algorithms 
aimed at hemodynamic endpoints may have improved outcome. It may be postulated 
that, if used and interpreted correctly and coupled with a treatment algorithm, the 
PAC may improve outcome compared to standard care. 
In this thesis we focused on the value of the PAC derived filling pressures versus 
transpulmonary dilution derived filling volumes because of potential diagnostic and 
therapeutic implications, in patients with different disease etiologies. Our data confirm 
the concept that disease etiology is relevant, suggesting that septic patients do have 
different cardiorespiratory (patho)physiology compared to nonseptic / postoperative 
(cardiac) surgery patients and that combining these conditions for the evaluation of 
protocols for hemodynamic management may conceal differences. Pressure-guided 
monitoring using PAC may help to better understand cardiac dynamics in patients with 
compromised cardiac function, as seen in patients with non-compliant stiff hearts as 
a result of myocardial stunning due to (controlled) ischemia-reperfusion after cardiac 
surgery53-55, as was also suggested previously56,57. The dynamics of PAOP measurements 
upon fluid loading may reflect diminished left ventricular reserve; an increase from 8 
up to 20 mm Hg for instance may warn the clinician for the development of hydrostatic 
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pulmonary edema if fluid loading will continue. In this way, fluid therapy can be guided 
by closely monitoring the changes in filling pressures upon fluid loading in order to 
prevent exceeding critical values, even if fluid responsiveness is present. 
 
Transpulmonary thermodilution technique
Global end-diastolic volume. Volumetric parameters such as GEDV have been 
proposed as a superior surrogate for cardiac preload than filling pressures48,49, since 
in mechanically ventilated patients atmospheric pressure-referenced filling pressures 
may be confounded by airway pressures, and may thereby poorly predict cardiac 
preload58,59. As a consequence, the use of GEDV has also been proposed in various 
treatment algorithms. Their use has pointed towards improved outcome in cardiac 
surgery patients49, which has led to the inclusion of this parameter into current 
guidelines for postoperative cardiac surgery patients60. In these guidelines, target 
values of 640-800 mL/m2 are recommended for GEDV60, which is approximately in line 
with the proposed algorithm of the PiCCO® technology manufacturer (700-800 mL/m2, 
Figure 1). However, there are important concerns to these proposed target values, as 
these values are primarily based on initial measurements in healthy individuals and on 
expert opinion, ignoring cardiac function, age, gender, and severity of illness. Indeed, 
it was demonstrated that GEDV, whether indexed or non-indexed, is dependent on 
age and gender, at least in spontaneous breathing patients without a hemodynamic 
compromised condition61. Furthermore, these measured mean values show wide 
confidence intervals due to a large variance between individuals (Table 1). Since 
GEDV also includes the volume of the aorta from the aortic valve to the tip of the 
thermistor on the arterial catheter, a possible explanation for the age related increase 
in GEDV, may be an increased aortic diameter at older age together with elongation 
of the aorta. Furthermore, as we demonstrated in chapter 7, high values of GEDV may 
represent (bi)ventricular dilatation and as a consequence, target values may depend 
on cardiac systolic function.
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Table 1. GEDVI means with 95% confidence intervals for males and females according to age groups.
GEDVI (mL/m2)
Age (years) male 95% CI Female 95% CI
≤ 40 633 (456-880) 559 (402-779)
41-50 667 (485-916) 592 (432-812)
51-60 736 (536-1011) 654 (478-897)
61-70 802 (585-1101) 713 (520-977)
≥ 70 812 (590-1117) 720 (520-997)
CI Confidence interval, GEDVI global end-diastolic volume index.
Recently, this concept has also been suggested by others62 and thus we propose 
that “normal” or “target” GEDV should be corrected to systolic cardiac function in 
critically ill patients. When used as an indicator for preload and preload optimization 
during fluid resuscitation, target values may differ considerably in this way (Table 2). 
This concept suggests important implications for the resuscitation algorithms being 
used. Recently, a meta-analysis demonstrated that the published data for GEDV 
are very heterogeneous, particularly in critically ill patients, and often exceeds the 
proposed normal values, in which septic patients had a significantly higher GEDV than 
postoperative patients63. When GEDVI (indexed for body surface area) is targeted at 
640-800 mL/m2 in order to define preload optimization, undertreatment may occur 
in older patients, with or without diminished cardiac function, or in patients with 
septic shock who may have cardiac dilatation and thus higher GEDV values, which is 
pivotal to maintain fluid responsiveness. In other words, a GEDV >800 mL/m2 may be 
adequate for one patient, and a GEDV <800 mL/m2 may be misleading and results in a 
non-optimal cardiac preload. Targeting GEDV as a parameter for preload optimization 
should therefore be assessed individually, taking age, gender, cardiac function, 
disease etiology and severity of illness into account.  
Table 2. GEF corrected volumetric target values. 
GEF 5% 10% 15% 20% 25% 30% 35% 40% 45% 50%
GEDVI-target (normal) 1175 1050 950 850 775 700 625 575 525 475
GEDVI-target (critically ill) 1450 1300 1050 1025 925 825 750 675 600 550
GEF global ejection fraction, GEDVI global end diastolic volume index. (Modified from reference 60).
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
200 Chapter 10
Extravascular lung water. A recent meta-analysis demonstrated that EVLW appears to 
be a good predictor of mortality in critically ill patients64. In one report, the increase in 
mortality was best predicted when EVLW exceeded >10 mL/kg PBW (predicted body 
weight) during the first 24 hours after admission to the ICU65, while in another study a 
value of a 3-day average EVLW >16 mL/kg even predicted mortality with 100% specificity 
and 86% sensitivity66. However, it must be emphasized that sequential EVLW data need 
to be interpreted carefully as both under and overestimation of EVLW values may 
occur as a result of the technique itself. For instance, extravascular lung water will not 
be measured in nonperfused lung areas (as seen in ARDS or when using PEEP) since 
the thermal indicator cannot equilibrate within the extravascular space67. Since PEEP 
levels and pulmonary perfusion usually alter during the disease process, the change 
in EVLW must be correlated to the changes in PEEP and pulmonary perfusion, which 
may impede the interpretation of sequential EVLW measurements for clinical decision 
making. Moreover, an increase in EVLW is difficult to predict since the amount of EVLW 
does not reflect (an increased) pulmonary filtration pressure. For EVLW, normal values 
of 3-7 mL/kg have been proposed. However, reviewing the available data on EVLW 
in critically ill patients revealed that in septic patients, all the mean values for EVLW 
exceeded the upper limit of 7 mL/kg and in nonseptic patients 50% of values63. Thus, 
even in nonseptic patients without long-term intensive care treatment and supposedly 
without clinically relevant pulmonary edema, half of the EVLW values exceeded the 
proposed normal value. This may lead to the suggestion that an upper limit of 7 mL/
kg is too conservative, and may perhaps induce impaired organ perfusion when fluid 
administration is withheld. On the other hand, an EVLW of 10 mL/kg is associated 
with the development of clinically manifest pulmonary edema49. Therefore, it may be 
hypothesized that a restrictive fluid policy when the EVLW is increased (>10 mL/kg) 
may affect outcome in terms of ventilator free days or even in mortality. In chapter 9 
we examined in both septic shock and nonseptic shock patients whether the risk of 
fluid overloading can be diminished if upper limits of EVLW (10 mL/kg) and GEDVI (850 
mL/m2) are taken into account to limit fluid loading, compared to a strategy limited by 
pulmonary arterial occlusion pressure (PAOP) obtained via a PAC, while safeguarding 
adequate resuscitation. EVLW values declined similarly in both septic and nonseptic 
patients over the course of shock treatment, and the cardiac index indeed increased 
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upon fluid administration, even when initial values of EVLW exceeded 10 mL/kg. This 
may seem surprising, but in line with our previous observations, we demonstrated 
that, regardless of initial EVLW, in fluid responsive hearts fluid administration mostly 
does not increase EVLW68. We speculate that the increase in interstitial pulmonary 
edema during fluid loading is predicted by a plateau of cardiac function and 
pulmonary vascular filling, rather than by pulmonary vascular permeability, and that 
pulmonary edema is not affected when fluid loading occurs in the steep part of the 
cardiac function curve68,69. In nonseptic shock patients however, the upper limit of 
10 mL/kg of EVLW may have been too high, as these patients had more days on the 
ventilator and ICU stay compared to those treated with the PAC algorithm. This may 
be attributable, in part, to greater cardiovascular comorbidity in the nonseptic shock 
patients, suggesting that the upper limits of EVLW for fluid administration may have 
been too high and interfered with ventilator weaning via intermittent hydrostatic 
pulmonary edema. Indeed, the course of EVLW did not differ between septic and 
nonseptic shock patients, but the frequency of ARDS was much higher in septic shock, 
so that hydrostatic pulmonary edema may have been more frequent in patients with 
nonseptic shock. We cannot exclude that fluid restriction (with an upper limit of EVLW 
≥7 rather than the 10 mL/kg) might have resulted in less prolonged ventilation in these 
patients. As suggested before, in patients with sepsis, values of up to 10-12 mL/kg 
may be tolerable, although more data is needed in this regard63, while in nonseptic 
patients, lower values should probably be proposed. Our results suggest that septic 
shock patients may have different cardiorespiratory physiology than nonseptic shock 
patients, and that stratification for disease etiology in the evaluation of hemodynamic 
management protocols may reveal important differences.  
Future perspectives
It may be presumed that developing tool-derived treatment protocols that are 
applicable across a heterogeneous population of critically ill patients with complex 
co-morbidities is a difficult task. Designing global protocols to guide therapy for 
every patient may virtually be a mission impossible. Nevertheless, the use of 
treatment algorithms aimed at (hemodynamic) resuscitation endpoints, allow us to 
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administer the amounts of fluids and inotropic agents more precisely. By evaluating 
– or even predicting - fluid responsiveness, fluid overloading may be prevented, 
which may affect length of stay in the ICU or even outcome. To address this issue 
randomized trials should be performed, comparing PAC or TPTD guided hemodynamic 
management based on predefined algorithms for fluid and inotropic/vasopressor 
therapy, including the evaluation of fluid responsiveness in order to optimize 
hemodynamics versus treatment based on CVP and/or S
cv
O2 measurements alone, as 
the current Surviving Sepsis Campaign guidelines recommend5. Currently the THEMIS 
trial (NCT01263977) is investigating whether duration of septic shock can be reduced 
through algorithm driven volume therapy, based on TPTD-derived parameters (GEDV 
and EVLW) compared to volume management based on the Surviving Sepsis Campaign 
guidelines5. Furthermore, it should be studied whether benefits of one monitoring 
technique over the other may depend on disease etiology; i.e. sepsis versus nonsepsis 
and/or the influence of impaired cardiac function. There are currently no studies being 
performed on this issue. 
Final conclusion
In the second part of this thesis we have focused on the differences between PAC-
derived pressure parameters and TPTD-derived volume parameters with regard to 
their value in fluid therapy and hemodynamic management of critically ill patients, 
taking underlying disease and cardiac function into account. The PAC provides 
clinicians numerous important hemodynamic variables that may be helpful to 
accurately evaluate the hemodynamic status. It must be stressed however, that the 
data generated by the PAC must be interpreted carefully, since numerous inaccuracies 
in measurements and interpretation have been reported. If measured and interpreted 
appropriately, the PAC helps the clinician to better understand cardiac dynamics in 
complex circulatory conditions and in patients with impaired (left ventricular systolic) 
cardiac function and may therefore be more useful in monitoring fluid therapy than 
volume guided monitoring. In contrast, in patients with sepsis or in patients at great 
risk of (increasing) pulmonary edema, as for instance seen in patients with ALI/ARDS, 
hemodynamic monitoring using TPTD and measurements of EVLW may be preferable 
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in order to prevent harmful overhydration and, as a consequence, prolongation 
of mechanical ventilation and ICU stay. Nevertheless, it must be emphasized that 
hemodynamic monitoring is unlikely to be associated with improved outcome, if 
the data obtained from the monitoring device is insufficiently accurate to be able 
to influence therapeutic decision making, if the data obtained are irrelevant to the 
patient being monitored, or if changes in management made as a result of the data 
obtained are unable to improve outcome. 
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Samenvatting voor niet-ingewijden
Inleiding
Het doel van deze samenvatting is om niet-ingewijden in kennis te stellen van de inhoud 
van dit proefschrift. De titel van het proefschrift is “optimizing fluid management in 
critically ill patients”, ofwel vrij vertaald “Het optimaliseren van vloeistof therapie bij 
ernstig zieke patiënten”. 
Ernstig zieke patiënten worden doorgaans op de Intensive Care (IC) opgenomen 
omdat er sprake is van een bedreiging van een of meerdere vitale functies zoals de 
bloedsomloop, ademhaling en/of bewustzijn, ten gevolge van een onderliggende 
ziekte, zoals een ernstige infectie (sepsis), of na een ingrijpende operatie zoals 
na hartchirurgie. De meeste patiënten die opgenomen worden op de Intensive 
Care hebben veelal te maken met een bedreiging van het in standhouden van de 
bloedsomloop, dit meestal ten gevolge van een absoluut of relatief vochttekort 
(hypovolemie). Dit uit zich meestal in een verlaagde bloeddruk waarbij de afgifte van 
zuurstof aan de weefsels en cellen tekort kan schieten, dit wordt circulatoire shock 
genoemd. Indien er binnen afzienbare tijd geen herstel optreedt dan zal de kans 
op progressief orgaanfalen en daarmee de sterftekans aanzienlijk toenemen. Het 
herstellen en het behouden van een effectief circulerend volume is dan ook één van 
de belangrijkste initiële doelen in de Intensive Care geneeskunde.
Het toedienen van artificiële vloeistoffen vormt de hoeksteen van de behandeling 
van circulatoire shock. Het doel van het toedienen van vloeistoffen is dat door een 
toegenomen voorbelasting van het hart (preload) en hartminuutvolume (cardiac 
output) de bloeddruk zal stijgen waardoor getracht wordt de doorbloeding 
(perfusie) van de organen en daarmee het zuurstoftransport te waarborgen. Indien 
namelijk te weinig vloeistof wordt gegeven bestaat er een risico op een aanhoudend 
perfusietekort van de organen, leidende tot orgaandysfunctie en uiteindelijk 
orgaanfalen. Echter, indien teveel vloeistof wordt toegediend neemt het risico op 
overvulling toe met als gevolg het ontstaan van vocht in de longen (longoedeem) en 
in andere organen; hierdoor kan de toestand van de patiënt verslechteren waardoor 
de beademingsduur en de kans op gerelateerde complicaties kan toenemen. Om te 
voorkomen dat een perfusietekort persisteert of juist overvulling kan ontstaan, zou 
het bewaken (monitoren) van vloeistoftherapie uitkomst kunnen bieden. 
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In dit proefschrift staan twee aspecten van het “optimaliseren van vloeistoftherapie” 
centraal. Ten eerste het soort vloeistof en ten tweede de wijze waarop de 
effectiviteit van vloeistoftherapie bewaakt zou kunnen worden (hemodynamisch 
monitoren).  
In het eerste gedeelte van het proefschrift wordt nader ingegaan op het soort 
vloeistof waarbij zogenaamde colloïdale vloeistoffen en kristalloïde vloeistoffen 
met elkaar vergeleken worden met betrekking tot enerzijds de effecten op het 
hartminuutvolume (hemodynamische effecten) en anderzijds eventueel nadelige 
bijwerkingen. 
In het tweede gedeelte van het proefschrift zal nader worden ingegaan op het 
monitoren van vloeistoftherapie, waarbij twee monitoringtechnieken centraal staan 
en met elkaar vergeleken worden; enerzijds de arteria pulmonalis katheter (PAC) 
en anderzijds de transpulmonale (thermo)dilutie techniek (TPTD). Beide technieken 
zullen bestudeerd worden met betrekking tot de behandeling van hypovolemie bij 
patiënten met verschillende ziektebeelden (sepsis en non-sepsis). In een aantal studies 
zal tevens onderzocht worden of de (ziekte gerelateerde) hartfunctie van invloed is 
op de toepasbaarheid van vullingsdrukken versus vullingsvolumina. 
DEEL I   
Vloeistoffen
Er zijn verschillende soorten artificiële vloeistoffen beschikbaar om het 
bloedplasmavolume te doen toenemen. Deze soorten kunnen grofweg worden 
ingedeeld in kristalloïde en colloïdale vloeistoffen. De meest gebruikte kristalloïde 
vloeistoffen zijn isotoon zout (NaCl 0,9%) en Ringer’s Lactaat. Een nadeel van 
kristalloïde vloeistoffen is dat het volume expanderend effect (toename van het 
bloedplasmavolume) van betrekkelijk korte duur is door snelle diffusie vanuit de 
bloedbaan via de celmembraan naar de weefsels. Slechts 20-25% van de toegediende 
hoeveelheid kristalloïde vloeistoffen blijft behouden voor (tijdelijke) volume expansie. 
Colloïdale vloeistoffen bevatten grote moleculen die minder snel door semipermeabele 
membranen kunnen diffunderen dan kristalloïden. Een theoretisch voordeel is dan 
ook dat colloïdale vloeistoffen langer in de bloedbaan blijven waardoor het volume 
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expanderend effect mogelijk langer aanhoudt. Colloïdale vloeistoffen zijn in te delen 
in natuurlijke colloïden (humaan albumine) en synthetische colloïden (hydroxyethyl 
zetmeel, gelatine).  
In hoofdstuk 2 hebben we onderzocht of het toedienen van colloïdale vloeistoffen 
tot een grotere toename van hartminuutvolume leidt in vergelijking met kristalloïde 
vloeistoffen. In zowel septische als niet-septische patiënten met klinische tekenen 
van hypovolemie werd gedurende 90 minuten, volgens randomisatie, colloïdale 
of kristalloïde vloeistoffen toegediend op geleide van een vooraf vastgesteld 
vloeistof toedieningsprotocol. Na toediening van vloeistof werden elke 30 minuten 
hemodynamische parameters gemeten. 
Uit onze observatie bleek dat onafhankelijk van onderliggende ziekte het 
hartminuutvolume een grotere stijging liet zien na toediening van een zelfde 
hoeveelheid colloïdale vloeistoffen vergeleken met kristalloïde vloeistoffen (12% versus 
2%). De verklaring hiervoor is een grotere toename van cardiale preload na toediening 
van colloïdale vloeistoffen met als gevolg een sterkere toename van cardiaal 
slagvolume. De groter toename van cardiale preload kan verklaard worden door een 
sterkere toename van de colloïd osmotische druk1 na colloïdale vloeistoftoediening, 
in tegenstelling tot kristalloïde vloeistoffen, waardoor waarschijnlijk een grotere 
toename van het plasmavolume en dus cardiale preload. Dat na toediening van 
colloïdale vloeistoffen de toename van de colloïd osmotische druk, cardiale preload 
en het hartminuutvolume even groot was onder septische als niet-septische 
omstandigheden - althans binnen het gemeten tijdstraject van 90 minuten - is verassend 
aangezien de veronderstelde toename van vaatwandlekkage (permeabiliteit) tijdens 
sepsis aanleiding geeft tot snellere equilibratie van geïnfundeerde vloeistoffen 
met het compartiment buiten de vaatwand (extravasculaire compartiment). 
Klaarblijkelijk is de toename van permeabiliteit hiervoor onvoldoende hoewel een 
tragere equilibratie niet uitgesloten is. Onze resultaten laten zien dat vergeleken met 
colloïdale vloeistoffen, 2-3 maal de hoeveelheid kristalloïde vloeistoffen toegediend 
moeten worden voor het bereiken van een zelfde toename van hartminuutvolume.
1  colloïd osmotische druk = het drukverschil dat tussen twee eiwitoplossingen (binnen- en buiten het 
bloedvat) van verschillende concentraties ontstaat ten gevolge van osmose. 
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In hoofdstuk 3 hebben we uitgezocht wat er in de bestaande literatuur bekend is 
over het volume verschil (volumeratio) tussen colloïdale en kristalloïde vloeistoffen. 
In hoofdstuk 2 is aangetoond dat vergeleken met colloïdale vloeistoffen er 2 tot 3 
keer meer kristalloïde vloeistoffen toegediend moeten worden om hetzelfde 
hemodynamische eindpunt te bereiken, echter hierover bestaat controverse, waarbij 
gesuggereerd wordt dat deze volumeratio hooguit 1:1.5 is. 
Wij beoordeelden alle studies waarbij colloïdale vloeistoffen vergeleken zijn met 
kristalloïde vloeistoffen. Het resultaat hiervan was dat de volumeratio inderdaad 1:2-
3 is, echter vooropgesteld dat dezelfde hemodynamische effecten zijn bereikt. Het 
verschil tussen onze observatie (1:2-3) en andere studies (1:1.5) lijkt derhalve gebaseerd 
te zijn op de variatie in hemodynamische eindpunten van de onderzochte studies. 
In hoofdstuk 4 zijn we ingegaan op de controverse die bestaat met betrekking tot 
vloeistof therapie bij patiënten met acute longbeschadiging (ALI)/ acuut respiratoir 
distress syndroom (ARDS). ALI/ARDS kant ontstaan bij patiënten met sepsis, 
na ernstig trauma of grote chirurgie. Deze ziektebeelden worden gekenmerkt 
door ontsteking (inflammatie) en een toegenomen lekkage/doorlaatbaarheid 
(permeabiliteit) van de longvaten. Deze toegenomen permeabiliteit kan leiden tot 
longoedeem. Het longoedeem belemmert de gaswisseling in de long waardoor 
zuurstoftekort en stapeling van koolzuur kan ontstaan. Toediening van vloeistof kan 
het longoedeem doen verergeren door lekkage vanuit de bloedvaten (extravasatie) 
naar het longweefsel met als gevolg dat de patiënt zijn conditie kan verslechteren. 
De mate van extravasatie wordt bepaald door de hydrostatische druk in de 
longhaarvaten (capillairen), de colloïd osmotische druk en de mate van permeabiliteit 
van de longcapillairen. Indien de druk in de capillairen de druk buiten de capillairen 
overschrijdt neemt de filtratiedruk toe waardoor toename van longoedeem kan 
ontstaan. Echter toediening van vloeistof bij ALI/ARDS leidt niet tot toename van 
oedeem indien de filtratiedruk lager is dan de druk in het longweefsel (interstitiële 
druk). Indien vloeistoftoediening plaats vindt tijdens hypovolemie waardoor het 
hartminuutvolume significant zal toenemen (vloeistofresponsiviteit), zal door een 
relatief lage filtratiedruk geen toename van longoedeem ontstaan, ongeacht het 
soort vloeistof (kristalloïden of colloïden) en ondanks een toegenomen permeabiliteit. 
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Indien het hartminuutvolume echter niet meer toeneemt na toediening van vloeistof 
neemt het risico op de vorming van longoedeem belangrijk toe. Toediening van 
vloeistof tijdens ALI/ARDS is geïndiceerd zolang er sprake is van orgaan hypoperfusie 
waarbij verondersteld wordt dat toediening van vloeistof de mate van hypoperfusie 
zal verminderen, echter vooropgesteld dat de patiënt vloeistofresponsief is en de 
pulmonale filtratiedruk de interstitiële druk in de long niet zal overschrijden tijdens 
vloeistoftoediening. Indien er geen sprake meer is van hypoperfusie dan zou vloeistof 
beperking kunnen bijdragen aan het terugdringen van longoedeem waardoor de 
beademingsduur verkort zou kunnen worden.
In hoofdstuk 5 hebben we gekeken naar de veiligheid van synthetische colloïden, 
in het bijzonder hydroxyethyl zetmeel oplossingen (HES) bij patiënten met sepsis. 
We hebben ons enerzijds gefocust op data inzake de relatie tussen het gebruik van 
colloïden en sterfte (mortaliteit), en anderzijds op het risico op HES geïnduceerd 
nierfalen. 
Onze resultaten lieten zien dat op basis van de beschikbare literatuur niet kan 
worden gesteld dat het gebruik van colloïden (versus kristalloïden) de mortaliteit 
negatief of positief beïnvloedt. Echter de meeste studies die zijn onderzocht waren niet 
gepowered op sterfte noch was mortaliteit gedefinieerd als primaire uitkomstmaat. 
Het gebruik van HES oplossingen lijkt geassocieerd te zijn met een toegenomen 
risico op hete ontstaan van acuut nierfalen. De oorzaak hiervan is niet geheel 
opgehelderd, mogelijk dat grote moleculen in HES oplossingen de niertubuli doen 
verstoppen waardoor nierfalen kan ontstaan. Dit verklaart wellicht waarom vooral 
oudere generatie HES oplossingen geassocieerd zijn met acuut nierfalen; oudere 
generaties HES oplossingen bevatten grotere moleculen dan de huidige HES 
oplossingen. Het gebruik van groot moleculaire HES oplossingen dient dan ook 
ontmoedigd te worden. Huidige generatie HES oplossingen lijken vooralsnog niet 
geassocieerd te zijn met een toegenomen risico op acuut nierfalen, ook niet bij 
patiënten met sepsis, hoewel er wel een dosisafhankelijk effect lijkt te bestaan. 
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Conclusie
Gesteld kan worden dat toediening van colloïdale vloeistoffen (versus kristalloïden) 
leidt tot een grotere expansie van het plasmavolume en dientengevolge tot snellere 
hemodynamische optimalisatie in zowel septische als niet-septische condities. In 
tegenstelling tot oudere generaties HES oplossingen lijkt het gebruik van de huidige 
generatie HES oplossingen vooralsnog niet geassocieerd te zijn met een toegenomen 
risico op acuut nierfalen, vooropgesteld dat de maximaal aanbevolen dosering niet 
wordt overschreden. 
DEEL II   
Hemodynamische monitoring van vloeistoftherapie
Het is aannemelijk dat toediening van vloeistof ten behoeve van het optimaliseren 
van de bloedsomloop tijdens ernstige ziekte maatwerk is. Enerzijds, toediening van 
te weinig vloeistof kan leiden tot een insufficiënt hartminuutvolume leidende tot 
een verminderd aanbod van zuurstof aan de organen (hypoperfusie). Anderzijds, 
toediening van teveel vloeistof kan juist leiden tot overvulling (oedeem), bijvoorbeeld 
in de longen, met als gevolg verdere verslechtering van orgaanfunctie, toename van 
beademingsduur en Intensive Care opname. 
Het bewaken van vloeistof therapie gebeurt door middel van hemodynamische 
monitoring. In dit proefschrift zijn twee hemodynamische monitoringstechnieken 
nader onderzocht, te weten de arteria pulmonalis katheter (PAC) en de transpulmonale 
(thermo)dilutie techniek (TPTD). 
De PAC techniek bestaat reeds enkele decennia en maakt gebruik van een katheter 
die wordt ingebracht in een grote ader (meestal in de hals of onder het sleutelbeen) 
en via de rechter harthelft wordt opgevoerd tot in de longslagader (figuur 1). Met deze 
techniek kan de druk worden bepaald in de bovenste holle ader (centraal veneuze druk, 
CVD), rechter hartboezem, rechter hartkamer en in de longslagader. Deze drukken 
worden de zogenaamde vullingdrukken genoemd. Daarnaast kan door het inspuiten 
van (koude) vloeistof een schatting worden gemaakt van het hartminuutvolume 
van de rechter harthelft. Door middel van het opblazen van een ballonnetje aan 
het uiteinde van de katheter stopt de flow distaal van de katheter waardoor de 
zogenaamde occlusie druk (PAOP) in de longslagader kan worden gemeten. Deze 
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occlusie druk is een surrogaat voor preload van de linker harthelft, terwijl de CVD een 
surrogaat is voor preload van de rechter harthelft. Een lage CVD en PAOP suggereren 
de mogelijkheid van preload toename en dus toename van hartminuutvolume na 
vloeistoftoediening, terwijl een hoge CVD en PAOP vloeistofresponsiviteit wellicht 
uitsluit. Deze drukken worden echter beïnvloed door de drukken die ontstaan tijdens 
mechanische beademing waardoor interpretatie kan worden bemoeilijkt. 
 
Figuur 1. Arteria Pulmonalis Katheter. De katheter wordt ingebracht via een centrale grote ader 
(catheter entrance) en via de bovenste holle ader (superior vena cava) door de rechter boezem (right 
atrium) door de tricuspidalis hartklep (tricuspid valve), via de rechter hartkamer (right ventricle) door 
de pulmonalis hartklep (pulmonary valve) in de longslagader opgevoerd (pulmonary artery).
De TPTD techniek is in de jaren 90 van de vorige eeuw ontwikkeld. Deze techniek 
vereist de aanwezigheid van een centraal veneuze katheter en een speciale katheter 
in de liesslagader. Door toediening van een zogenaamde indicator wordt door 
middel van subtractie (vullings)volumina berekend. Omdat geen gebruik gemaakt 
wordt van een katheter die door het hart opgevoerd dient te worden, wordt deze 
techniek als minder invasief beschouwd. Initieel werd gebruik gemaakt van een 
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dubbele indicator: een kleurstof indicator (indocyanine groen) en thermale indicator 
(koude vloeistof). Inmiddels is de dubbele indicator techniek vervangen door gebruik 
van alleen een thermale indicator. De thermale indicator wordt toegediend via de 
centraal veneuze katheter. Na toediening detecteert de katheter in de liesslagader 
de temperatuursverandering in de tijd (figuur 2). Een computer berekent onder 
andere het hartminuutvolume, het (virtuele) volume van de hartkamers als maat voor 
cardiale preload (globaal einddiastolisch volume, GEDV) en de mate van longoedeem 
(extravasculair longwater, EVLW). Door het monitoren van het EVLW kan in theorie 
vloeistof overbelasting worden voorkomen, een extra voordeel van deze techniek. 
Een ander voordeel van deze techniek is dat de gegenereerde parameters niet 
beïnvloed worden door mechanische beademing. 
In dit gedeelte van dit proefschrift hebben we bovengenoemde monitoringstechnieken 
met elkaar vergeleken en onderzocht of de klinische toepasbaarheid beïnvloed wordt 
door onderliggende ziekte (sepsis of non-sepsis) en/of (gerelateerde) hartfunctie.
Figuur 2. Transpulmonale thermodilutie techniek (PiCCO™). Benodigd zijn een katheter in een centrale 
grote ader (standard CVC) en een katheter in de liesslagader (PiCCO® Catheter) die tevens fungeert 
als invasieve bloeddruk meter (pressure connection cable). Via een injectie met koude vloeistof in de 
centrale grote ader wordt in de katheter in de liesslagader gedetecteerd hoelang het duurt voordat de 
koude bolus hier arriveert. Een computer die aangesloten is op beide katheters (injectate sensor cable, 
arterial connection cable) berekent vervolgens het hartminuutvolume, het globaal einddiastolisch 
volume (GEDV) en het extravasculair longwater (EVLW). 
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In hoofdstuk 6 hebben we verondersteld dat bij patiënten met een verminderde 
hartfunctie (systolische dysfunctie) na hart- en vaatchirurgie, vullingsdrukken (CVD 
en PAOP) superieur zijn aan vullingsvolumina (GEDV) voor het voorspellen van 
vloeistofresponsiviteit. 
Hiertoe hebben we 32 patiënten onderzocht (18 na hartchirurgie, 14 na 
vaatchirurgie) op de Intensive Care. Deze patiënten hadden allemaal klinisch tekenen 
van hypovolemie. Colloïdale vloeistof werd gegeven gedurende 3 achtereenvolgende 
intervallen van 30 minuten op geleide van een vooraf vastgesteld algoritme gebaseerd 
op verandering van centraal veneuze druk. Patiënten werden onderverdeeld in twee 
groepen; verminderde systolische hartfunctie en normale systolisch hartfunctie. In 
totaal werden 32 maal 3 = 96 vloeistofstappen geëvalueerd, waarbij onderscheid 
werd gemaakt tussen responders (toename van hartminuutvolume na toediening van 
vloeistof) en non-responders. 
Uit de resultaten bleek dat de CVD voorspellende waarde had in beide 
groepen. Echter PAOP bleek superieur aan GEDV inzake het voorspellen van 
vloeistofresponsiviteit bij patiënten met systolische dysfunctie, terwijl bij patiënten 
met een normale systolisch functie dit juist andersom was. 
Het lijkt erop dat in patiënten met systolisch dysfunctie, preload toename meer 
afhankelijk is van drukken dan van volumes. Derhalve kan worden gesuggereerd dat 
bij patiënten na hart- of vaatchirurgie met een verminderde systolische hartfunctie, 
het gebruik van vullingsdrukken gegenereerd door de arteria pulmonalis katheter 
wellicht de voorkeur heeft boven het gebruik van volume parameters zoals de TPTD 
techniek. 
In hoofdstuk 7 hebben we ons gericht op patiënten met ernstige sepsis / septische 
shock2. Een deel van de patiënten met ernstige sepsis / septische shock ontwikkelt 
cardiale dysfunctie zich uitend in systolisch falen en dientengevolge verwijding 
(dilatatie) van de hartkamers. Gesuggereerd wordt dat deze dilatatie een adaptief 
mechanisme is ten behoeve van het in stand houden een hoog hartminuutvolume, 
hetgeen geassocieerd is met overleving. Door toepassing van de TPTD techniek kan 
deze cardiale dilatatie worden gereflecteerd door een verhoogd GEDV. 
2 Septische shock is de ernstigste manifestatie van sepsis. Hierbij is er meestal sprake van aanhoudend 
lage bloeddrukken ondanks het toedienen van adequate hoeveelheden vloeistoffen waarbij het 
functioneren van organen ernstig bedreigd is. 
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Wij onderzochten of een verhoogd GEDV als uiting van cardiale dilatatie ten gevolge 
van systolisch dysfunctie inderdaad geassocieerd is met het in stand houden van 
vloeistofresponsiviteit. Hiertoe bestudeerden we 16 patiënten met ernstige sepsis/
septisch shock op de Intensive Care. Colloïdale vloeistof werd gegeven gedurende 3 
achtereenvolgende intervallen van 30 minuten op geleide van een vooraf vastgesteld 
algoritme gebaseerd op verandering van centraal veneuze druk. Patiënten werden 
onderverdeeld in twee groepen; verminderde systolische hartfunctie ( 9 patiënten) 
en normale systolisch hartfunctie (7 patiënten). In totaal werden 16 maal 3 = 48 
vloeistofstappen geëvalueerd, waarbij onderscheid werd gemaakt tussen responders 
(toename van hartminuutvolume na toediening van vloeistof) en non-responders.
Uit de resultaten bleek dat in de groep van patiënten met een verminderde 
systolisch functie basaal GEDV hoger was in de responders dan in de non-responders. 
Echter in de groep patiënten met een normale systolische functie was er geen verschil 
in basaal GEDV tussen responders en non-responders. Onze bevinding bevestigt de 
resultaten van ander onderzoek dat de voorspellende waarde van basaal GEDV voor 
vloeistofresponsiviteit imperfect is omdat deze waarde afhangt van systolisch functie. 
Geconcludeerd kan worden dat bij patiënten met een sepsis geïnduceerde 
systolische dysfunctie en dilatatie een hoog GEDV vloeistofresponsiviteit niet uitsluit, 
en GEDV dus nog verder kan toenemen. Dit is belangrijk gegeven omdat in de literatuur 
lagere normaalwaarden of streefwaarden worden gesuggereerd. 
In hoofdstuk 8 hebben we het principe en de toepasbaarheid van door de TPTD 
techniek verkregen extravasculaire longwater nader beschreven. Er is aangetoond 
dat EVLW metingen zeer goed correleren met de goudstandaard via post mortem 
gravimetry in proefdieren. Klinische studies bij patiënten toont aan dat aanhoudend 
verhoogd EVLW sterk gecorreleerd is met sterfte. Het is derhalve aannemelijk dat 
EVLW-geleide (vloeistof) therapie van invloed zou kunnen zijn op beademingsduur en 
wellicht opnameduur op de IC. 
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In hoofdstuk 9 hebben we onderzocht of het risico op vloeistof overbelasting minder 
groot is wanneer vloeistof management wordt bepaald aan de hand van GEDV 
en EVLW metingen in vergelijking met PAOP metingen met de PAC. 120 patiënten 
opgenomen op de Intensive Care werden gerandomiseerd en geïncludeerd waarvan 
60 patiënten werden voorzien van een PAC en 60 patiënten van de TPTD techniek. 
Patiënten werden gestratificeerd naar onderliggende ziekte: septische shock versus 
non-septische shock. Gedurende een periode van 72 uur werd op basis van vooraf 
gedefinieerde algoritmes vloeistof toegediend. Vloeistoftoediening was toegestaan 
zolang bovenste limieten van PAOP, GEDV of EVLW niet waren bereikt. Primaire 
uitkomstmaat was beademingsvrije dagen, secondaire uitkomstmaten waren 
orgaanfalen en sterfte. 
Uit de studie kwam naar voren dat zowel primaire als secundaire uitkomstmaten 
in beide groepen (PAC versus TPTD) vergelijkbaar was, maar dat TPTD monitoring 
geassocieerd was met langere beademingsduur en een langer verblijf op de Intensive 
Care een ziekenhuis in de niet-septische shock groep, doch niet in de septische shock 
groep. De verklaring hiervoor zou kunnen zijn dat in de non-septische groep er meer 
patiënten zaten met bijkomende hartziekten. Toepassing van een maximale limiet 
van 10 ml/kg EVLW zou in deze groep wellicht te hoog kunnen zijn waardoor er een 
grotere kans bestaat op het ontstaan van longoedeem, met als gevolg een langere 
beademingsduur. Onze resultaten lijken te bevestigen dat patiënten met septische 
shock een anders reageren met betrekking tot cardiorespiratoire fysiologie dan 
patiënten met niet-septische shock. 
Conclusie
We mogen stellen dat de interpretatie van parameters verkregen door 
hemodynamische monitoring met de PAC of TPTD techniek gerelateerd dient te 
worden aan onderliggende ziekte en (gerelateerde) hartfunctie. De PAC faciliteert 
het inzichtelijk maken van de cardiale dynamiek tijdens vloeistoftherapie, met name 
bij patiënten met een verminderde systolische functie. De TPTD techniek daarentegen 
kan door de mogelijkheid van het relatief betrouwbaar schatten van de mate van het 
extravasculaire longwater behulpzaam zijn tijdens vloeistoftherapie bij patiënten 
die een verhoogd risico hebben op (toename van) longoedeem, zoals patiënten met 
ARDS, om schadelijke overvulling te voorkomen. 
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om deel te nemen aan de beschreven studies in dit proefschrift. Toestemming geven 
te (laten) participeren in wetenschappelijk onderzoek wanneer een van je dierbaarste 
naasten levensbedreigend ziek is getuigt van hoop en vertrouwen, ook al weet je dat 
de kans op overleving soms zeer klein is.
Mijn promotor professor dr. A.B.J. Groeneveld, 
Beste Johan, een ding is zeker: zonder jou was het niet gelukt. Zeker bij mijn overstap 
naar Enschede in 2008 heb ik ervaren dat het verrichten van promotie onderzoek in 
een niet-academisch klimaat een zaak is van volhardendheid, maar ook van intensieve 
begeleiding; 1731 (!) mailwisselingen tussen ons zijn noodzakelijk geweest voor de 
totstandkoming van dit proefschrift. Je (bijna neurotische) gedrevenheid werkt 
inspirerend en je analytisch talent is bewonderenswaardig. Ik heb veel van je geleerd 
en ik hoop dat we in de nabije toekomst zullen blijven samenwerken.
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Mijn promotor professor dr. A.R.J. Girbes, 
Beste Armand, ik heb veel van je mogen leren tijdens mijn verblijf in de VU. Jouw 
stelling dat besluitvorming altijd via “de Koninklijke weg” dient te worden genomen 
stelde mijn geduld aardig op de proef, maar ik realiseerde me uiteindelijk wel dat dit 
het meeste rendement oplevert. Jouw visie op de IC, zowel medisch inhoudelijk als 
ook organisatorisch, heeft me diep geïnspireerd. “IC Nederland” kan trots zijn op 
jouw bijdrage aan de ontwikkeling van de IC geneeskunde in dit land. Ik wil je danken 
voor het gestelde, wederzijdse, vertrouwen. 
Mijn copromotor dr. A. Beishuizen,
Allerbeste Bert, al vanaf het begin van onze samenwerking in 2004 wist ik dat het 
goed zat. Jouw visie op de IC geneeskunde sluit feilloos aan bij die van mij. Ik heb 
bewondering voor je doorzettingsvermogen en geduld; ik ken maar weinigen die zich 
niet uit het veld laten slaan door frustraties, helaas veelal veroorzaakt door anderen. 
Jouw komst naar Enschede zie ik als een bekroning op de Intensive Care van het MST. 
Ik dank je als collega, maar bovenal als vriend. 
Geachte leden van de promotiecommissie,
Dank voor uw beoordeling van dit proefschrift en de bereidheid zitting te nemen in de 
promotiecommissie. 
Ik dank alle medewerkers van de afdeling Intensive Care Volwassenen van het VUMC 
voor hun bijdrage aan de totstandkoming van dit proefschrift. In het bijzonder dank 
ik Alex Cornet voor het rekruteren van patiënten nadat ik de overstap maakte naar 
Enschede, ik weet hoe hoeveel inspanning het soms kost om informed consent te 
verkrijgen. Ook mijn oud collega’s Emmy Rijnsburger, Annelies Tacx, Ellen Smit, Rose-
Marieke Breukers, Jan Jaap Spijkstra, Hagen Biermann, Erik Lust en wijlen Rob Strack 
van Schijndel dank ik voor hun support. Voorts wil ik Joanne Verheij danken voor het 
beschikbaar stellen van de data.
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De Intensive Care afdeling van het MST. Mijn dank is groot voor allen die mij hebben 
gesteund tijdens een van de zwaarste periodes uit mijn carrière. Gelukkig is de storm 
gaan liggen zonder uiteindelijk schipbreuk te hoeven lijden. De spirit is beter dan ooit 
en we zijn goed op weg om er iets moois van te maken. Harold, Wytze, Alaattin, Ralph, 
Bert en Vera, ik spreek de vurige wens uit dat onze verhoudingen zullen blijven zoals 
ze zijn!
Paranimfen Harald Vonkeman en Peter Mensink,
Beste Harald en Peter, ruim tien jaar collega’s en dierbare vrienden. Wat fijn dat jullie 
mij bij willen staan tijdens deze toch wel spannende dag. Met veel genoegdoening 
kijk ik terug op onze periode als assistent in het MST. Onze wegen scheidden, maar 
uiteindelijke toch weer verenigd! Ik hoop dat we er nog vele mooie jaren van zullen 
maken. 
Ik dank mijn ouders voor hun onvoorwaardelijke vertrouwen om me te kunnen laten 
worden wie ik wil zijn. Lieve mam, ook deze mijlpaal had je nog samen met ons willen 
beleven, helaas was die tijd jou niet meer gegund. Niettemin weet ik dat je ook vandaag 
bij ons zult zijn. Lieve Peter, mijn grote broer, fijn dat je altijd voor ons klaar wilt staan.
Als laatste mijn allerliefsten. Lieve Cathelijne, I know that living with me is not always 
easy, maar samen vormen we een sterk team en we komen er altijd weer bovenop, je 
bent een verrijking van mijn leven! Lieve Maryleine, Quinten en Constantijn, mijn liefde 
voor jullie is onvoorwaardelijk en onoverwinnelijk, vergeet dat nooit, en wees trots op 
wie je bent!
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Curriculum Vitae
Ronald Jan Trof werd geboren op 21 april 1973 in Veendam, als laatste uit een gezin 
van 2 kinderen. Na het eindexamen VWO in 1991 aan het Wessel Gansfort College te 
Groningen was hij voornemens Geneeskunde te gaan studeren. Helaas moest door 
uitloting een andere richting worden gekozen, waarop hij Rechten ging studeren aan 
de Rijksuniversiteit Groningen (RUG). Doch de drang naar de medische wetenschap 
bleef bestaan en gelukkig kon een jaar later alsnog worden begonnen met de studie 
Geneeskunde, eveneens aan de RUG. Tijdens zijn studietijd was Trof zeer actief op 
de studenten volleybalvereniging GSVV Donitas alwaar hij enkele seizoenen op het 
hoogste niveau acteerde en twee jaar lang deel uit maakte van het bestuur. Na het 
behalen van de doctoraalbul werd gestart met de coschappen, onder andere in 
het Scheperziekenhuis te Emmen en het Universitair Medisch Centrum Groningen 
(UMCG). In 1998 werd het artsexamen afgelegd (cum laude) waarna hij begon als arts-
assistent Interne Geneeskunde en Cardiologie in het Scheperziekenhuis. Al snel werd 
duidelijk dat hij een carrière verkoos als internist zodat hij in 2000 de overstap naar het 
Medisch Spectrum Twente in Enschede maakte met als doel de opleiding tot internist 
te gaan volgen. In 2001 werd gestart met de opleiding onder leiding van dr. Bonno 
Hylkema, die hem enthousiasmeerde voor de Intensive Care Geneeskunde. Via een 
korte terugkeer naar het UMCG begon Trof in december 2004 zijn fellowship Intensive 
Care Geneeskunde op de afdeling IC Volwassenen van het VUMC in Amsterdam, onder 
supervisie van prof.dr. Armand Girbes. Trof behaalde zijn registratie als internist-
intensivist in december 2006 waarna hij qualitate qua zijn promotietraject startte bij 
prof.dr. Johan Groeneveld. In mei 2008 besloot Trof terug te keren naar het Medisch 
Spectrum Twente om Bonno Hylkema op te volgen als intensivist. Trof is getrouwd 
met Cathelijne Ziedses des Plantes, eveneens medisch specialist (radioloog). Zij 
hebben samen drie kinderen: Maryleine (2006), Quinten (2008) en Constantijn (2011). 
Ronald Jan Trof was born on the 21th of April 1973 in Veendam, The Netherlands. 
After graduating from the Wessel Gansfort College in Groningen in 1991, he studied 
Dutch law at the University of Groningen for one year. In 1992 he commenced his 
study medicine also at the University of Groningen. He obtained his Master of Science 
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in medicine in 1996. Trof performed his interns at Scheper Hospital, Emmen and at 
University Medical Center Groningen. After obtaining his degree as Medical Doctor 
(cum laude) in 1998 he became a non-resident in the department of Internal Medicine 
at Scheper Hospital, Emmen. In 2000 he moved to Enschede where he started his 
residency in Internal Medicine at Medisch Spectrum Twente (dr. Bonno Hylkema). In 
December 2004 he started his fellowship Intensive Care at the VU Medical Center, 
Amsterdam, under the supervision of Prof. dr. Armand Girbes. In December 2006 he 
finished his fellowship and became consultant intensivist at VU Medical Center where 
he started his PhD on “optimizing fluid management in critically ill patients” under 
the supervision of Prof. dr. Johan Groenveld. In 2008 Trof moved back to Enschede 
to become consultant intensivist in the department of Intensive Care at Medisch 
Spectrum Twente where he is still working. In 2012 he married Cathelijne Ziedses des 
Plantes. Together they have three children: Maryleine (2006), Quinten (2008) and 
Constantijn (2011).  
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van de Vrije Universiteit
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Receptie na afloop
Ronald J Trof
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